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This Ph.D. dissertation describes the synthesis of arborescent copolymers of generations 
G1 and G2 designed to serve as drug delivery nanocarriers for cancer treatment. Poly(γ-
benzyl L-glutamate) (PBG) building blocks were generated by ring-opening 
polymerization of γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-NCA) initiated with 
n-hexylamine. Partial or full deprotection of the benzyl ester groups followed by coupling 
with PBG chains yielded a comb-branched (arborescent polymer generation zero or G0) 
PBG structure. Additional cycles of deprotection and grafting yielded G1 and G2 
arborescent polypeptides. Optimization of the arborescent PBG synthesis was carried out 
in terms of the reaction temperature, solvent composition, reaction time, and mole ratio of 
reactants and coupling agents. Side chains of poly(ethylene oxide) (PEO) were then grafted 
either randomly or at the chain ends of the arborescent PBG substrates to produce 
amphiphilic arborescent copolymers denoted as PBG-g-PEO and PBG-eg-PEO, 
respectively.  
The branching density of the G0PBG substrates was controlled by varying the length and 
the deprotection level of the linear PBG substrates used in their synthesis. Three G0PBG 
cores with branching densities varying from a compact and dense to a loose and porous 
structure were thus synthesized. The arborescent PBG-g-PEO amphiphilic copolymers 
formed mostly unimolecular micelles with small amounts of aggregation in aqueous media, 
whereas arborescent PBG-eg-PEO were completely devoid of aggregation. The 
hydrodynamic diameter of the copolymers varied from 13 to 39 nm, depending on their 
generation number and the branching density of the G0PBG cores.  
 
v 
The ability of these unimolecular micelles to encapsulate and release doxorubicin (DOX), 
an anticancer drug, was correlated with their generation number and the branching density 
of the hydrophobic cores. Both the drug loading content (DLC) and the drug loading 
efficiency (DLE) increased with the generation number of the copolymers as a result of 
increasing the PBG content in the micelles. For each generation, slightly higher values of 
DLE and DLC were observed for micelles with a denser core structure. The release profiles 
indicated that the drug release rate could be modulated by the generation number of the 
copolymers or by controlling the branching density, and thereby the porosity of the cores: 
Micelles with more densely branched cores decreased the diffusion rate of the drug. Three 
different strategies were examined to load DOX into G1PBG-eg-PEO and G2PBG-eg-
PEO. The DOX was either physically entrapped (PBG-eg-PEO/DOX), loaded via 
electrostatic interactions (PGA-eg-PEO-DOX), or covalently conjugated to the 
unimolecular micelles via a pH-sensitive hydrazone bond (PGA-eg-PEO-Hyd-DOX). 
While all these systems had a good drug loading capacity, encapsulation via electrostatic 
interactions yielded the highest DLC and DLE. All these systems exhibited sustained and 
pH-responsive drug release behavior, with slower release at physiological pH (7.4) than at 
pH 5.5, but PGA-eg-PEO-Hyd-DOX had the best overall pH-responsive release behavior. 
The versatile encapsulation and release properties of these unimolecular micelles show that 
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1.1 Opening Remarks 
Dendritic polymers are a unique and versatile type of macromolecules characterized by 
a highly branched tree-like architecture, incorporating multiple branching levels, resulting 
from coupling reactions of either small molecule monomers (hyperbranched polymers and 
dendrimers), or macromolecular building blocks (dendrigraft polymers).1 Amphiphilic 
dendritic polymers are particularly interesting because they can display micelle-like 
properties and provide excellent in vivo colloidal stability which makes them ideal for 
applications in drug delivery.2 Dendrigraft polymers (referring collectively to arborescent 
and dendrimer-like star polymer structures) are the most recently reported subset of 
dendritic polymers.3,4 Due to the vast array of architectures that can be obtained for these 
systems, dendrigraft polymers are an excellent alternative in the design of unimolecular 
micelles.5-7 In contrast to the other dendritic polymers, high molecular weight polymers 
can be obtained for these systems in relatively few steps, while maintaining fairly narrow 
molecular weight distributions (Mw/Mn < 1.1).
1  
The encapsulation and release properties of arborescent copolymers were investigated 
using various polycyclic aromatic hydrocarbon probes as well as indomethacin and 
lidocaine as model drugs.5,6 Unfortunately, the system used (based on polystyrene and 
poly(2-vinylpyridine) building blocks) lacked the biocompatibility necessary for 
biomedical applications. Biocompatible arborescent copolymers were recently synthesized 
and evaluated as unimolecular micelles,7 but the ability of these copolymers to encapsulate 
and control the release of hydrophobic drugs has not yet been explored. 
 
3 
1.2 Research Objectives and Thesis Outline 
The design of drug delivery nanocarriers that can encapsulate hydrophobic drug 
molecules efficiently, transport their cargo to specific target sites and release it in a 
sustained and controlled manner is of great interest for cancer chemotherapy. This 
Dissertation focuses on the synthesis and the micellar properties of two families of 
amphiphilic arborescent copolymers, namely arborescent poly(γ-benzyl L-glutamate) 
(PBG) substrates grafted either randomly or at the end of the PBG chain segments with 
poly(ethylene oxide) (PEO) chain segments (denoted PBG-g-PEO and PBG-eg-PEO, 
respectively). The main goals of the work were to study their aqueous solution behavior 
and to investigate the ability of these biocompatible copolymers to encapsulate and control 
the release rate of hydrophobic drugs in aqueous media. For each system, the influence of 
varying the generation number and the branching density of the core on micelle properties 
such as the drug loading capacity and the release kinetics was investigated. Three different 
strategies were used to load doxorubicin (DOX), an anticancer drug, into G1PBG-eg-PEO 
and G2PBG-eg-PEO. The DOX was either physically entrapped (PBG-eg-PEO/DOX), 
loaded via electrostatic interactions (PGA-eg-PEO-DOX), or covalently conjugated to the 
unimolecular micelles via a pH-sensitive hydrazone bond (PGA-eg-PEO-Hyd-DOX). 
This dissertation is comprised in seven chapters. Following this Foreword, a literature 
review is presented (Chapter 2) that is divided into two sections: The first part reviews 
different families of polymeric micelles used as drug carriers including amphiphilic block 
copolymer micelles, unimolecular micelles and cross-linked micelles; the second part 
provides an overview of methods currently available for the synthesis, modification, and 
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drug delivery applications of dendritic polymers with various structures. Chapter 3 reports 
on the synthesis and the optimization of well-defined dendritic graft (arborescent) 
polypeptides from amine-terminated poly(γ-benzyl L-glutamate) (PBG) chains. The 
influence of reaction conditions such as the temperature, solvent, reaction time, and the 
mole ratio of reactants and coupling agents was investigated. The design and synthesis of 
biocompatible arborescent poly(γ-benzyl L-glutamate) (PBG) substrates randomly grafted 
with linear poly(ethylene oxide) (PEO) are discussed in Chapter 4, whereas the use of chain 
end-grafted PBG substrates is discussed in Chapter 5. In both Chapter 4 and Chapter 5, 
arborescent copolymers with PBG cores of generations G1 and G2, derived from G0PBG 
substrates with different branching densities, were examined as drug nanocarriers. The 
effects of the branching density on the micelle size, the drug loading capacity, the drug 
loading efficiency, and the drug release rate were investigated. Different strategies to load 
doxorubicin (DOX), an anticancer drug, into these unimolecular micelles are compared in 
Chapter 6. DOX was either physically entrapped, loaded via electrostatic interactions, or 
covalently conjugated to the unimolecular micelles via a pH-sensitive hydrazone bond. 
Chapter 7 provides overall concluding remarks drawn from the Thesis work, a summary of 
original contributions to knowledge, and suggestions for future work. 
In agreement with the University of Waterloo Thesis guidelines, Chapters 2-6 are 
organized as individual manuscripts for publication in scientific journals. Included within 
each chapter are an abstract, an introductory section providing relevant background 
information on the subject matter, experimental methods, discussion of the results, and 
conclusions. An extended abstract for the whole Thesis is also provided in the preliminary 
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pages of this Dissertation, and a single list of references is given at the very end of the 









2.1 Background: Cancer and Its Treatment 
Cancer is a group of diseases characterized by the uncontrolled growth and spread of 
abnormal cells.1 Cancer is usually caused by genetic changes (mutations) in cells. It is 
presently a major public health problem throughout the world in many forms including 
leukemia, myeloma, carcinoma, lymphoma and sarcoma, and is one of the leading causes 
of death. A recent report from the World Health Organization (WHO) stated that there were 
14.1 million new cancer cases and 8.2 million cancer deaths in 2014.2 With an increasing 
global population, the number of new cancer cases has also grown from 12.7 million in 
2008 to 14.1 million in 2014. It is estimated by the World Health Organization that new 
cancer incidence will rise from 14.1 million in 2014 to 19 million by 2025, and to 24.4 
million by 2035 as shown in Figure 2.1. As a result, much effort in research has focused 




















Figure 2.1. Estimated global cancer incidence, 2012-2035.2 
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Most cancers are treated by radiation therapy, surgery and/or chemotherapy.1 Radiation 
therapy uses high energy electromagnetic waves to kill or damage cancer cells. It is one of 
the most common treatments for cancer, either by itself or along with other treatments. The 
radiation may come from outside the body or from radioactive materials inserted into the 
tumor.  Surgery is the oldest known method and is often the first treatment option if the 
tumor can be removed from the body. Surgery can be used to diagnose or even help prevent 
cancer in some cases. Sometimes surgery may leave residual cancer cells that can change 
their growth rate and trigger a faster metastatic process. Therefore chemotherapy, radiation, 
or both methods may be used to make the tumor shrink before or after surgery.  
Chemotherapy is an effective method using therapeutic agents to treat cancers that have 
spread, since the small size of anticancer drugs allows them to travel easily through the 
entire body. Chemotherapy conventionally involves small molecule drugs to kill rapidly 
dividing cancer cells by damaging their RNA or DNA. Although conventional cancer 
treatment options have progressed significantly over the last few years, chemotherapy is 
still far from optimal due to a few problems, namely: The non-specific distribution of 
anticancer drugs throughout the body; most of the drugs used for chemotherapy have a low 
solubility in water, and thus are not solubilized properly in the bloodstream to provide 
sustained therapeutic efficacy; and the fact that repeated doses of anticancer drugs are 
required for therapeutic efficacy. Consequently, there has been increased interest in 
developing drug delivery carriers for the effective transportation of anticancer drugs to 
specifically target tumor tissues and kill mainly cancer cells.1,3 
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In the first section of this Chapter, we provide an overview of polymeric drug delivery 
systems in cancer chemotherapy. Special attention is given to polymeric micelles based on 
polypeptides that are coated with poly(ethylene glycol) (PEG). We first briefly describe 
amphiphilic block copolymers micelles as nanocarriers for drug delivery applications. We 
then discuss two approaches that can be used to produce more stable micelles, either by 
constructing unimolecular micelles or by crosslinking block copolymer micelles.  
2.1.1 Drug Delivery Systems  
A drug delivery system (DDS) is defined as a device or a formulation that enables the 
introduction of therapeutic agents in the body to overcome the limitations of traditional 
chemotherapy, by improving its efficacy and safety through controlling the rate, time, and 
place of release of the drugs. A wide range of nanometric drug delivery systems have been 
designed, including liposomes, polymeric micelles, nanoparticles, dendrimers, silica 




Figure 2.2. Some examples of nanometric drug delivery systems explored for 
applications in cancer therapy.  
Reprinted from ref. 4, with permission from John Wiley & Sons, Inc. 
Drug delivery systems have multiple advantages: (A) they can increase significantly 
the solubility of hydrophobic drugs in aqueous environments, by encapsulation or 
incorporation of the drugs within amphiphilic materials; (B) they can improve the 
pharmaceutical properties of drugs, potentially without the need to alter them; (C) they can 
carry drugs to their site of action, thereby limiting their toxicity and enhancing the 
therapeutic efficacy; (D) it is possible to achieve a high carrying or loading capacity for a 
drug within a single macromolecular entity or assembly; and (E) since nanocarriers can 
escape quick clearance and elimination, the circulation time of the drug-loaded carrier in 
the blood is increased (ranging from hours to days) in comparison to the free drug.5 As a 
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result, cancer chemotherapy using drug delivery systems is expected to increase treatment 
efficacy with fewer side-effects.  
Drug-loaded carriers can passively accumulate in tumors through the enhanced 
permeation and retention (EPR) effect.6,7 Nanocarriers can be designed to be large enough 
to escape premature elimination in the kidneys via glomerular filtration, but small enough 
to participate in the EPR effect and passively accumulate in tumor tissues (Figure 2.3).8 
Blood vessels surrounding tumor tissues are “leaky” in comparison to normal blood 
vessels, and thus drug-loaded carriers can effectively travel across the fenestrations to reach 
and accumulate in tumor tissues, thereby exerting their therapeutic effect as the drug is 
being released. In contrast, free small molecule drugs diffuse non-specifically to tissues. 
Through passive targeting of tumor tissues by drug-loaded carriers, the side-effects of the 




Figure 2.3. The EPR effect, describing the mechanism of enhanced macromolecule 
accumulation in tumor tissues.  
Reprinted by permission from Macmillan Publishers Ltd: Nature Nanotechnology, from ref. 8, 
copyright 2007. 
To date some drug delivery systems have been clinically approved, and several more 
are under clinical investigation and development (Table 2.1). The first drug-loaded carrier 
Doxil®, approved in 1995, uses poly(ethylene glycol)- (PEG)-modified liposomes to 
encapsulate doxorubicin (DOX).9 Doxil® was prepared with a 100 nm diameter to target 
specifically tumor tissues while leaving healthy tissues unaffected. The serious side-effects 




Table 2.1. Nanocarrier-based therapeutics in clinical use and undergoing clinical 
trials. 












paclitaxel approved   13 
Myocet liposomes doxorubicin approved   14 
NK105 micellar nanoparticles paclitaxel phase III   15 
BIND-014 polymer matrix docetaxel phase II   16 
Genexol-PM methoxy PEG-PLA paclitaxel phase II   17 
AuroLase gold nanoparticles _ phase I   18 




Among all the nanocarrier systems available, this literature review will focus on 
polymeric micellar systems as drug carriers including amphiphilic block copolymers 
micelles, unimolecular micelles and crosslinked micelles. 
2.1.2 Polymeric Micelles as Drug Carriers 
Recent developments in the knowledge of the human body have opened the door to the 
identification and understanding of the mechanisms underlying many challenging 
diseases. Many of these diseases cannot be treated using conventional small molecule 
drugs.20 It has been recognized that enhancing one or more of the intrinsic adsorption, 
excretion, distribution, and metabolism characteristics of a small molecule drug is a crucial 
step in developing more effective drug therapies. This requires multidisciplinary 
collaboration between researchers with expertise in chemistry, biology, and engineering to 
manufacture new drug delivery systems for effective treatment.21 Over the last couple of 
decades, a considerable number of new drug delivery systems have been developed to 
improve the bioavailability of drugs, enhance their aqueous solubility, increase their 
circulation time in the bloodstream, and specifically deliver them to target tissues. In this 
context, polymeric micelles (e.g. amphiphilic block copolymers micelles, unimolecular 
micelles and crosslinked micelles) with tunable properties have shown great promise and 
are in the front line of development for drug delivery systems.22,23   
Among drug carriers, polymeric micelles show great potential due to their higher 
loading capacity and great stability in the bloodstream. Furthermore, the physicochemical 
properties of the polymers can be tuned to meet specific requirements. In addition, 
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polymeric micelles may be coated with hydrophilic polymers such as poly(ethylene glycol) 
(PEG), which helps the micelles escape recognition by the mononuclear phagocytic system 
and thus prolongs their circulation time in the bloodstream.24 The size of polymeric 
micelles usually falls within the range of 10-100 nm in diameter, which is above the 
threshold for filtration by the kidneys, and therefore polymeric micelles have the ability to 
carry many drugs with prolonged circulation times. Ligands or/and antibodies can be 
attached to the surface of polymeric micelles to specifically target certain parts of the 
body.22 Some polymeric nanoparticles can achieve high drug loading, which maximizes 
the drug/excipient ratio. In addition, the incorporation of drugs in polymeric matrices 
controls their release rate, which can be sustained or stimuli-responsive.25 The use of a 
specific stimuli-sensitive delivery system allows the release of the encapsulated drug only 
when one or more stimuli are present. For instance, the pH around tumor tissues in the 
body tends to be more acidic (5.4 to 6.5) relatively to the physiological pH (7.4).26 
Furthermore, the small size of polymeric micelles allows them to accumulate passively in 
tumors, through the so-called enhanced permeation and retention effect (EPR).6 
Despite the remarkable therapeutic potential of polymeric micelles as drug 
nanocarriers, the availability of well-defined water-soluble synthetic polymers of uniform 
dimensions, that are nontoxic and biocompatible, and therefore suitable for in vivo 
applications, is still limited.27 Degradable polymeric biomaterials are preferable for 
therapeutic devices such as sustained release drug delivery nanocarriers. Biodegradable 
polymers can be defined as polymers that are degradable in vivo, either enzymatically or 
non-enzymatically, to produce biocompatible or nontoxic by-products.28 Therefore, it is 
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possible to implant these materials into the body without subsequent removal by surgery 
or other procedures. For example, poly(lactic-co-glycolic acid) (PLGlyA), poly(amino 
acid) (PAA), poly(glycolic acid) (PGlyA), poly(ethylene glycol) (PEG), poly(methyl 
methacrylate) (PMMA) and poly(lactic acid) (PLA) (Figure 2.4) have been approved by 
the US Food and Drug Administration (FDA) for use in humans. If a polymer is not totally 
biodegradable, it should be completely eliminated from the body within a reasonable time 
period. 
 




The biodegradable polymers used in the fabrication of nanocarriers for drug delivery 
applications can be categorized, according to their origin, into natural, synthetic or 
semisynthetic. Natural polymers include proteins (e.g. collagen, gelatin and albumin) and 
polysaccharides (e.g. dextran, hyaluronic acid, pullulan, cellulose and inulin). Natural 
polymers are generally more biocompatible and biodegradable, as most of them are present 
within structural tissues of living organisms. In comparison to natural polymers, synthetic 
biodegradable polymers have a high mechanical strength but a low degradation rate. In 
addition, these materials can be tailored to meet absorption time requirements, which 
potentially facilitates dosage reproducibility and scale-up, without concerns about disease 
transmission, that can be a problem with naturally occurring polymers.32 Examples of 
synthetic polymers used in the construction of nanocarriers include aliphatic polyesters, 
polypeptides, polyanhydrides, polyorthoesters and polycyanoacrylates.  
Polypeptides are increasingly receiving attention as building blocks for the construction 
of biological nanostructures for biomedical applications. Poly(amino acid)s, especially 
poly(L-glutamic acid), poly(L-lysine) and poly(L-aspartic acid) and their derivatives, are 
widely used as components of nanocarriers for drug delivery because of their remarkable 
characteristics such as their high biocompatibility, easy biodegradability and relatively low 
cost, in addition to the presence of versatile functional groups such as hydroxyl, carboxyl 
and amino functionalities useful for a variety of chemical modification reactions.29 In 
addition, polypeptides have the ability to form well-defined secondary structures (α-helices 
and β-sheets) that contribute to the self-assembling of polypeptide chains, leading to novel 
nanostructured materials. All these features make poly(amino acid)s and their derivatives 
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excellent polymers for drug delivery applications. Several micellar formulations based on 
polypeptides are currently undergoing clinical testing or preclinical evaluation (Table 2.2). 
Table 2.2. Various polypeptide-based materials currently undergoing clinical 
testing or preclinical evaluation for drug delivery. 
Polymer Drug Phase completed Ref. 
PEG-b-PGA Doxorubicin Phase II 30 
mPEG-b-P(PGA-co-
Phe) 
Doxorubicin Phase I 31 
PEG-b-PBLA Doxorubicin Phase I 32 
PGA Paclitaxel Phase III 33 
γ-PGA-b-PLLA Paclitaxel Phase I 34 
PEG-b-PGA: poly(ethylene glycol)-b-poly(L-glutamic acid); (mPEG-b-P(PGA-co-Phe)): 
poly(ethylene glycol)-b-poly(L-glutamic acid-co-L-phenylalanine); PEG-b-PBLA: 
poly(ethylene glycol)-b-poly(β-benzyl-L-aspartate); PGA: poly(γ-glutamic acid); γ-PGA-
b-PLLA: poly(γ-glutamic acid)-b-poly(lactide). 
Traditionally, amino acids have been polymerized by solid-phase peptide synthesis, but 
the synthesis of peptides with more than 100 residues often results in undesired by-products 
due to incomplete deprotection and coupling steps. As a result, a number of alternate 
approaches have been developed to prepare poly(amino acid)s. The synthetic technique 
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most commonly used to that end is the ring-opening polymerization of N-carboxyanhydride 
(NCA) derivatives of α-amino acids initiated by primary amines.35 
The polymerization of γ-benzyl-L-glutamate N-carboxyanhydride (Glu-NCA) initiated 
by primary amines is subject to termination by end group cyclization, which prohibits 
further growth of the poly(γ-benzyl-L-glutamate) (PBG) chain. Chain end cyclization can 
be practically eliminated, thus preserving the terminal amine group on the chain, by 
lowering the reaction temperature (Scheme 2.1).36 This technique is economical and can 
lead to large quantities of polymer in good yield.  
 
Scheme 2.1. Synthesis of poly(γ-benzy-L-glutamate) by ring-opening 
polymerization of the corresponding NCA monomer. 
Poly(ethylene glycol) (PEG), a polymer of either ethylene glycol or ethylene oxide, is 
a biocompatible, hydrophilic and non-toxic polymer approved by the FDA for internal use 
in drug delivery applications. It is the polymer most successfully used to coat nanoparticles 
(a procedure called PEGylation) to avoid the interaction of nanoparticles with components 
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of biological fluids and prevent the adsorption of plasma proteins, thus avoiding 
recognition by the mononuclear phagocytic system (MPS) and subsequent clearance by the 
kidneys. PEGylation also increases the blood circulation time for polymeric nanoparticles, 
while providing steric hindrance and protection for cargoes that are sensitive towards 
particular environments.37 
There has been extensive research in designing polymeric nanocarriers of different 
types, sizes, morphologies and stabilities for drug delivery applications. In the following 
section, amphiphilic block copolymers micelles, unimolecular micelles and crosslinked 
micelles developed to that end will be briefly reviewed.  
2.1.2.1 Amphiphilic Block Copolymer Micelles 
Amphiphilic copolymer micelles have recently emerged as colloidal drug carriers 
formed in aqueous media through the self-assembly of amphiphilic copolymers with 
different architectures (e.g. block and graft), albeit block copolymers are most common.22 
Micellar solutions of amphiphiles are an effective way to deliver drugs to their targets. 
Block copolymer micelles are usually spherical, have a size in the range of 10-200 nm and 
a core-corona structure as shown in Figure 2.5.23 Copolymers that form micelles in aqueous 
environments consist of two segments with different affinities for water: one is 
hydrophobic, while the other is hydrophilic. The major driving force behind the self-
assembly of amphiphilic copolymers is the decrease in free energy of the system as the 
hydrophobic segments withdraw from the aqueous medium to minimize their unfavorable 
interaction with water. The formation of polymeric micelles, or self-assembly, starts only 
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when a certain minimum concentration of the amphiphile in water, called the critical 
micelle concentration (CMC), is exceeded. The hydrophilic segment of the block 
copolymer then forms the corona or shell of the micelles, while the hydrophobic segment 
forms the core. Polymeric micelles of amphiphilic block copolymers with low CMC values 
exhibit enhanced stability. Therefore, increasing the hydrophobicity of the nonpolar 
component reduces the CMC and thus micelle stability increases.38 
 
Figure 2.5. Polymeric micelle formed by the self-assembly of amphiphilic block 
copolymer molecules in aqueous media. 
Polymeric micelles are great nanocarriers for drug delivery applications in cancer 
treatment due to their remarkable core-shell structure that gives them many advantages. 
One of the most important properties of polymeric micelles is their ability to solubilize 
hydrophobic or poorly water soluble anti-cancer drugs within their core, and thus enhance 
their bioavailability. The hydrophobic core offers a good microenvironment for the 
solubilization of hydrophobic drugs. For instance, polymeric micelles of poly(lactic acid)-
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b-poly(ethylene glycol) (PLA-b-PEG) increased the aqueous solubility of the anticancer 
drugs paclitaxel and doxorubicin 5,000-fold and 12,000-fold, respectively.39,40 Polymeric 
micelles not only solubilize hydrophobic drugs but also protect them from inactivation in 
the biological milieu, control their release, decrease their side effects and protect them 
against degradation, thus increasing their overall therapeutic efficacy.22 In addition, the 
small size of polymeric micelles allows them to circulate in the bloodstream for extended 
periods of time, since their size is large enough to prevent fast renal clearance. The 
hydrophilic shell of the polymeric micelles confers them aqueous solubility, reduces their 
uptake by cells of the immune system, and provides an effective steric barrier maintaining 
colloidal stability and increasing their circulation time. This, in turn, gives the polymeric 
micelles a better chance of accumulating in tumor tissues through passive targeting via the 
EPR effect.41 
Polymeric micelles have been prepared from various amphiphilic copolymers including 
diblock (A-B), triblock (A-B-A) and graft copolymers. A number of different polymers 
have been used as core-forming segments including poly(L-amino acids), polyesters (e.g. 
PLA, PCL, PLGA) and polyethers (e.g. poly(propylene oxide)).22 Poly(ethylene glycol) is 
the most commonly used shell-forming segment of polymeric micelles, although other 
hydrophilic polymers such as poly(N-vinyl-2-pyrrolidone), poly(acrylic acid) (PAA), 
poly(N-isopropylacrylamide) and poly(carboxybetaine)s have also been used.37 
Poly(amino acid)s or their derivatives, especially hydrophobic forms of poly(L-glutamic 
acid), poly(L-lysine) and poly(L-aspartic acid), are widely used as core-forming segments 
in polymeric micelles due to their remarkable characteristics.29 Some examples of 
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polymeric micelle-based anticancer drug formulations having passed the experimental 
stages and currently undergoing clinical trials are provided in Table 2.3. 
Table 2.3. Polymeric micelle-based formulations currently undergoing clinical 
trials. 
Trade name Polymer Drug Phase completed Ref. 
NK-105 PEG-PPBA Paclitaxel Phase I 42 
Genexol®-PM PEG-PDLLA Paclitaxel Phase II 43 
NK-012 PEG-PGA SN-38 Phase I 44 
SP-1049C PEG-PPO-PEG Doxorubicin Phase I 45 
NK-911 PEG-PAsp-DOX Doxorubicin Phase I 46 
PEG: poly(ethylene glycol); PAsp: poly(aspartic acid); PDLLA: poly(D,L-lactide); 
PPBA: poly(4-phenyl-1-butanoate)-L-aspartamide; PGA: poly(glutamic acid); SN-38: 7-
ethyl-10-hydroxycamptothecin.  
Although the stability of amphiphilic block copolymer micelles has been enhanced, 
they remain sensitive to solvents and different experimental parameters such as 
concentration and temperature. Most importantly, these self-assembled systems may 
dissociate upon dilution in the human body, which leads to uncontrolled drug release and 
reduces the efficacy of the treatment. Polymeric micelles can be stabilized via crosslinking 
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of either the core or the corona, or by constructing unimolecular structures that remain 
stable regardless of their environment. These approaches to stabilizing micellar structures 
will be considered next. 
2.1.2.2 Unimolecular Micelles 
Unimolecular micelles are single-molecule micelles with distinct core and shell 
components that are covalently bonded. In contrast to conventional block copolymer 
micelles obtained via noncovalent interactions, unimolecular micelles do not dissociate 
upon dilution and are very stable regardless of their concentration, as shown in Figure 2.6.47 
Their size and morphology can also be precisely controlled. Moreover, different numbers 
and types of functional groups can be attached to every single-molecule micelle. As a 
result, different tasks can be achieved simultaneously. For instance, multiple drugs and/or 
diagnosing agents can be delivered at the same time to the same site in the body. All the 
above features make unimolecular micelles especially attractive as nanocarriers for drug 
delivery applications. Examples of these unique structures include dendrimers, dendrigraft 




Figure 2.6. Different behaviors of unimolecular and supramolecular micelles 
under dilution.  
Reprinted from Biotechnology Advances 33, Lukowiak, M. C., Thota, B. N. S. and Haag, R., 
Dendritic core–shell systems as soft drug delivery nanocarriers, 1327, Copyright 2015, with 
permission from Elsevier. 
Dendritic polymers are a type of branched macromolecules characterized by a highly 
branched tree-like architecture incorporating multiple branching levels, resulting from 
coupling reactions of either small molecule monomers (hyperbranched polymers and 
dendrimers), or macromolecular building blocks (dendrigraft polymers). In solution (e.g. 
water and organic solvents), amphiphilic dendritic polymers exist either as unimolecular 
species or form multimolecular aggregates.47 Dendritic polymer properties can be fine-
tuned to suit certain therapeutic needs, and the possibility to construct them with specific 
functional groups that can be used to attach drugs, targeting moieties or imaging agents. 
makes them ideal carriers for drug delivery applications (Figure 2.7).48 In these dendritic 
unimolecular micellar systems, the bioactive compounds can be physically entrapped 
within the dendritic scaffold and/or covalently conjugated to the terminal functional 
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groups. Their release behavior can be controlled and/or tuned in the biological 
environment, for example via pH, enzymatic, redox, irradiation or temperature-triggered 
cleavage.49 
Despite the desirable characteristics of dendritic polymers, their use in biological 
systems is limited due to toxicity issues associated with some of them. For instance, 
polyamidoamine (PAMAM) dendrimers are cytotoxic for in vivo applications. The 
cytotoxicity of these dendrimers can be greatly reduced by modifying their surface with 
hydrophilic polymers such as PEG.37 Thus coating PAMAM dendrimers with PEG 
(PEGylation) not only decreased their cytotoxicity, but also improved their stability and 
increased their circulation time in the bloodstream. 
 
Figure 2.7. Schematic illustration of multifunctional nanocarriers as bearers for 
drugs, imaging agents, and/or targeting moieties.  
Reprinted with permission from “Larson, N. and Ghandehari, H., Chemistry of Materials, 2012, 
24, 840-853”. Copyright 2012 American Chemical Society. 
Dendritic polymers have been used as delivery vehicles for various hydrophobic drugs, 
to improve their aqueous solubility and enhance their therapeutic efficacy. Various 
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dendritic platforms such as polyamidoamine (PAMAM), poly(propylene imine) (PPI), 
poly(L-lysine), poly(ether hydroxylamine) (PEHAM), poly(ester amine) (PEA) and 
polyglycerol have been synthesized and explored as drug delivery vehicles.50 Some 
dendritic polymer-based products are currently being evaluated in clinical trials.51 For 
example, Starpharma have been granted authorization by the FDA for Phase III clinical 
trials of Vivagel®, a dendrimer-based treatment for bacterial vaginosis.52  
2.1.2.3 Crosslinked Micelles 
Regular polymeric micelles, obtained by the self-assembly of amphiphilic copolymers, 
have attracted much attention over recent years as they are very useful to solubilize 
hydrophobic drugs, thus increasing their overall therapeutic efficacy. Unfortunately, 
polymeric micelles are always at equilibrium with non-associated single polymer chains. 
When applied in vivo, polymeric micelles face several difficulties, primarily related to their 
dilution in the body, which shifts the micellar equilibrium toward the unimer state (Figure 
2.8).53 As a result, there has been significant interest in the stabilization of polymeric 
micelle structures. In recent years, an easy technique developed to stabilize polymeric 
micelles is crosslinking.  Covalently connecting the polymer chains within polymeric 
micelles can successfully prevent self-assembled micelles from dissociating, can control 




Figure 2.8. Micelle formation: (A) Self-assembly of amphiphilic copolymers above 
the critical micelle concentration (CMC), and (B) Different methods applied for core-
crosslinking of polymeric micelles: radical polymerization, bifunctional agents (R—
R), and the oxidation of thiols.  
Reprinted from Nano Today 10, Talelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. 
E. and Lammers, T., Core-crosslinked polymeric micelles: Principles, preparation, biomedical 
applications and clinical translation, 93, Copyright 2015, with permission from Elsevier. 
In crosslinked micelles the assembly of the building blocks (unimers) is based on 
hydrophobic interactions, but is stabilized via the formation of crosslinks either within the 
core or the shell of the micelles. This can be done by incorporating stable bonds between 
the unimers after self-assembly, to keep the micellar structures together during their 
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circulation in the bloodstream. Crosslinked micelles are very interesting as nanocarriers for 
drug delivery, mainly because of their improved in vivo stability but also to control their 
drug release kinetics, and thereby to improve their therapeutic efficacy.  
In general, side chain or end group functionalized block copolymers are required to 
covalently core-crosslink the structure after micelle formation.  Core-crosslinked micelles 
can be obtained by different techniques such as through the addition of bifunctional 
reagents when the core of the micelles carries reactive functional groups, by radical 
polymerization when double bonds are present, or via disulfide bridges derived from thiol 
groups. The latter method is interesting in that it provides an option for stimuli-responsive 
drug release, since disulfides are intrinsically biodegradable in reducing environments such 
as the cytosol of cells. For instance, Cheng and coworkers54 developed camptothecin-
conjugated, reduction-sensitive, core-crosslinked micelles with built-in disulfide bonds. 
Camptothecin (CPT) was reacted with 2-hydroxyethyl disulfide to yield CPT-S-S-OH, 
which initiated the ROP of tyrosine(alkynyl)-O-carboxyanhydride to afford CPT-SS-
poly(tyrosine(alkynyl)-OCA). Core-crosslinking was achieved via azide-alkyne click 
chemistry, by the co-precipitation of CPT-S-S-poly(tyrosine(alkynyl)-OCA), mPEG-
poly(tyrosine(alkynyl)-OCA), and a diazide crosslinker to obtain micelles that could 
undergo disassembly and concurrent drug release upon redox triggering. The study showed 
that core-crosslinked polymeric micelles had enhanced stability over non-crosslinked 
micelles under physiological conditions, while exhibiting rapid degradation and drug 
release in a reductive environment. Shell-crosslinked polymeric micelles were also 
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prepared to physically encapsulate the hydrophobic drug camptothecin  as therapy against 
the hepatitis C virus.55 Lower cytotoxicity was observed as compared to the free drug. 
Despite the great advantages of crosslinking micelles to obtain nanocarriers with high 
in vivo stability, this can cause very slow drug release and/or reduce the biodegradability 
of the nanocarriers, and thus reduce their therapeutic efficacy. In contrast, due to the vast 
array of architectures that can be obtained, unimolecular micelles obtained from dendritic 
polymers are an ideal alternative in the design of nanocarriers. In addition, the properties 
of these unimolecular micelles can be easily fine-tuned to suit certain therapeutic needs, 
and the possibility to construct them with many functional groups to attach drugs, imaging 
agents, targeting moieties, etc. makes them highly desirable nanocarriers for drug delivery 
applications. These dendritic polymer micelles will be reviewed next. 
2.2 Dendritic Polymer Micelles for Drug Delivery 
Branched polymers have physical properties distinct from their linear analogues. For 
example high-density polyethylene, a linear polymer without any branches, has a high 
degree of crystallinity making it a tough material. On the other hand, the multiple short 
branches present along the backbone of low-density polyethylene lead to a lower degree of 
crystallinity and increased ductility.56,57 By controlling the degree of branching, it is thus 
possible to obtain polymers with properties tailored for specific applications. 
Dendritic polymers are a class of macromolecules characterized by a tree-like 
architecture (Figure 2.9), with multiple branching levels resulting from coupling reactions 
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of either small molecule monomers (hyperbranched polymers and dendrimers) or 
macromolecular building blocks (dendrigraft polymers).58-61 These materials can be 
synthesized with good control over their molecular size, branching functionality, and the 
chemical functionality of the chain ends.62 These molecules have a unique combination of 
features including a compact globular topology and diameters ranging from 1 to over 100 
nm, the presence of internal cavities, and a large number of functional groups at their 
periphery. Due to these remarkable features, a broad spectrum of applications are being 
developed for these materials in areas including microencapsulation, drug delivery, nucleic 
acid therapy, diagnostic agents, light harvesting, and catalysis. 
 
Figure 2.9. Schematic representation of dendritic polymers: (a) dendrimer, (b) 
hyperbranched polymer, and (c) dendrigraft polymer. 
Dendrimers, the first family of dendritic polymers reported in the literature, ideally have 
a perfectly branched, defect-free structure. Their synthesis involves successive cycles of 
protection, condensation, and deprotection steps to obtain each branching level 
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(generation). This stepwise synthesis leads to strictly controlled branching and a very 
narrow molecular weight distribution (Mw/Mn < 1.01).
61 However many synthetic steps are 
required to produce high molecular weight materials due to the use of low molecular weight 
monomers as building blocks. On the other hand, high molecular weight hyperbranched 
polymers can be obtained in one pot self-condensation reactions of ABn–type monomers 
without protecting groups, but generally with poor control over their structure. The 
completely random branching process used in the synthesis of hyperbranched polymers 
provides the least defined structures, and results in broad molecular weight distributions 
(Mw/Mn > 2) in most cases.
63,64 The third family of dendritic polymers is dendrigraft 
polymers, typically obtained in a generation-based scheme analogous to dendrimers, but 
with cycles of polymerization and grafting reactions.65,66 The use of polymeric chain 
segments rather than small molecules as building blocks leads to very rapid growth, such 
that high molecular weights are obtained in only a few steps. In contrast to dendrimers, the 
random distribution of coupling sites over the substrate makes arborescent polymer growth 
less sensitive to side reactions, since the structural defects are also randomly distributed 
over the whole molecule. Under appropriate conditions very high molecular weights can 
be achieved quickly for these systems, while maintaining narrow molecular weight 
distributions (Mw/Mn < 1.1). 
The unique structure and interfacial properties of dendritic polymers make them 
suitable as nanocarriers for applications such as drug and gene delivery, and as diagnostic 
agents.67-70 While polymeric micelles obtained by the self-assembly of amphiphilic block 
copolymers have been widely investigated for the encapsulation of drugs within their 
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hydrophobic core, they can be very sensitive to variations in their environment. For 
example, self-assembled nanocarriers can become unstable and dissociate into free chains 
when subjected to pH or temperature variations, or upon dilution in the bloodstream. In 
contrast, dendritic polymers can be designed to behave like unimolecular micelles, namely 
single molecules with an amphiphilic, covalently bonded core-shell morphology. They are 
stable irrespective of their concentration or the solvency conditions, which makes them 
especially attractive as nanocarriers for drug delivery. The numerous advantages of 
dendritic polymers in drug delivery have been discussed in several papers.68,69,71-75 Beyond 
providing a hydrophobic microenvironment that can greatly increase the solubility limit of 
the free drug in aqueous environments, these can provide a high loading capacity,68 are 
able to cross biological barriers,47,76-79 have tunable surface charges,77 and can improve the 
pharmaceutical and pharmacological properties of drugs, potentially without the need to 
alter the drug but rather through suitable design of the molecular architecture of the 
carrier.50,80 Their small size allows them to passively accumulate in tumors through the 
enhanced permeation and retention (EPR) effect.77,79 Active targeting can be achieved by 
introducing ligands on the carrier that can interact with overexpressed cell receptors,80,81 
and the protection they afford minimizes drug degradation and loss.82,83 In these 
nanocarrier systems, the bioactive compound can either physically interact with the 
dendritic scaffold or be covalently conjugated with functional groups located on the 
branching or terminal units, and their release can be triggered and/or tuned in the biological 




In this section, an overview is provided for the methods currently available for the 
synthesis, modification, and drug delivery application of dendritic polymers with various 
structures. The following section is divided according to the three main subclasses of 
dendritic polymers, namely dendrimers, hyperbranched polymers, and dendrigraft 
polymers, respectively. For each dendritic polymer type, well-established and more recent 
synthetic routes are described. Some of these approaches are illustrated using either 
seminal articles or examples that illustrate well that particular strategy. Specific dendritic 
polymers showing promise as nanocarriers for drug delivery applications are then 
discussed. While many systems have potential applications in drug delivery, only selected 
examples will be discussed here. Special attention is provided to the different modification 
methods proposed to achieve desirable nanocarrier properties. This approach is expected 
to spark new ideas and to motivate continued investigations in this emerging research area. 
2.2.1 Dendrimers 
The most extensively investigated subset of dendritic polymers, dendrimers, were first 
synthesized in a so-called divergent (core-first) fashion and were termed “cascade 
molecules” by Vögtle in 1978.84 The word “dendrimer”, coined by Tomalia in 1985 from 
the Greek words dendri (tree-branch-like) and meros (part), was first used in his paper on 
polyamidoamine (PAMAM) molecules.85 Since this first report, many compositions and 
surface modifications have been reported for dendrimeric materials. The two most widely 




2.2.1.1 Dendrimer Synthesis: Divergent and Convergent Methods 
Dendrimers have a core–shell structure with three distinct architectural components: a 
central core, an interior shell composed of repeating units, and terminal functional groups 
forming the outer shell. The strictly controlled structure of dendrimers results from the 
layered assembly of repeating units surrounding the core, which is obtained through 
sequential reaction cycles. This can be achieved in two different ways, namely by divergent 
(core-first) or convergent (arms-first) strategies as shown in Scheme 2.2. These syntheses 
involve repetitive stepwise growth and deprotection/activation protocols with careful 
purification steps for each generation. 
 




In the divergent growth method a multifunctional core is coupled with an excess of 
reagent containing at least two protected branching sites, followed by purification and 
removal of the protecting groups. The synthesis of PAMAM dendrimers by the 
condensation of amines with acrylates is provided in Scheme 2.3 to illustrate this strategy. 
An initiating core containing two or more amine functionalities is first reacted with an 
excess of methyl acrylate in a Michael addition, resulting in an alkyl ester branch for each 
amine proton. Amidation of the ester groups with a large excess of ethylenediamine yields 
the primary amine terminal groups of a ‘generation zero’ (G0) dendrimer. Each amino 
group in this branched molecule is again reacted sequentially with methyl methacrylate 
and ethylenediamine to yield the first-generation (G1) PAMAM dendrimer, and so on. 
Each reaction cycle yields dendrimers of successive generation numbers, with increasing 
size and molecular weight. 
 




Polyamidoamine or PAMAM dendrimers were the first dendritic materials 
commercialized, under the trade name Starburst®, and are likely the dendritic polymers 
most widely investigated to date. Dendrimers synthesized by the divergent approach 
require extensive purification at each reaction step, since a large excess of reagents is 
necessary to avoid defects in the structure due to incomplete reactions. This can be 
achieved by ultrafiltration or column chromatography. The divergent approach is currently 
the preferred strategy for the commercial production of dendrimers. 
In the convergent growth method, individual dendrons or dendrimer wedges are first 
synthesized by protection/coupling/deprotection strategies analogous to the divergent 
approach described above, but starting from the periphery of the molecules. When the 
growing dendrons have reached the desired size (generation), they are coupled with a 
multifunctional core to give a complete dendrimer. In convergent growth, a small number 
of reactive sites are involved at each step, which restricts the number of possible side 
reactions. Another advantage of this method over the divergent strategy is that the growth 
of the dendrons can be more easily monitored and controlled, since the dendrons are 
structurally simpler. Furthermore there is a larger difference in molecular weight between 
the starting material and the product, which enables straightforward separation of the 
reactants and the product. 
Newkome first reported a convergent dendron synthesis scheme in 1985 for the 
preparation of so-called arborol molecules, but the generation number and the molecular 
weight attained initially were very limited.86 Hawker and Fréchet subsequently developed 
another convergent approach in 1990,87 whereby they achieved the synthesis of polyether 
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dendrimers by coupling benzyl bromide with 3,5-dihydroxybenzyl alcohol (DHBA) to 
create dendrons (dendritic fragments) as shown in Scheme 2.4. Conversion of the G1 
dendritic benzyl alcohol to a benzylic bromide and further cycles of DHBA monomer 
coupling led to the following dendron generations. The dendritic fragments thus obtained, 
carrying a bromide functionality at their focal point, were finally coupled with a 
multifunctional core such as l,l,l-tris(4′-hydroxypheny1)ethane to obtain a symmetrical 
dendrimer. One of the most interesting advantages of the convergent method is the ability 
to obtain bifunctional dendrimers (e.g. Janus micelles) if dendrons containing functional 




Scheme 2.4. Synthesis of a Fréchet-type benzyl ether dendrimer by a convergent 
approach. 
The main drawbacks of both the divergent and convergent dendrimer synthesis schemes 
described above is that they are tedious and time-consuming. Fortunately, several 
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improvements have been suggested for these methodologies over the past years.89 The 
necessity for deprotection or activation steps was thus eliminated by introducing the 
concept of orthogonality, namely the use of functional groups reacting under different 
conditions.90 For example, an orthogonal coupling strategy was applied to the synthesis of 
a G6 dendrimer from AB2 monomer units containing two pairs of complementary coupling 
functionalities in just three steps.91 The most commonly employed reaction for that purpose 
is the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition (click reaction) between 
azides and primary acetylenes (CuAAC), selectively forming 1,4-disubstituted 1,2,3-




Scheme 2.5. Convergent approach toward triazole dendrimers. a) CuSO4 (5 
mol %), sodium ascorbate (10 mol %), H2O/tBuOH (1:1); b) 1.5 equiv NaN3, 
CH3COCH3/H2O (4:1). 
Unfortunately, complete removal of the copper (I) catalyst from the CuAAC reaction 
can be difficult, especially in the synthesis of dense (upper generation) dendrimers. 
Recently, Gonzaga et al. achieved the synthesis of upper-generation dendrimers in high 
yield, and with only water-soluble salt byproducts.94 The strategy was based on the metal-
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free cycloaddition of alkynes to azides with electron-deficient alkynes such as derivatives 
of acetylene dicarboxylate. The reaction between acetylenedicarboxylic acid and 2-
bromopropanol yielded an activated monomer that coupled with azides in a metal-free click 
reaction. More recently, click reactions were combined with orthogonal reactions to further 
improve dendrimer syntheses. For example, a combination of thiol–ene click addition (a 
reaction between a thiol and an alkene to form an alkyl sulfide) with esterification led to 
G5 dendrimers in only 5 steps.95 Furthermore, a combination of thiol–ene click chemistry 
(radical-mediated addition of thiols across double bonds) with SN2 nucleophilic 
substitution reactions was employed to synthesize multifunctional dendrimers from 
carbohydrate building blocks.96,97 In this approach (Scheme 2.6) Roy and coworkers 
reacted a glucose-based AB4 monomer (8), possessing four allyl groups and a N-(2-
(glucosyloxy)ethyl)-2-chloroacetamide group, with thioacetylated 16 in the presence of a 
slight excess of 1 M MeONa–MeOH solution, to obtain dendrimer 17 (containing 24 allyl 
groups) in high yield. A subsequent thiol–ene reaction between 17 and thiogalactoside 18 
provided glycodendrimer 19, with 24 sugar residues. The uniformity of the structure was 
confirmed by gel permeation chromatography, which clearly showed a symmetrical 
Gaussian pattern with a low PDI of 1.064. Very recently, the same group reported the 
synthesis of G3 dendrimers with 108, 180, and 252 hydroxyl surface groups using AB3, 
AB5 and AB7 hypermonomers, respectively.
98 The dendrimers were constructed using a 
combination of microwave-assisted highly efficient CuAAC and thiol–ene reactions not 
requiring protection and deprotection steps. Low polydispersity indexes (PDI) of 1.03-1.08 




Scheme 2.6. Synthesis of a dendrimer containing 24 galactoside groups.  
Reproduced from ref. 96, with permission from the Royal Society of Chemistry. 
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Dendrimers possess several features making them attractive as nanocarriers for drug 
delivery applications, among which the presence of open cavities allowing the 
encapsulation of poorly water-soluble drugs.99 For example, dendrimers based on glycerol 
and succinic acid were used to encapsulate 10-hydroxycamptothecin (10HCPT), a poorly 
water-soluble anticancer drug.100 The study showed that encapsulation not only increased 
cellular uptake of the drug 16-fold as compared to the free drug, but it also improved the 
cellular retention of 10HCPT. The inability of nanocarriers acting by simple physical 
entrapment to precisely control the rate of drug release has led to a shift in attention toward 
the covalent conjugation approach. In this case, the release kinetics of the drug from the 
dendrimer are governed by the nature of the chemical linkage used to couple the drug with 
the dendrimer. A wide range of linking strategies have been reported for that approach. For 
example, drugs can be linked to the dendritic scaffold through amide, hydrazone, ester, 
imine, carbamate or disulfide groups, as well as enzymatically cleavable peptide 
sequences.49 As a result, many researchers have attempted to develop new dendrimer 
systems taking advantage of their high density of functional groups for ease of drug 
conjugation. For instance, Kurtoglu et al. investigated the drug release properties of G4 
polyamidoamine (PAMAM) dendrimer–ibuprofen conjugates with ester, amide, and 
peptide linkers. The amide-linked conjugates were relatively stable against hydrolysis, 
whereas the ester-linked conjugates displayed pH-dependent release behavior.75 
The development of targeted drug delivery is urgently required to further increase 
therapeutic efficacy and reduce toxicity. This was addressed, for example, using 
multifunctional dendrimers conjugated with drugs, targeting moieties, and imaging agents 
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as drug delivery nanocarriers.101 A PAMAM G5 dendrimer possessing 128 primary amino 
groups on its surface was thus used to covalently attach fluorescein isothiocyanate (FITC, 
an imaging agent), folic acid (FA) to target folate receptors overexpressed in cancer cells, 
and methotrexate (MTX), an anticancer drug conjugated through an ester bond. The results 
demonstrated that the PAMAM dendrimers were suitable for the targeted delivery of 
chemotherapeutic molecules capable of killing cancerous cells. Stimuli-responsive drug 
nanocarriers are another approach to promote therapeutic efficacy and reduce toxicity by 
controlling drug release at target sites. Different stimuli have been considered in the 
development of smart dendrimers for drug delivery including specific enzymes, pH, 
temperature, and light. For instance, Zhang et al. prepared novel enzyme-sensitive 
dendrimer–doxorubicin conjugates for ovarian cancer therapy.102 They obtained 
PEGylated peptide dendrimer–DOX conjugate nanocarriers through a two-step copper-
catalyzed click reaction. The surface of the peptide dendrimer was modified with alkynyl 
groups twice. Azido-terminated PEG chains were first conjugated with a dendrimer via a 
click reaction, and then coupled with glycylphenylalanyl-leucylglycine tetra-peptide (Gly–
Phe–Leu–Gly, GFLG)-modified DOX on the surface of the dendrimer through a click 
reaction as shown in Scheme 2.7. The GFLG spacer served as an enzyme-responsive linker 
to connect the anticancer drug DOX to the PEGylated peptide dendrimer, to be cleaved by 
cathepsin B, overexpressed in tumor cells. The study showed higher antitumor activity for 




Scheme 2.7. Synthesis of a PEGylated dendrimer–GFLG–DOX conjugate.  
Reproduced from ref. 101, with permission from the Royal Society of Chemistry. 
Another study compared the anticancer activity of G4−paclitaxel dendrimers and 
PEG−paclitaxel conjugates. The data provided evidence that the G4−paclitaxel conjugate 
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enhanced the activity of the drug as compared to PEG−paclitaxel.103 These results further 
demonstrate the great potential of dendritic polymers as drug carriers. 
2.2.2 Hyperbranched Polymers 
As early as 1952, Flory developed a theory concluding that highly branched polymers 
could be synthesized by the polycondensation of an ABn-type monomer (n ≥ 2) for which 
only the A and B functional groups can react with each other.104 However it is only in 1988 
that the first experimental example of a hyperbranched polymer was reported by 
Gunatillake et al.105 Since then, hyperbranched polymers also gained much attention in 
both academia and industry due to their unique properties and ease of preparation. They 
are obtained in a single reaction step (Scheme 2.8), and hence are more readily available 
than other dendritic polymers such as dendrimers. 
 




The synthetic strategies used for hyperbranched polymers fall into two main categories. 
In the single-monomer methodology (SMM), hyperbranched polymers are directly 
synthesized by the polymerization of an ABn-type monomer, while in the double-monomer 
methodology (DMM), either two types of ABn monomers or an A2 + B3 monomer pair 
serves to generate the molecules. The SMM includes at least four specific approaches, 
depending on the reaction mechanism involved: The step-growth polycondensation of ABn 
monomers, self-condensing ring-opening polymerization (SCROP), self-condensing vinyl 
polymerization (SCVP), and proton transfer polymerization (PTP). The DMM can be 
further divided into two main subclasses based on the monomer pair and reaction pathway 
selected, namely the ‘A2 + B3’ approach and the couple-monomer methodology (CMM), 
which is a combination of the SMM and ‘A2 + B3’ schemes.
64 Hyperbranched polymers 
are closer to conventional polymers than dendrimers in terms of molecular weight 
distribution, which can even be broader than for linear polymers. Furthermore, for 
hyperbranched polymers the addition of each monomer takes place randomly, and thus a 
large number of geometrical isomers can be formed for a given molecular weight.64 
The synthesis of hyperbranched polymers carried out as one-pot reactions offers limited 
control over the molecular weight of the products, and ultimately leads to gelation. Another 
problem is that intramolecular side reactions such as cyclization resulting from 
“backbiting” processes are common in these systems. One technique developed to 
minimize the occurrence of side reactions is a slow monomer addition protocol, whereby 
the monomer is added throughout the reaction. This method was termed “concurrent slow 
addition”.106,107 Polyfunctional initiators used in batch reactions have also shown promise 
 
49 
in controlling the molecular weight and reducing the polydispersity index (PDI = Mw/Mn) 
of the product.106,108 
Kim and Webster reported the first example of a single-monomer polycondensation 
technique, using 3,5-dibromophenylboronic acid and aqueous sodium carbonate in the 
presence of a Pd catalyst.109 A representation of this reaction and the resulting 
hyperbranched structure obtained are shown in Scheme 2.9. 
 
Scheme 2.9. Hyperbranched polyphenylene synthesis by the single-monomer 
polycondensation method. 
The most versatile approach to hyperbranched polymer synthesis is likely the DMM, 
due to the wide range of monomers and chemical functionalities to which it can be applied. 
A hyperbranched analogue of the commercially available PAMAM dendrimers (HYPAM) 
was thus synthesized by a one-pot method as shown in Scheme 2.10.110 This approach can 
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be described as an A6 + B6 reaction of tris(2-aminoethyl)amine with tris(2-di(methyl 
acrylate)aminoethyl)amine. 
 
Scheme 2.10. Synthesis of hyperbranched PAMAM (HYPAM). 
In 1995, Fréchet et al.111 first reported the radical polymerization of monomers by the 
so-called self-condensing vinyl polymerization (SCVP) technique to synthesize 
hyperbranched polymers with numerous reactive groups.  This technique uses vinyl 
monomers also containing a pendant group that can be converted into an initiating moiety 
(represented as AB*), and thus can introduce branches in the polymer structure. Chain 
extension of the branched polymer with linear polymer chains can also be achieved by the 
atom transfer radical polymerization (ATRP) technique. The combination of these 
techniques can be used to produce hyperbranched polymers with various architectures and 
compositions, some of which may be promising as nanocarriers for drug delivery 
applications. For instance, Porsch et al. reported the synthesis of high molecular weight 
hyperbranched dendritic-linear polymer (HBDLP) hybrids in a two-step process via a 
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combination of self-condensing vinyl (co)polymerization (SCV(C)P) and atom transfer 
radical polymerization (ATRP; Scheme 2.11).102 A hydrophobic hyperbranched 
macroinitiator (HBMI) was first produced by SCV(C)P utilizing ATRP, with 1,1,1-tris(4-
(2-bromoisobutyryloxy)phenyl)ethane (TBBPE) as trifunctional ATRP initiator, and the 
inimer 2-(2-bromoisobutyryloxy)ethyl methacrylate (BBEMA) in combination with hexyl 
acrylate (HA). The active end groups were subsequently used to chain-extend the 
hyperbranched macroinitiators (HBMIs) with linear, hydrophilic poly(ethylene glycol) 
methacrylate (PEGMA) segments via ATRP, to form a high molecular weight amphiphilic 
HBDLP. The chain-extension reactions proceeded in a controlled manner, resulting in 





Scheme 2.11. Synthesis of hyperbranched dendritic-linear polymers by sequential 
SCV(C)P-ATRP and ATRP techniques.  
Reprinted with permission from “Porsch, C.; Zhang, Y.; Ducani, C.; Vilaplana, F.; Nordstierna, 
L.; Nyström, A. M.; Malmström, E. Biomacromolecules 2014, 15, 2235”. Copyright 2014 
American Chemical Society. 
The HBDLP served to encapsulate doxorubicin to achieve sustained delivery. In 
addition, one of the HBMIs was chain-extended with a fluorine-containing copolymer, so 
that the unimolecular micelles would have potential as theranostic nanoagents.  
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     The therapeutic efficacy of many anticancer drugs is limited by their poor 
penetration into tumors; targeted drug delivery is needed to address this challenge. 
Hyperbranched polymers are potentially useful as carriers for active drugs and, when 
coupled with targeting ligands, may further enhance the therapeutic efficacy and reduce 
the toxicity of the drugs. For example, arginylglycylaspartic acid (RGD) peptides are one 
of the promising ligands for targeting αvβ3 integrin, overexpressed in various cancer cells. 
Seleci et al.112 fabricated a tumor-targeting amphiphilic star-hyperbranched block 
copolymer derived from a hyperbranched substrate, namely hyperbranched poly(methyl 
methacrylate)-block-poly(2-hydroxyethyl methacrylate) (PMMA-b-PHEMA), as a 
targeted drug delivery nanocarrier. The copolymer was prepared via sequential visible 
light-induced self-condensing vinyl polymerization (SCVP) and conventional vinyl 
polymerization. This involved a manganese-based visible light photoinitiator system 
(Mn2(CO)10) in the copolymerization of methyl methacrylate (MMA) with 2-bromoethyl 
methacrylate (BEMA), possessing both polymerizable and initiating sites within its 
structure. The subsequent visible light-induced polymerization of HEMA in the presence 
of the hyperbranched PMMA macroinitiator resulted in the formation of amphiphilic 
PMMA-b-PHEMA copolymers, possessing a hydrophobic hyperbranched PMMA core 
and hydrophilic PHEMA chains. DOX was successfully encapsulated within these 
copolymer micelles. It was concluded that the RGD-mediated amphiphilic star-
hyperbranched block copolymers were more efficiently internalized by cells than star 
polymers without the targeting moiety on their surface. 
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While the physical entrapment of drugs by hyperbranched polymers has been 
successfully demonstrated, some limitations still exist for efficient drug encapsulation and 
controlled release by these systems. The major limiting issue is the relatively rapid and 
uncontrollable release of the drug from the hyperbranched polymer core. The preparation 
of covalently bonded hyperbranched polymer-drug conjugates stable in buffer solutions is 
the most obvious solution to this problem, and thus much research has focused on covalent 
drug attachment. Several types of covalent linker groups have been used to regulate drug 
release from HBP nanocarriers,49 as well as co-delivery systems based on HBP designed 
to promote therapeutic efficiency through synergistic effects. For example, Zhu and 
coworkers reported the covalent conjugation of a polyacylhydrazone (HPAH) 
hyperbranched polymer with DOX through acid-sensitive acylhydrazone bonds.113 
Subsequently, the autophagy inhibitor LY was loaded into the HPAH−DOX micelles core 
to yield an effective chemotherapeutic system for oral squamous cell carcinoma. The 
hyperbranched polymer HPAH was synthesized by the polycondensation of 2,3-
butanedione (BD) and 1-(2-aminoethyl)piperazine tripropionylhydrazine (AEPNHNH2), 
yielding a weight-average molecular weight (Mw) of 4.0×10
3 g/mol and a polydispersity 
index (PDI) of 1.6 (Scheme 2.12).114 Then HPAH−DOX was prepared by conjugation of 
DOX onto the surface of HPAH, through further condensation of its ketone functionality 
with the acylhydrazine groups. The study showed that DOX and LY were released in a 
controlled manner. Furthermore, the in vitro investigation revealed that, as compared to the 
HPAH−DOX micelles and a physical mixture of HPAH−DOX with LY, the LY-loaded 
HPAH−DOX micelles resulted in synergistic inhibition of tumor cell proliferation. This 
HBP-based stimulus-responsive co-delivery system for chemotherapy drugs and 
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autophagy inhibitors provides a promising platform for clinically applicable combination 
therapies. 
 
Scheme 2.12. Synthesis of HPAH–DOX and autophagy inhibitor LY-loaded HPAH-
DOX micelles.  
Reprinted with permission from “Saiyin, W.; Wang, D.; Li, L.; Zhu, L.; Liu, B.; Sheng, L.; Li, Y.; 
Zhu, B.; Mao, L.; Li, G.; Zhu, X. Molecular Pharmaceutics 2014, 11, 1662”. Copyright 2014 
American Chemical Society. 
Very recently, the same group synthesized redox-responsive hyperbranched polymer–
drug conjugates by coupling a thiol-functionalized hyperbranched polymer with thiol-
containing drugs.115 The HBP poly((S-(4-vinyl) benzyl Ś-propyltrithiocarbonate)-co-
(poly(ethylene glycol) methacrylate)) or poly(VBPT-co-PEGMA), with multiple thiol 
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groups, was synthesized by a one-pot reaction via reversible addition-fragmentation chain 
transfer (RAFT) copolymerization (Scheme 2.13). The branched poly(VBPT-co-PEGMA) 
substrate was obtained by RAFT copolymerization of a vinyl-containing trithiocarbonate 
RAFT agent and PEGMA with a weight-average molecular weight of 1.8×104 g/mol and a 
PDI around 2.0. The trithiocarbonate worked as both monomer and RAFT chain transfer 
agent. The trithiocarbonate terminal groups of poly(VBPT-co-PEGMA) were easily 
transformed into thiol groups using propylamine, to be coupled with the hydrophobic thiol-
containing anticancer drug 6-mercaptopurine (MP) by a thiol−disulfide exchange reaction, 
resulting in the formation of the poly(VBPT-co-PEGMA)-S-S-MP conjugate. 
 
Scheme 2.13. Synthetic route to poly(VBPT-co-PEGMA)-S-S-MP.  
Reprinted with permission from “Zhuang, Y.; Su, Y.; Peng, Y.; Wang, D.; Deng, H.; Xi, X.; Zhu, 
X.; Lu, Y. Biomacromolecules 2014, 15, 1408.”. Copyright 2014 American Chemical Society.  
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Since the concentration of glutathione (GSH), a thiol-containing tripeptide capable of 
reducing disulfide bonds in biological environments, is much higher in tumors than in 
normal tissues, the redox-responsive HBP–drug conjugate selectively released the drug at 
tumor sites and thus increased the anticancer drug efficacy. This redox-responsive HBP–
drug conjugate provides a promising platform for the delivery and controlled release of 
thiol-containing drugs or biological molecules. 
Given the broad range of synthetic techniques and potential applications reported for 
hyperbranched polymers, the reader is referred to excellent reviews for more details on the 
synthetic strategies, characterization, properties, functionalization, and potential 
applications of hyperbranched polymers as therapeutic agents.77,80,116 
2.2.3 Dendrigraft Polymers 
Dendrigraft polymers, referring collectively to arborescent and dendrimer-like star 
polymer structures, are the third and most recently reported subset of dendritic 
polymers.65,66 Whereas monomers are invariably employed in constructing dendrimers, 
reactive polymers serve as building blocks in successive grafting reactions for the synthesis 
of dendrigraft systems. Since a large number of coupling sites are randomly distributed on 
the grafting substrates, a rapid increase in molecular weight is observed per arborescent 
polymer generation and high molecular weight species are obtained in a few steps, while 
narrow molecular weight distributions (Mw/Mn < 1.1) are maintained in most cases. The 
closely related dendrimer-like star polymers, in contrast, have a terminally branched 
structure achieved through coupling sites strictly located at the chain ends of the previous 
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generation.117 As a result, a lower rate of molecular weight increase per generation is 
observed in these systems. Dendrigraft polymers have been synthesized by divergent (core 
first) approaches, including both grafting onto and grafting from methodologies, and by 
convergent (arms first) approaches, that are essentially grafting through methodologies. In 
the following section it is not intended to present a comprehensive overview of all the 
synthetic strategies developed to date, but rather to provide examples illustrating the 
potential of these materials in drug delivery applications. For a more detailed overview of 
the synthesis and properties of dendrigraft polymers, the reader is directed to a review by 
Teertstra and Gauthier.60 
2.2.3.1 Divergent Grafting Onto Strategy 
The divergent approach relies upon successive grafting reactions starting from a linear 
substrate (equivalent to the core in dendrimer syntheses) as illustrated in Scheme 2.14. The 
first examples of dendrigraft polymer syntheses, using grafting onto strategies, were 
reported independently by Gauthier and Möller65 and by Tomalia et al.66 in 1991. Gauthier 
and Möller achieved the synthesis of branched polystyrenes, denominated arborescent 
polymers, by anionic grafting, while Tomalia et al. used cationic grafting to obtain 
branched polyethylenimines called Comb-burst® polymers. The synthesis of these 
materials starts with grafting linear side chains onto a linear polymer substrate 
functionalized with coupling sites to yield a comb-branched (generation zero or G0) 
polymer. The introduction of further coupling sites on the G0 polymer and grafting with 




Scheme 2.14. General grafting onto scheme for the synthesis of arborescent polymers. 
The first example of the synthesis of arborescent polystyrene used chloromethyl 
coupling sites on the polystyrene substrates, and “living” polystyryllithium as side chains.65 
Repetition of the functionalization and grafting reactions as shown in Scheme 2.15 led to 
arborescent polymers of generations up to G3. To achieve a high grafting yield, it was 
necessary to “cap” the polystyryl anions with a single 1,1-diphenylethylene unit to suppress 
metal-halogen exchange reactions competing with coupling. To avoid the use of 
chloromethyl methyl ether, a potent carcinogen, a modified coupling method using acetyl 
coupling sites was subsequently developed by Li and Gauthier.118 It was also necessary to 
cap the polystyryl anions with a few 2-vinylpyridine units in that case, to minimize side 
reactions of the macroanions and increase the grafting yield. Repetition of acetylation and 





Scheme 2.15. Arborescent polystyrene synthesis by grafting onto chloromethylated 
polystyrene substrates. 
The grafting onto strategy developed for arborescent polystyrene was subsequently 
extended to the synthesis of different arborescent homopolymers of polyisoprene119 and 
polybutadiene,120 but also to graft copolymers potentially useful as drug nanocarriers such 
as arborescent polystyrene-graft-poly(2-vinylpyridine)121 and polystyrene-graft-
poly(methacrylic acid).122 Fully biocompatible arborescent polymers constructed from 
poly(γ-benzyl L-glutamate) (PBG) side chains were also synthesized recently via 
successive grafting reactions (Scheme 2.16).123 In this case linear PBG building blocks 
were obtained by the ring-opening polymerization of γ-benzyl L-glutamate N-
carboxyanhydride initiated by n-hexylamine. A fraction of the benzyl groups on a linear 
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PBG substrate were deprotected and coupled with linear PBG using N,N'-
diisopropylcarbodiimide and 1-hydroxybenzotriazole as coupling agents to give a 
generation zero (G0) arborescent PBG. Further partial deprotection and grafting cycles led 
to arborescent PBG reaching Mn > 10
6 g/mol and Mw/Mn = 1.06 for a G3 polymer. 
Amphiphilic PBG-based arborescent copolymers incorporating a hydrophilic shell of 
poly(ethylene oxide), polyglycidol or poly(glutamic acid), potentially very useful for drug 
release, have also been reported.124 Very recently, doxorubicin hydrochloride (DOX∙HCl) 
was loaded into hydrophilic arborescent poly(L-glutamic acid)-g-poly(ethylene oxide) 
copolymers via electrostatic interactions between the anionic polypeptide core and the 
cationic drug, to achieve a loading content of 14% w/w and a loading efficiency of 83%. 
Drug release from the loaded micelles was sustained over 1 month at 37 °C. The release 
rate was slow at physiological pH (7.4) but significantly increased at pH 5.5, mimicking 





Scheme 2.16. Synthesis of G0 arborescent PBG with a comb-branched structure. 
The arborescent polystyrene-graft-poly(2-vinylpyridine) copolymers were also tested 
as model drug delivery systems. Njikang et al. thus investigated the encapsulation in 
aqueous solutions of various polycyclic aromatic hydrocarbon (PAH) probes within the 
hydrophobic core of arborescent polystyrene-graft-poly(2-vinylpyridine) (PS-g-P2VP) 
unimolecular micelles with different structures.126 The study showed that the copolymers 
with a high polystyrene content were far better sorbents, albeit the capacity difference was 
less important for the less hydrophobic probes such as naphthalene. Variations in the 
structure of the unimolecular micelles also had a significant influence on the solubilization 
process: The highly hydrophobic probes were solubilized mostly in the hydrophobic core, 
while those of higher polarity remained in the ionic shell and the core-shell interfacial 
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region. The solubilization capacity of copolymers of similar composition was also lower 
for the higher generation samples, presumably due to their increased structural rigidity. In 
a subsequent study, the release characteristics of these systems loaded with indomethacin 
and lidocaine as model drugs were investigated.127 The in vitro release of indomethacin 
and lidocaine in dilute HCl solutions was sustained, with an initial burst followed by slower 
release. The arborescent PS-g-P2VP copolymers used in this investigation were obviously 
not biocompatible, and the in vitro test conditions were different from real biological 
systems. These results were nevertheless useful in showing that the solubilization and 
release characteristics of arborescent copolymers could be controlled through variations in 
their structure and composition, and to understand the influence of branching on the release 
profile.  
The efforts dedicated initially to the synthesis of dendrigraft polymers, namely the 
arborescent and Comb-burst® polymers, inspired many researchers to develop other 
strategies for the synthesis of related materials in recent years. A broad range of branched 
polymer architectures have been reported in the literature as a result of this, and the naming 
of these polymers likewise varied extensively. Selected examples of the different 
architectures reported, and a discussion of their potential as drug nanocarriers are provided 
below. 
Dendrigraft polymers can be designed to have a core-shell morphology, to behave like 
covalently bonded unimolecular micelles. These can be designed to have therapeutic drug 
carrying ability, to act as imaging agents, and may be functionalized with targeting ligands 
for a wide range of biomedical applications. For example, drug nanocarriers that also act 
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as imaging agents can be easily monitored in vivo to determine their biodistribution by 
fluorescence microscopy.70 Different strategies have been proposed to obtain fluorescent 
drug nanocarriers including the encapsulation or conjugation of organic dyes, and the use 
of inorganic fluorescent nanocarriers or other metallic nanoparticles.128 Yang et al. thus 
reported novel biodegradable photoluminescent polymers (BPLPs)129 that were used by 
Gong et al. to construct fluorescent multi-arm star amphiphilic block copolymer drug 
nanocarriers.130 This was achieved by first reacting citric acid with 1,8-octanediol, 
followed by condensation with L-cysteine via their carboxyl group to yield a hydrophobic 
fluorescent BPLP segment as shown in Scheme 2.17. In a second step, an amphiphilic 
linear block copolymer BPLP-PEG-cRGD was synthesized by conjugating the hydrophilic 
PEG segment with cRGD peptide, and then with the BPLP. Finally, fluorescent 
unimolecular micelles H40-BPLP-PEG-cRGD were obtained with a weight-average 
molecular weight of 1.6×105 g/mol and PDI of 1.43 by conjugating the BPLP-PEG-cRGD 
block copolymer with Boltorn® H40 (a 4th generation hyperbranched polymer) core 
through an esterification reaction. The successful encapsulation of DOX within the 
hydrophobic core was demonstrated by achieving a drug loading of 15.7 wt %. The multi-
arm star amphiphilic block copolymer H40-BPLP-PEG-OCH3/cRGD thus not only proved 





Scheme 2.17. Synthesis of fluorescent multi-arm star amphiphilic block copolymer 
H40-BPLP-PEG-OCH3/cRGD.  
Reprinted from ref. 129, with permission from John Wiley & Sons, Inc.  
One major limitation to the simple physical entrapment of a drug within the core of 
dendritic polymers is that it is difficult to precisely control the rate of drug release. This 
may lead to rapid drug release before the dendritic polymers reach their designated targets, 
and thus result in low therapeutic efficacy, apart from eliciting severe side effects.73 As 
mentioned earlier, much attention has been paid to covalent drug conjugation to further 
improve drug delivery efficacy. However, the covalent conjugation chemistry must be 
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carefully selected to allow bond cleavage and release of the drug molecules under specific 
biological conditions. For instance, water-soluble and pH-responsive star polymers 
analogous to the dendrimer-like systems, including imaging probes, were obtained for the 
treatment and/or visualization of solid tumors.131 The star polymer nanocarriers were 
prepared by coupling semitelechelic or heterotelechelic N-(2-
hydroxypropyl)methacrylamide copolymers containing thiazolidin-2-thione end groups 
with the terminal amino groups of PAMAM dendrimers. Controlled radical RAFT 
polymerization was used for the synthesis of a multivalent copolymer of N-(2-
hydroxypropyl)methacrylamide with a Boc-protected hydrazide group-bearing monomer 
(copolymers 1 and 2 in Scheme 2.18). The anticancer drug DOX was then attached via pH-
sensitive hydrazine linkages. Finally dibenzocyclooctyne (DBCO), a fluorescent dye, was 
conjugated with the star polymer by a copper-free click reaction. The study demonstrated 





Scheme 2.18. Synthesis of star copolymers prepared by RAFT polymerization. 
2.2.3.2 Divergent Grafting From Strategy 
The divergent grafting from method starts with a substrate acting as a multifunctional 
initiator, from which polymer chains are grown. Unfortunately, in most cases it is difficult 
to characterize the structure of the graft polymers generated by this approach, and the 
molecular weight distribution of the products is generally broad; thus this method has 
received less attention than the grafting onto strategy. In spite of these limitations, this 
approach has allowed the synthesis of novel dendritic polymers inaccessible by other 
methods. The first example of this methodology was reported in 1995 by Six and Gnanou 
for the synthesis of dendrimer-like star poly(ethylene oxide) through a strictly controlled 
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terminal branching process.132 This involved the synthesis of a star polymer, and 
conversion of the terminal groups to a difunctional initiator to allow chain extension for 
the synthesis of the next generation. They also obtained amphiphilic and water-soluble 
dendrimer-like star polymers by similar strategies.133-135 The preparation of a dendrimer-
like star polymer incorporating three poly(ethylene oxide) and six poly(acrylic acid) side 
chains by a combination of living anionic polymerization of ethylene oxide (EO) and 
subsequent atom transfer radical polymerization (ATRP) of tert-butyl acrylate, followed 
by hydrolysis, is provided in Scheme 2.19 to illustrate this strategy. 
 
Scheme 2.19. Synthesis of a dendrimer-like star copolymer with a poly(ethylene 
oxide) core and poly(acrylic acid) side chains. 
In comparison to traditional linear polymers, dendritic polymers have a large number 
of functional groups – on the surface of the dendritic core, along or at the end of the 
polymer-forming arms – which can be used for two, or even more different tasks such as 
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to deliver a drug, to serve as a targeting agent, and as a probe for imaging. Thus the 
construction of multifaceted dendritic polymers – also called Janus micelles – with 
different types of peripheral groups to perform multiple functions is in high demand for 
biomedical applications. Recently, Gnanou and coworkers constructed Janus-type 
dendrimer-like poly(ethylene oxide) molecules (PEOs) of three generation carrying 
terminal hydroxyl groups on one side and cleavable ketal groups on the other, that were 
conjugated with folic acid (FA) to target folate receptors, and subsequently used to 
encapsulate camptothecin (CPT) as a therapeutic agent (Figure 2.10).136 The conjugation 





Figure 2.10. Structure of three Janus-type dendrimer-like PEOs used for 
conjugation.  
Reprinted from ref. 135, with permission from John Wiley & Sons, Inc. 
Structural variables such as the size and porosity of dendrigraft polymers can be 
designed to meet specific requirements for drug delivery applications. For example, the 
loading and release properties of these materials can be tailored by adjusting the 
composition, the branching density and the size of the side chains in the core and the 
corona. Very recently, Libera et al. evaluated the effects of macromolecular composition 
and structure on the encapsulation efficiency. They synthesized dendritic copolymers 
containing a hydrophobic core of poly(tert-butyl glycidyl ether) of controllable density, 
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and a hydrophilic polyglycidol shell with a comparable molar mass and number of 
hydroxyl groups by anionic sequential polymerization.137 The poorly water-soluble 
ruthenium complex Ru(NH3)3Cl3, a potential anticancer drug, was either encapsulated 
within the hydrophobic core of the nanoparticles by entrapment from a suspension in water 
or water/methanol mixtures, or bound to the polymer shell by complexation with the 
hydroxyl groups. The solubilization capacity of two dendritic copolymers with different 
core densities did not differ significantly, but interestingly, the copolymer with the lower 
molar mass and smaller hydrodynamic radius core had a higher encapsulation efficiency 
in both encapsulation methods. 
One advantage of dendritic nanocarriers is that they can be designed as delivery systems 
for combined drugs, to maximize their therapeutic effect on tumors. Thus He et al. prepared 
a unimolecular micelle-like multilayered nanocarrier (PPDP) based on polyamidoamine 
(PAMAM) dendrimers as dual drug (paclitaxel and doxorubicin) containers, by combining 
a layer of hydrophobic oligo(3-caprolactone) (PCL) with hydrophilic PEGylated 
amidoamine dendrons within each molecule (Scheme 2.20).138 Two nanocarrier variations 
were examined, either by encapsulating DOX and PTX in the different layers of the carrier 
(PPDP-enc-DOX + PTX), or by conjugating DOX through a pH-sensitive linkage on the 
exterior and encapsulating PTX in the core of the nanocarrier (PPDP-coj-DOX-enc-PTX) 
as shown in Scheme 2.20. The study showed that for both systems, the release of PTX was 
achieved in a sustained manner over 48 h in vitro. The DOX release profile displayed a 
burst for the PPDP-enc-DOX + PTX system, while for the PPDP-coj-DOX-enc-PTX 
system the DOX release profile was sustained. Both systems displayed higher cytotoxicity 
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towards MCF-7/ADR and MCF-7 cells than free DOX and PTX alone, due to the 
synergistic effect of the drugs. 
 
Scheme 2.20. Synthesis of PAMAM dendrimer-based multilayered drug delivery 
systems.  
Reproduced from ref. 137, with permission from Royal Society of Chemistry. 
Dendrimer-like star polymers are typically composed of a hydrophobic star polymer 
core and a shell of hydrophilic arms, which makes them very attractive for drug delivery 
applications. Their large number of surface functional groups can serve not only to 
conjugate drugs, but also ligand molecules for targeted delivery. For instance, a folate-
functionalized degradable amphiphilic dendrimer-like star polymer (FA-DLSP) 
incorporating a well-defined poly(L-lactide) (PLLA) star polymer as hydrophobic core and 
six hydrophilic polyester dendrons based on 2,2-bis(hydroxymethyl)propionic acid 
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forming a hydrophilic shell was successfully synthesized by a combination of living ring-
opening polymerization (ROP) of L-lactide and dendrimer synthesis.139 To further enhance 
the water solubility of the unimolecular micelles, their surface was functionalized with 
carboxylic acid groups that were coupled with PEG segments (Scheme 2.21), and then with 
folate groups. The hydrophobic anticancer drug DOX was successfully encapsulated into 
the hydrophobic core of the micelles, with a drug loading of 4 wt% as determined by 
spectroscopic analysis. The in vitro release study showed that release of the encapsulated 
DOX was strongly pH-dependent: DOX was released more rapidly at pH 5.3 than that at 
pH 7.4, because of the higher solubility of DOX in water at lower pH. Cellular uptake 
studies showed that the FA-DLSP micelles had greater cellular uptake than FA-deficient 
DLSP. The above results suggest that the FA-DLSP unimolecular micelles may be 
promising nanocarriers for targeted cancer therapy. 
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Scheme 2.21. Synthesis of a folate-functionalized dendrimer-like star polymer, FA-
DLSP.  
Reprinted with permission from “Cao, W.; Zhou, J.; Mann, A.; Wang, Y.; Zhu, L. 
Biomacromolecules 2011, 12, 2697”. Copyright 2011 American Chemical Society. 
2.2.3.3 Convergent Grafting Through Strategy 
Puskas et al.140 developed the first convergent cationic polymerization strategy to 
synthesize arborescent isobutylene homopolymers in a single reaction pot. This was 
achieved by the cationic copolymerization of isobutylene with a small amount of an inimer 
such as 4-(2-methoxyisopropyl) styrene to yield a “living” branched polymer structure with 
multiple cationic active sites at the chain ends, which were subsequently used to initiate 




Scheme 2.22. One-pot synthesis of hyperbranched polyisobutylene with polystyrene 
end-blocks. 
The approval of polystyrene-b-polyisobutylene-b-polystyrene linear triblock 
copolymers by the Food and Drug Administration (FDA) as a coating material on the 
Taxus® coronary stent has opened a new door for polyisobutylene-based biomaterials. For 
instance, Puskas and Hoerr also studied drug release from arborescent polyisobutylene with 
polystyrene end blocks. ElectroNanosprayTM, a proprietary technology for coating 
materials on the surface of medical devices, was used to coat coronary stents with 
arborescent polyisobutylene-b-polystyrene loaded with Dexamethasone, a model drug. The 
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study showed that the drug release profiles were influenced by both the molecular weight 
of the dendritic polyisobutylene-b-polystyrene scaffold and by the spraying conditions 
used for the polymer-drug mixture.142 
Characteristics such as the size and porosity of amphiphilic dendrigraft copolymers can 
be designed to meet specific requirements for drug delivery applications by adjusting their 
composition, branching functionality, generation number, and the size of the side chains in 
their core and corona. Internal functionality can be introduced easily within the repeating 
units in many cases. Furthermore, as mentioned earlier, dendrigraft copolymers can be 
produced in one-pot reactions in some cases with very high molecular weights and 
relatively narrow molecular weight distributions. As a result, dendrigraft polymers seem to 
represent a good compromise solution between achieving a low dispersity comparable to 
dendrimers and maintaining a reasonably low production cost. We therefore believe that 
these materials have great potential in drug delivery applications. 
2.3 Conclusions 
Drug delivery systems overcome the limitations of traditional chemotherapy by 
improving its efficacy and safety through controlling the rate, time, and place of release of 
drugs in the body. A broad range of drug delivery systems have been developed over the 
last 10 years. Among these systems, polymeric micelles including amphiphilic block 
copolymers micelles, unimolecular micelles and crosslinked micelles have been shown to 
improve drug bioavailability, enhance their aqueous solubility, increase the circulation 
time of drugs in the blood, and allow their delivery to a specific target. In this context, 
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polymeric micelles with tunable properties have shown a great promise and are in the front 
line of development for drug delivery systems. 
Dendritic polymers are a unique and versatile class of branched polymers ideal for a 
number of high value applications, and particularly for drug delivery. Numerous methods 
have been reported to synthesize dendritic polymers while achieving control over the 
characteristics of the polymers, to achieve desirable properties or functionality. While the 
commercialization of dendrimers has been restricted by their tedious and costly synthesis, 
the one-pot syntheses reported for hyperbranched and dendrigraft polymers make these 
materials more viable for (large scale) commercial production and applications. The field 
of dendritic drug delivery nanocarriers has rapidly evolved over the past decade, with an 
increasing number of candidates currently being under clinical evaluation. A wide range 
of dendritic polymer architectures and chemistries are currently being developed 
specifically for drug delivery applications. The collaboration between polymer chemists, 
medicinal and pharmaceutical scientists, and clinicians is critical for the development of 




 Synthesis Optimization 





Polypeptides are receiving increasing attention as building blocks to create 
nanostructures for biomedical applications. The goal of this investigation was to explore 
the influence of the reaction conditions in the synthesis of well-defined dendritic graft 
(arborescent) polypeptides from amine-terminated poly(γ-benzyl L-glutamate) (PBG) 
chains. The ring-opening polymerization of γ-benzyl L-glutamate N-carboxyanhydride 
(Glu-NCA) was initiated by different initiators to yield linear PBG building blocks. 
Cleavage of a fraction of the benzyl groups on a linear PBG substrate and coupling with 
linear PBG side chains using a carbodiimide reagent yielded a comb-branched or 
generation zero (G0) arborescent PBG. The optimization was carried out in terms of the 
reaction temperature, solvent, reaction time, and mole ratio of reactants and coupling 
agents. Two carbodiimide reagents, namely N,N′-diisopropylcarbodiimide (DIC) and 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) in combination 
with 1-hydroxybenzotriazole (HOBt) as a coupling additive were used to increase the 
reactivity of the carboxyl groups. The graft polymers were characterized by size exclusion 
chromatography (SEC) and NMR spectroscopy analysis. Size exclusion chromatography 
served to evaluate the grafting reaction in terms of grafting yield (fraction of side chains 
coupled with the substrate) and coupling efficiency (fraction of coupling sites consumed 
on the substrate). The maximum grafting yield and coupling efficiency achieved under the 




Dendritic polymers are a type of macromolecules characterized by a highly branched 
tree-like architecture, incorporating multiple branching levels, resulting from coupling 
reactions of either small molecule monomers (hyperbranched polymers and dendrimers), 
or macromolecular building blocks (dendrigraft polymers).1,2 The unique structure and 
interfacial features of dendritic polymers make them suitable for biomedical applications 
such as nanocarriers for drugs, genes and diagnostic agents.3-5 Dendrigraft polymers 
(referring collectively to arborescent and dendrimer-like star polymer structures) are the 
third and most recently reported subset of dendritic polymers.6,7 Whereas monomers are 
invariably employed in constructing dendrimers, reactive polymers serve as building 
blocks in successive grafting reactions for the synthesis of dendrigraft molecules. Since a 
large number of coupling sites are randomly distributed on the grafting substrates, a rapid 
increase in molar mass is observed for each arborescent polymer generation while a narrow 
molar mass distribution (Mw/Mn < 1.1) is maintained. 
Polypeptides are receiving increasing attention as building blocks to construct 
nanostructures for biomedical applications such as micelles.8 The development of synthetic 
polypeptides with tunable dendritic topologies and well-defined structures is therefore of 
great interest. Peptides are commonly synthesized by sequential coupling of the carboxylic 
group of one amino acid with the amino group of another amino acid as shown in Scheme 




Scheme 3.1. General peptide coupling reaction. 
Peptide coupling is performed in the presence of coupling reagents, which allows the 
reaction to occur under mild conditions while minimizing side reactions. Carbodiimide 
reagents such as N,N'-dicyclohexylcarbodiimide (DCC) and N,N′-diisopropylcarbodiimide 
(DIC) have been widely used, and are still in use today to activate the carboxylic acid group 
of amino acids.12 Some of the reagents commonly used in peptide coupling are shown in 
Figure 3.1.10 
 
Figure 3.1. Commonly used carbodiimide reagents. 
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The general mechanism of activation by carbodiimides is shown in Scheme 3.2. The 
initial step is the addition of the carboxylic group of the amino acid to the carbodiimide to 
form an O-acylisourea, a species that rapidly reacts with amine groups to yield a peptide 
bond and produces the corresponding urea as a by-product (path A, Scheme 2.3). The O-
acylisourea may also undergo attack by a second acid group to give the symmetrical 
anhydride, if an excess of carboxylic acid is used (path B, Scheme 2.3). The anhydride can 
also react with the amine to give the peptide. Furthermore, an undesirable rearrangement 
of the highly reactive O-acylisourea may occur (path C, Scheme 2.3) to give a highly stable 
N-acylurea. The high reactivity of carbodiimides allows fast reactions, however its use 





Scheme 3.2. Activation of an amino acid by a carbodiimide and side product 
formation. 
Nowadays, most peptide bond-forming reactions are done in the presence of additives 
such as 1-hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole (HOAt) to 
inhibit side reactions.14-16 These additives react with the O-acylisourea to form the 
corresponding active esters that are less reactive than O-acylisourea. These additives also 
increase the efficiency of carbodiimide-mediated reactions by preventing the formation of 




Scheme 3.3. Activation of an amino acid by onium reagents such as HOBt and 
HOAt. 
One of the most facile routes to the preparation of polypeptides is through the 
polymerization of α-amino acid N-carboxyanhydrides (NCAs). Our laboratory used this 
latter approach for the synthesis of well-defined (Mw/Mn<1.07) arborescent polypeptides 
using poly(γ-benzyl L-glutamate) (PBG) building blocks. Molar masses reaching 1.1×106 
were thus obtained, but the grafting yield (fraction of side chains reacted) and the coupling 
efficiency (fraction of coupling sites reacted) for this system were limited to 62% and 41%, 
respectively.17 Considering that every peptide is susceptible to different side reactions, it is 
impossible to develop a universal procedure for the synthesis of these materials.  
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One of our goals was to further optimize the grafting yield and the coupling efficiency 
in the synthesis of arborescent polypeptides derived from PBG. Different carbodiimide 
coupling reagents and additives were investigated to promote the availability of the amino 
termini and/or to increase the reactivity of the carboxyl groups in the coupling reaction. 
The optimization was also carried out in terms of the reaction temperature, solvent, reaction 
time, and mole ratio of reactants and coupling agents. Size exclusion chromatography 
(SEC) analysis served to evaluate the grafting reaction in terms of grafting yield and 
coupling efficiency. The arborescent polypeptides thus obtained can serve as intermediates 
in the preparation of unimolecular micelles, potentially useful for controlled drug delivery 
applications. 
3.3 Experimental Procedures 
3.3.1 Characterization and Sample Preparation 
Proton nuclear magnetic resonance (1H NMR) spectroscopy was used to estimate the 
degree of polymerization of linear poly(γ-benzyl L-glutamate) (PBG), and to determine the 
deprotection level of the PBG substrates. The instrument used was a Bruker 300 MHz 
spectrometer. Fluorine Nuclear Magnetic Resonance 19F NMR spectroscopy on the same 
instrument was used to determine the chain end primary amine functionality level, fNH2, of 
the polymers used in the grafting reactions. 
Analytical SEC was used for the characterization of the PBG substrates, the PBG side 
chains, the crude reaction products, and the purified graft polymers. The analytical SEC 
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system consisted of a Waters 510 HPLC pump, a 50 μL injection loop, a Waters 2410 
differential refractometer (DRI) detector, and a MiniDAWN laser light scattering detector 
operating at a wavelength of 690 nm, to allow the determination of the absolute molecular 
weight of the samples. A Jordi DVB Mixed-bed Linear column (500 mm × 10 mm, 
molecular weight range 102 – 107 g/mol) was used for the separation. The system was 
operated at a flow rate of 1 mL/min at room temperature (25 ˚C), using N,N-
dimethylformamide (DMF) with LiCl (1 g/L) as the mobile phase. 
Preparative SEC was carried out on a system consisting of a Waters M45 HPLC pump, 
a 2 mL sample injection loop, a Waters R401 differential refractometer detector, and a 
Jordi Gel DVB 1000 Å, 250 mm × 22 mm preparative SEC column. N,N-
Dimethylformamide with 0.2 g/L LiCl served as the mobile phase. The concentration of 
the crude polymer injected was around 25 mg/mL. The system was operated at a flow rate 
of 3 mL/min at room temperature (25 ˚C). 
3.3.2 Solvent and Reagent Purification  
Dimethyl sulfoxide and n-hexylamine were purified by stirring overnight with CaH2 
and distillation under reduced pressure. N,N’-Dimethylformamide serving in the polymer 
synthesis (DMF; Aldrich, >99%), 3-amino-1-propanol and 5-amino-1-pentanol were 
purified by distillation under reduced pressure. Ethyl acetate (Fisher, 99.9%) was distilled 
from LiAlH4 under nitrogen. γ-Benzyl L-glutamic acid (Bz-Glu; Bachem, >99%), diethyl 
ether (EMD Millipore OmniSolv), HBr solution (Aldrich, 33% in acetic acid), N,N’-
diisopropylcarbodiimide (DIC; Aldrich, 99%), triphosgene (Aldrich, 98%), 1-ethyl-3-(3-
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dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl), 1-hydroxybenzotriazole 
(HOBt; Fluka, water content ca. 15% w/w), tetrahydrofuran (THF, EMD Millipore 
OmniSolv), methanol (EMD Millipore OmniSolv), trifluoroacetic acid (TFA, Caledon, 
99.9%), LiAlH4 (Aldrich, 95%), acetic anhydride (Caledon, 97%), deuterated DMSO 
(DMSO-d6, Cambridge isotopes, 99.9% D), and triethylamine (TEA, EMD) were used as 
received from the suppliers. 
3.3.3 Synthesis of γ-Benzyl L-Glutamic Acid N-Carboxyanhydride (Glu-
NCA) 
The monomer was synthesized from γ-benzyl L-glutamic acid and triphosgene as 
described in the literature.18 γ-Benzyl L-glutamic acid (Bz-Glu) (10.0 g; 42.0 mmol) was 
dissolved in 300 mL of freshly distilled ethyl acetate in a 1-L round-bottomed flask fitted 
with a reflux condenser and a N2 bubbler. After heating to reflux, triphosgene (4.8 g, 16 
mmol) was added at once and refluxing was continued for 3.5 h longer. The reaction was 
allowed to cool to room temperature, and then stored in a refrigerator (5 ˚C) for 2 h. The 
cold reaction mixture was transferred to a cold separatory funnel, washed with 100 mL of 
distilled water chilled to 0 ˚C, and 100 mL of chilled 0.5% aqueous NaHCO3 solution. The 
ethyl acetate layer was dried over anhydrous MgSO4, filtered by gravity, and concentrated 
to 100–120 mL on a rotary evaporator. An equal volume of cold hexane was then added to 
induce crystallization of the monomer. After chilling to -5 ˚C overnight, the monomer 
crystals were collected by filtration in a Schlenk funnel under N2. For further purification, 
in some cases, the obtained monomer was recrystallized twice from n-hexane and ethyl 
acetate (n-hexane/ethyl acetate v/v: 2/1), to remove the last traces of HCl and remaining 
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impurities. The product was dried under vacuum and stored under N2 in a freezer until 
used. Yield = 9.7 g (88 %); 1H NMR (300 MHz, CDCl3): 7.55–7.22 (s, 5H), 6.72 (s, 1H), 
5.09 (s, 2H), 4.35–4.31 (t, 1H), 2.57–2.51 (t, 2H), 2.33–2.19 (m, 1H), 2.18–2.00 (m, 1H). 
3.3.4 Synthesis of Poly(γ-benzyl L-glutamate) PBG Serving as Side Chains 
A linear polymer serving as side chain material was synthesized as described 
previously.17 Briefly, γ-benzyl L-glutamate N-carboxyanhydride (Glu-NCA, 12.5 mmol) 
was dissolved in dry DMF (8 mL) at 0 ˚C. n-Hexylamine (0.50 mmol, for a target Xn = 25) 
was then added to the monomer and the reaction was allowed to proceed for 3 days at 0 ˚C. 
The linear polymer was recovered by precipitation in cold methanol, centrifugation, and 
drying under vacuum overnight before characterization. Yield = 83%, Mw/Mn = 1.09. 
1H 
NMR (300 MHz, DMSO-d6): Xn = 24.0, δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–4.88 (s, 
2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 4H), 1.31–1.15 (b, 0.4H), 0.76–0.74 (s, 0.12H). 
3.3.5 Synthesis of Poly(γ-benzyl L-glutamate) PBG Serving as Substrate 
The Glu-NCA monomer (8.00 mmol) was dissolved in dry DMF (6.00 mL) and n-
hexylamine (0.16 mmol, for a target Xn = 50) was added. The reaction was allowed to 
proceed for 4 h at room temperature. Then the reaction was quenched with acetic anhydride 
(310 μL, 3.26 mmol) to deactivate the terminal amine moiety. After 1 h the product was 
precipitated in cold methanol, centrifuged and dried under vacuum overnight before 
characterization. Yield = 90%, Mw/Mn = 1.19. 
1H NMR (300 MHz, DMSO-d6): Xn = 49.0, 
δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–4.88 (s, 2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 4H), 
1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 0.06H). 
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3.3.6 Synthesis of Partially Deprotected Linear PBG Substrate   
A linear PBG sample with Xn = 49 (1.10 g, 5.02 mmol Bz-Glu units) was dissolved in 
TFA (11 mL) and 0.31 mL of 33% (w/w) HBr solution in acetic acid was added. The 
reaction was stirred for 3 hours before the polymer was precipitated in diethyl ether and 
recovered by suction filtration, to yield a polymer with 29 mol % of free glutamic acid 
moieties. Yield = 0.65 g (69%). 
3.3.7 Synthesis of G0 Arborescent PBG 
In a typical coupling reaction, the partially deprotected polymer substrate (0.21 g, 0.312 
mmol -CO2H) and the polymer serving as side chains (1.67 g, 0.31 mmol chains) were 
dissolved in 15 mL of dry DMSO. The peptide coupling reagents DIC (0.24 mL, 1.56 
mmol) and HOBt (0.21 g, 1.56 mmol) were then added to the reaction with TEA (0.22 mL, 
1.56 mmol) as a base. The reaction was allowed to proceed for 36 h at room temperature 
before adding n-hexylamine (0.19 mL, 1.87 mmol), to deactivate residual activated 
carboxylic acid sites. After 3 h, the product was precipitated in cold methanol and 
recovered by suction filtration. Unreacted side chain material was removed from the G0 
crude polymer by preparative size exclusion chromatography (SEC). 
3.3.8 Quantification of Primary Amines by 19F NMR Analysis 
19F NMR spectroscopy was used to determine the chain end primary amine 
functionality level, fNH2, of the linear polymers used in the grafting reactions as described 
in literature.19 The PBG sample (0.10 g, 1.72×10-5 mol chains) was first dissolved in 3 mL 
of deuterated DMSO (DMSO-d6). A solution of 4-trifluoromethylbenzaldehyde (TFBA, 
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0.0901 g, 5.17×10-4 mol) and benzotrifluoride (α,α,α-trifluorotoluene, BTF, 0.0756 g, 
6.16×10-4 mol) in 2 g of DMSO-d6 was then prepared, and 0.1706 g of that reagent solution 
(4.563×10-5 mol TFBA, 4.531×10-5 mol BTF) was added to the PBG solution which was 
stirred for 2 h before it was transferred to an NMR tube for analysis.   
3.4 Results and Discussion 
3.4.1 Synthesis of Monomer (Glu-NCA) 
The synthesis of α-amino acid N-carboxyanhydrides (NCAs) is a key step in the 
synthesis of the polypeptides used in this work. This requires a high monomer purity, in 
addition to a good yield in this first synthetic step. There are three main procedures for the 
synthesis of NCAs in the literature, namely the Leuchs and the Fuchs-Farthing methods. 
The Leuchs technique is based on the cyclization of N-alkoxycarbonyl amino acid halides, 
while the Fuchs-Farthing approach, based on the direct phosgenation of unprotected α-
amino acids, is most convenient due to the ease of removal of by-products.20,21 Phosgene, 
a highly toxic gas, was the reagent initially used in that protocol, but triphosgene was 
subsequently suggested as an alternative, economically viable, and solid material much 
safer to manipulate.22 The preferred approach to prepare the Glu-NCA monomer in the 
current investigation was using triphosgene in ethyl acetate, with monomer purification as 
suggested by Poché et al. and as shown in Scheme 3.4.18 The initially turbid solutions 
became clear during the reaction, due to the conversion of the poorly soluble amino acid 
into the more soluble Glu-NCA monomer. The Glu-NCA monomer thus obtained was 
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purified by repeated recrystallizations from n-hexane and ethyl acetate, to remove the last 
traces of HCl and remaining impurities, yielding a white crystalline material. 
 
Scheme 3.4. Synthesis of γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-NCA).   
Figure 3.2 shows the 1H NMR spectrum obtained for Glu-NCA in CDCl3, with 




Figure 3.2. 1H NMR spectrum for Glu-NCA.   
3.4.2 Synthesis of PBG Serving as Side Chains 
The polymerization of Glu-NCA monomers has been widely investigated in recent 
years. The polymers are usually prepared through amine-initiated ring-opening 
polymerization (ROP) of the corresponding monomers at room temperature.23 
Unfortunately, PBG synthesized by this method is sensitive to chain termination through 
chain end cyclization resulting from the intramolecular nucleophilic attack of the terminal 
amino group on the benzyl ester functionality (Scheme 3.5). This can lead to uncontrollable 
molecular weights, broad molecular weight distributions, and most importantly for the 
current investigation, to the loss of the primary amine end group.24-26 The amine terminus 
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on the PBG side chains should be preserved not only during the ring-opening 
polymerization of Glu-NCA, but also during sample workup and storage. It was reported 
that side reactions in the polymerization of NCAs could be eliminated, while also 
preserving the primary amine chain end of PBG, by lowering the reaction temperature.27,28 
Recently, Whitton and Gauthier reported the synthesis of well-defined (Mw/Mn<1.07) PBG 
with high amine functionality levels (fNH2 reaching 98%), using n-hexylamine as initiator  
at 0 ˚C.17 End group cyclization in the polymerization reaction was also investigated to 
some extent. 
 
Scheme 3.5. Chain termination of linear PBG by end group cyclization. 
In the current investigation, PBG with a “living” amino end group was synthesized by 
the ring-opening polymerization of Glu-NCA in N,N-dimethylformamide (DMF) at 0 ˚C 
or at 25 ˚C, using different primary amine initiators. Confronted to the difficulty of 
achieving a high grafting yield and coupling efficiency in the preparation of arborescent 
polypeptides using the peptide coupling reaction, an initiating system was sought that 
would provide control over the ROP of Glu-NCA and include both a primary amine (for 
initiation) and an alcohol functional group (for coupling via an esterification reaction), in 
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addition to n-hexylamine used previously. Steglich esterification is a widely used method 
under mild conditions, resulting in the condensation reaction of carboxylic acids and 
alcohols to form esters.29 The reaction usually utilizes N,N'-dicyclohexylcarbodiimide 
(DCC) as a coupling reagent and 4-dimethylaminopyridine (DMAP) as a catalyst (Scheme 
3.8B). Three different amine initiators were therefore investigated for the polymerization 
of Glu-NCA, namely n-hexylamine, 3-amino-1-propanol and 5-amino-1-pentanol (Scheme 
3.6). Despite the presence of the –OH group in the amino alcohol initiators, the 
nucleophilicity of the primary amine in the ring-opening polymerization of the Glu-NCA 
monomers should be comparable, and thereby the initiation of the ring-opening reaction 
should proceed similarly. The polymerization of Glu-NCAs with 3-amino-1-propanol and 
5-amino-1-pentanol was conducted under conditions identical to n-hexylamine. As shown 
in Table 3.1 the initiators, under identical conditions, exhibited different behaviors in the 
ROP of Glu-NCA. Among these, n-hexylamine gave the best control over the 
polymerization reaction by yielding PBG with the expected molecular weight and the 




Scheme 3.6. Polymerization of γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-
NCA) using primary amine initiators. 
Table 3.1. Synthesis of PBG using different initiators. 






(SEC) PDI fNH2 
n-hexylamine  20 4,900 4,880 1.11 97 
3-amino-1-
propanol 
18 4,200 4,700 1.18 87 
5-amino-pentanol  18 4,300 3,500 1.22 83 
All polymerizations carried out at 0 ˚C with a target Xn = 20.  
Indeed, the polymerization initiated by n-hexylamine yielded PBG with a degree of 
polymerization Xn = 20 for a monomer/initiator ratio M/I = 20, in excellent agreement with 
the targeted Xn = 20. Furthermore, n-hexylamine yielded PBG with a low polydispersity 
index (PDI = 1.11) and a high amine functionality level (fNH2 = 97%, Figure 3.3). The 
19F 
NMR spectroscopy technique used to determine the chain end primary amine functionality, 
 
96 
fNH2, will be discussed further in Section 3.4.3. Control of polymerization can be achieved 
only when the polymer end group is the only initiating species and termination is 
insignificant. In contrast to n-hexylamine, 3-amino-1-propanol and 5-amino-1-pentanol 
yielded PBG with higher PDI values (suggesting slower initiation) and uncontrolled 
molecular weights (with Xn lower than the target value), possibly due to chain termination 
through end group cyclization leading to the loss of the primary amine end group. 
Consequently, in the current investigation, arborescent polypeptide synthesis was only 
investigated using PBG building blocks with an amine terminus, obtained with the n-
hexylamine initiator (Scheme 3.8A), and the exploration of esterification as an alternate 
coupling technique was abandoned. 


















Figure 3.3. SEC Analysis of PBG polymers obtained by ROP of Glu-NCA using 
(A) 3-amino-1-propanol, (B) 5-amino-1-pentanol and (C) n-hexylamine initiators. 
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To further investigate initiation by n-hexylamine, the effects of the molar ratio of 
monomer to initiator (M/I) and of the reaction temperature were investigated. The 
polymerizations were conducted with ratios of M/I = 20, 25 and 50 at 0 ˚C in DMF. As 
shown in Table 3.2, n-hexylamine consistently yielded low dispersities (PDI = 1.08-1.11) 
under these conditions. 













(SEC) PDI fNH2 
20 2.5 21 4,900 5,200 1.11 97 
25 2.5 25 5,800 5,700 1.08 98 
50 4 49 11,000 12,700 1.10 95 
All polymerizations carried out at 0 ˚C for 2.5-4 days. 
The reaction temperature is an important parameter in the ROP of Glu-NCA monomers. 
The relationship between the amine functionality level fNH2 and the reaction temperature is 
shown in Table 3.3. As the reaction temperature was increased from 0 to 25 ˚C, fNH2 
decreased from about 98% to 68%. Mn also decreased slightly, while PDI increased. These 
results clearly demonstrated the non-living and uncontrolled behavior of the Glu-NCA 
polymerization even at room temperature, while higher Mn and lower polydispersities were 
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obtained at 0 ˚C, which is consistent with decreased chain end cyclization at low 
temperature (Figure 3.4). 















(SEC) PDI fNH2 
0 25 25 5,800   5,700 1.08    98 
25 25 23 5,400 5,200  1.17      68 
 
Consequently, the PBG building blocks used in the subsequent work were synthesized 
by ring-opening polymerization of Glu-NCA in N,N-dimethylformamide (DMF) at 0 ˚C, 
using n-hexylamine as initiator. That initiator not only ensured reproducible batch-to-batch 
results but also scalability (from 1- to 10-g scale syntheses). Another advantage of that 
initiator is that it provides a well-defined signal for the terminal methyl group facilitating 
the determination of the degree of polymerization (Xn) of the product. The absolute values 
of Mn and Xn were determined by 
1H NMR analysis of the linear PBG samples as shown 
in Figure 3.5, by comparing the integrated peak intensities for the benzylic methylene 
protons in the repeating units (ca. 4.9 ppm) and the terminal methyl group signal from the 
n-hexylamine initiator around 0.75 ppm. The Xn for the sample of Figure 3.5 was calculated 
as (2.00/2H) / (0.12/3H) = 25.0 by that approach. 
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Figure 3.4. SEC Analysis of PBG obtained at 0 ˚C. 
 
Figure 3.5. 1H NMR spectrum for linear PBG with Xn = 25 obtained at 0˚C. 
3.4.3 Synthesis and Deprotection of PBG Serving as Substrate 
A linear PBG substrate was synthesized by ring-opening polymerization (ROP) of the 
corresponding Glu-NCA monomer as described above for the side chains with Xn = 49, but 
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quenching the reaction with acetic anhydride to deactivate the terminal amine moiety as 
shown in Scheme 3.7. The linear PBG with Xn = 49 was partially deprotected to serve as 
substrate in the synthesis of a G0 polymer. Coupling sites (carboxyl groups) for the grafting 
reaction were thus randomly introduced on the substrate through deprotection of a portion 
(ca. 30%) of the benzyl ester groups. This corresponds to around 15 coupling sites on the 
substrate. The PBG side chains in the synthesis of the arborescent polymers had Xn = 25 in 
all cases. Steric crowding of the chains should be minimized during the grafting reaction 
under these conditions. Better resolution of the SEC peaks for the graft polymer and 
unreacted side chain material is also expected, enabling more accurate calculation of the 
grafting yield and the coupling efficiency. 
 
Scheme 3.7. Synthesis and deprotection of linear PBG substrate. 
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The treatment of linear PBG with a mixture of HBr/TFA allowed the cleavage of a 
controlled fraction of benzyl ester protecting groups under mild conditions to generate the 
coupling sites. The functionalization (deprotection) level of the PBG substrates was 
determined by 1H NMR analysis as shown in Figure 3.6. The ratio of intensities for the 
benzylic methylene protons (2H at 4.9 ppm) on the remaining protected structural units 
and for the methine protons (1H at 3.9 ppm), respectively, was used to determine the 
deprotection level. Taking Figure 3.6 as an example, dividing the methylene protons 
integral (1.00/2H) by the methine protons integral (0.70/1H) gives the fraction of repeat 
units still protected as 0.70, or 70%. The corresponding deprotection level is therefore 30%. 
 






To ensure that no degradation occurred during deprotection, the stability of PBG under 
acidic conditions was investigated using SEC analysis. The SEC profiles overlaid in Figure 
3.7 for PBG and partially deprotected PBG-COOH display a small decrease in molecular 
weight corresponding to the deprotection of a fraction of the benzyl ester moieties, but no 
significant change in the breadth of the molecular weight distribution (PDI = 1.05 and 1.07 
before vs. after deprotection, respectively). This clearly confirms that HBr/TFA 


















Figure 3.7. SEC Analysis of a PBG polymer before and after partial deprotection 
with HBr. 
3.4.4 Optimization of the Grafting Reaction 
Some of the methods described in the literature to improve the coupling yield were 
evaluated for the synthesis of arborescent polymers. The successful coupling of amino 
acids in the synthesis of peptides depends on the reactivity of the carboxyl group on the 
peptide substrate, and on the accessibility of the primary amine on the amino acid to be 
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added.9 Activation of the carboxyl group is a prerequisite for the synthesis of an amide 
bond. While many activation procedures have been developed to this end, the use of 
dicyclohexylcarbodiimide (DCC) is still widespread. In this study however, other 
carbodiimides such as diisopropylcarbodiimide (DIC) were preferred because they yield 
urea coupling by-products that are more soluble than the dicyclohexylurea formed by 
DCC.16 The synthesis of arborescent G0 polypeptides from amine-terminated poly(γ-
benzyl L-glutamate) (PBG) chains and a carboxyl-functionalized PBG substrate is shown 





Scheme 3.8. Synthesis of a branched arborescent G0 polypeptide from PBG 
building blocks using peptide coupling (A) and esterification (B). 
Since the main goal of this investigation was to optimize the grafting reaction of PBG 
side chains onto a partially deprotected PBG-CO2H substrate, it was necessary to determine 
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the “living” characteristics of the primary amine end groups in the PBG side chains before 
the optimization of grafting. Deactivation of the primary amine end groups not only leads 
to linear PBG chains incapable of coupling with the substrate, but also to errors in the 
estimation of the grafting yield and coupling efficiency. For these reasons, a method 
developed by Ji et al.19 was used to determine the functionality level of the “living” primary 
amines in the PBG side chains. This method used the reaction of 4-
trifluoromethylbenzaldehyde (TFBA) with the primary amine to produce an imine 
functionality at the chain end of the polymer as shown in Scheme 3.9. 19F NMR 
spectroscopy was employed to observe the chemical shift of the fluorine atoms when the 
imine was formed, to be compared with the signal for benzotrifluoride (BTF) serving as 
internal standard. 
 
Scheme 3.9. Reaction of 4-trifluoromethylbenzaldehyde (TFBA) with the primary 
amine end group in a PBG chain. 
The 19F NMR spectrum obtained for a PBG sample (Table 3.2, sample with Xn=25), 
synthesized at 0° C using n-hexylamine as initiator, is shown in Figure 3.8. The amine 
functionality level fNH2 of the PBG side chains was calculated by integrating the peaks in 
the 19F NMR spectrum as shown in Equation 3.1. The number of moles of chains present 
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in the reaction was determine by comparing the integration value for the imine fluorides 
(0.374) to the integration value for the internal standard BTF fluorides (1.000). An amine 




















= 0.983                                       (3.1) 
 
Figure 3.8. 19F NMR spectra for linear PBG synthesized at 0° C with primary 
amine end groups, after treatment with 4-trifluoromethylbenzaldehyde (TFBA). 
Since n-hexylamine initiation of the ROP of Glu-NCA in DMF at 0 ˚C led to better 
controlled polymerization reactions, with lower dispersities and a high primary amine 
functionality level fNH2 > 98%, all the PBG serving as side chain material subsequently 
used in the optimization of the grafting reaction was synthesized under these conditions.  
 
107 
Variations in the reaction temperature and time, solvent, and in the mole ratio of 
reactants and coupling reagents were used to maximize the grafting yield. For each 
reaction, short (Mn  5,800 g/mol, Xn = 25) PBG side chains were grafted onto a partially 
(30%) deprotected, Mn  11,000 g/mol (Xn = 49) linear PBG substrate with 15 coupling 
sites on average. This approach should provide better resolution of the SEC peaks for the 
graft polymer and unreacted side chain than when using components of equal molecular 
weight, and thus more accurate calculation of the grafting yield and coupling efficiency. 
The grafting yield, defined as the fraction of side chains becoming coupled with the 
substrate in a grafting reaction, was determined from the relative areas of the peaks for the 
graft polymer and the side chains in SEC analysis of the crude product. For Sample 3 in 
Figure 3.9, for example, the peak on the left (graft polymer) and the right (unreacted side 
chain material) have areas (in arbitrary units) of 35.8 and 15.0, respectively. The weight 
fraction of the substrate in the graft polymer was 13%, and therefore the corrected peak 
area for the graft polymer was 35.8 × 0.87 = 30.7.  A grafting yield of 30.7 / (30.7+ 15.0) 
= 0.67 (67%) was thus calculated. The fraction of coupling sites consumed in a grafting 
reaction, defined as the coupling efficiency, was estimated by comparing the number of 
side chains grafted with the number of coupling sites present on the substrate.17 Thus for a 
G0 sample having a branching functionality fn of 10.9 side chains, derived from a substrate 
having 14.7 coupling sites (Sample 3, Table 3.7), the coupling efficiency was 10.9 / 14.7 
= 0.745 or 74%. 
 
108 















Figure 3.9. SEC analysis of crude Sample 3 in Table 3.7. 
Two carbodiimide reagents, namely N,N′-diisopropylcarbodiimide (DIC) and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl), in combination with 
1-hydroxybenzotriazole (HOBt) as coupling additive, were used to increase the reactivity 
of the carboxyl groups. The two coupling reagents (DIC and EDCHCl) with HOBt, at 
room temperature with a 1:1 side chain:substrate molar ratio, yielded no significant 
difference in grafting yield nor coupling efficiency (Table 3.4). Thus DIC was selected as 
the coupling reagent for the rest of the investigation due to its lower cost. 

















DMF DIC 65,800          1.02 55 64 
Acetonitrile/DMF EDC·HCl 67,100          1.02 51 66 
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The coupling protocol was further optimized in terms of the reaction temperature and 
time in DMF, using DIC/HOBt as coupling agents with a 1:1 molar ratio of side chains to 
–CO2H groups on the substrate (Table 3.5). A lower coupling rate was observed at 0 ˚C as 
expected. Starting the reaction at 0 ˚C and then allowing it to proceed at room temperature 
increased the grafting yield when using DMF as solvent. Increasing the reaction 
temperature and/or time apparently favored the coupling reaction more than competing 
chain end cyclization, which increased the grafting yield and the coupling efficiency. The 
results in Table 3.5 clearly show that increasing the reaction temperature enhanced the rate 
of the coupling reaction. While only 28% of the side chains were coupled with the substrate 
after 32 h in DMF at 0 ˚C, the yield increased to 53% after only 12 h in DMF at 25 ˚C. 
Further increase in reaction temperature to 40 ˚C led to no significant difference in grafting 
yield nor coupling efficiency. As a result, all subsequent coupling reactions were carried 




Table 3.5. Influence of the reaction temperature and time on the coupling reaction 

















0 12 - 7 - 
0 32 - 28 - 
25* 24    59,500          1.02 57 56 
10 12 - 12 - 
10 32 - 27 - 
10 64 53,400          1.03 52 47 
25 12 - 53 - 
25 32 - 53 - 
25 64 65,800          1.02 55 64 
40 12 - 55 - 
40 32 - 55 - 
40 64 63,100          1.06 54 61 
* The reaction was started at 0 ˚C for 32 h and then allowed to proceed at 25 ˚C for 24 h. 
The influence of the solvent composition and the reaction time on the grafting yield and 
the coupling efficiency, using DIC/HOBt as coupling agents with a 1:1 molar ratio of side 
chains to substrate, was also examined (Table 3.6). When the reaction was carried out in 
DMF, the grafting yield was maximized after 12 h, without further improvements even 
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after 64 h. As the reaction proceeds, the accessibility of the remaining coupling sites on the 
substrate is expected to decrease, thus making further grafting reactions more difficult. 
When the reaction was carried out in DMSO the coupling rate was slower, but the grafting 
yield and the coupling efficiency were much improved after 64 h. Low grafting yields were 
observed in a DCM/DMF mixture, probably due to its lower polarity favoring side reaction 
in the activation process. DMSO therefore yielded the best results. 

















DMF 12 - 53 - 
- 64 65,800          1.02 55 64 
DMSO 12 - 46 - 
- 64 78,400          1.03 59 79 
DCM/DMF 12 - 47 - 
- 64 59,500          1.02 50 55 
 
We then evaluated the effects of the CO2H:NH2 (substrate:side chain) stoichiometry on 
the grafting yield and the coupling efficiency. Given the inaccessibility of some of the 
CO2H coupling sites on the substrate, using a slight excess of substrate was investigated as 
a means to maximize the grafting yield without sacrificing the coupling efficiency (Table 
3.7). The reactions carried out in DMSO at 25 ˚C for at least 36 h, using a 1.25 : 1 ratio of 
CO2H:NH2, were deemed optimal because they provided a reasonable grafting yield (67%) 
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and a coupling efficiency of 74%, close to the maximum efficiency observed in the 
equimolar reactions (78%). Interestingly, using a 1.25:1 ratio of CO2H:NH2 groups led to 
a 13% (as opposed to 25%) increase in grafting yield, from 59% to 67%. This result 
suggests that steric hindrance was not the only limiting factor in these grafting reactions, 
but that other side reactions may have occurred that led to deactivation of the carboxylic 
acid moieties on the substrates during the grafting reaction. It is important to mention that 
we did not correct any of the grafting yields reported by taking into consideration the 
fraction of active chains (fNH2), because side chains with a amine functionality level (fNH2 
> 98%) were used in all the reactions. 
Table 3.7. Influence of the CO2H:NH2 molar ratio on the coupling reaction. 
Sample 
Molar ratio 
CO2H : NH2 
MALLS 
M










1 1 : 1.25  75,300               1.04 47 75 
2 1 : 1 76,200              1.02 59 76 
3 1.25 : 1 74,600              1.04 67 74 
4 1.5 : 1 68,300              1.04 76 66 
5 2 : 1 48,000              1.05 86 43 
 
The CO2H:NH2 ratio of 1.25, while increasing the coupling efficiency for Sample 3, 
only led to a small decrease in the total number of side chains added in the reaction (Table 
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3.7 and Figure 3.10). This approach was therefore deemed to be optimal, although larger 
stoichiometric ratios could also be considered if the goal were to minimize the presence of 
side chain contaminant in the product while sacrificing the coupling efficiency. 

















Figure 3.10. SEC analysis of crude Samples 1 and 3 (Table 3.7) showing the 
influence of the CO2H:NH2 stoichiometry on the grafting yield. 
To minimize the amount of coupling agents used in the reaction, while maximizing the 
grafting yield and the coupling efficiency, the effects of the DIC/HOBt:CO2H (coupling 
agents:substrate) stoichiometry was investigated while the DIC/HOBt ratio was kept 
constant at 1. The grafting reaction was also carried out with a 2-fold excess molar ratio of 
carboxyl groups to primary amines, to determine whether carboxyl group deactivation 
during the grafting reaction could be a significant factor (along with steric hindrance of the 
substrate) contributing to lowering the grafting yield and coupling efficiency in these 
reactions. For Sample 6 (Table 3.8), a stoichiometric amount (DIC/HOBt:CO2H = 1) was 
used. Samples 7, 5 and 8 were obtained with DIC/HOBt:CO2H ratios of 2, 5 and 10, 
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respectively, to maximize the activation of the carboxyl groups, and thus the grafting yield 
and the coupling efficiency. As mentioned earlier, the initial step in amide bond formation 
is the activation of the carboxyl group by addition of the carbodiimide to form an 
intermediate O-acylisourea species. If activation of the carboxylic acid is inefficient, an 
excess of coupling reagents should help to maximize carboxyl group activation. 
Table 3.8. Influence of the CO2H:coupling agents molar ratio on the coupling 
reaction. The reactions were carried out in DMSO at 25 ˚C for at least 36 h, using a 













6 1  38000          1.07 76 31 
7 2  40500          1.04 79 34 
5 5  48000          1.05 86 43 
8 10  46000          1.05 84 41 
 
As shown in Table 3.8, a 1:1 molar ratio of coupling agents (DIC/HOBt) to CO2H 
groups (Sample 6) led to a grafting yield of 76% and a coupling efficiency of 31%. When 
a 5-fold molar ratio of coupling agents was used (Sample 5), the grafting yield and coupling 
efficiency were maximized at 86% and 43%, respectively. Further increasing the 
 
115 
stoichiometric amount of coupling agents to a 10-fold ratio (Sample 8) yielded no 
significant differences in grafting yield nor coupling efficiency. Thus a 5:1 molar ratio of 
coupling agents (DIC/HOBt) to CO2H groups was selected as optimal, as it reduced the 
amounts of chemicals to be used and disposed, and simplified sample purification. Since a 
2-fold excess of coupling sites was added in the reactions relatively to the side chains, the 
coupling efficiency (defined as the fraction of coupling sites consumed on the substrate) 
could only reach a maximum value of 50% if all the side chain material were consumed. 
Despite the excess of coupling sites used, only 86% of the side chains reacted, which means 
that 14% of the chain ends were deactivated during the coupling reaction (Sample 5, Table 
3.8). It is therefore clear that not only steric hindrance was a limiting factor in these 
coupling reactions, but also deactivation of the amino chain ends during the grafting 
reaction, as it is unlikely that over 50% of the carboxyl coupling sites were deactivated. 
Another factor may nevertheless also have contributed to lowering the grafting yield and 
coupling efficiency in the G0PBG synthesis, namely the distribution of carboxylic acid 
moieties on the substrate. We assumed that the partial deprotection of PBG would lead to 
randomly distributed coupling sites on the substrate, but the deprotection of adjacent 
structural units is certainly possible. In that case, the grafting yield and coupling efficiency 
may decrease due to increased steric crowding for coupling on adjacent carboxylic acid 
moieties. The SEC analysis results for crude Samples 6 and 5 are compared in Figure 3.11 
to show the influence of the CO2H:coupling agents molar ratio on the coupling reaction. 
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Figure 3.11. Comparison of the SEC analysis of crude Samples 6 and 5 (Table 3.8) 
to show the influence of the CO2H:coupling agents molar ratio on the coupling 
reaction. 
3.4.5 Purification of Arborescent Polymers 
All the crude graft polymer samples were contaminated with linear side chain material 
that did not react in the coupling reaction. Since it was impossible to remove these side 
chains by precipitation or fractionation, it was necessary to use preparative size exclusion 
chromatography (SEC) for that purpose. The purified G0 polymer, recovered by 
evaporation of the solvent under vacuum, dissolution in TFA and precipitation in methanol, 
was obtained free of linear PBG contaminant, as shown in Figure 3.12. 
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Figure 3.12. Comparison of SEC curves for G0 PBG, crude and purified by 
preparative SEC. 
3.5 Conclusions 
Since the main goal of this investigation was to optimize the grafting reaction of poly(γ-
benzyl L-glutamate) (PBG) side chains onto partially deprotected PBG substrates, a series 
of reactions was planned in a systematic fashion to allow direct comparisons. After 
determining that n-hexylamine as initiator yielded the best results for the ring-opening 
polymerization of Glu-NCA in DMF at 0 ˚C, yielding narrow molecular weight 
distributions and high primary amine functionality levels (fNH2 > 98%), “living” PBG side 
chains were synthesized under these conditions to be used in the optimization of the 
grafting reaction in the synthesis of G0 PBG. For each reaction, short (Mn  5,800 g/mol) 




It was demonstrated that the efficiency of the polypeptide coupling reactions used to 
synthesize arborescent PGB could be optimized by varying the solvent, temperature, 
reaction time, and reactant stoichiometry used. Different carbodiimide coupling agents had 
no influence on the grafting yield nor the coupling efficiency; thus DIC was preferred on 
the basis of its lower cost. Starting the reaction at 0 ˚C and then allowing it to proceed at 
room temperature increased the grafting yield when using DMF as solvent. Allowing the 
temperature to increase to room temperature apparently favored the grafting reaction more 
than chain end cyclization, as it increased both the grafting yield and coupling efficiency. 
Further increase to 40 ˚C led to no significant difference in grafting yield nor coupling 
efficiency however. When the reaction was carried out in DMF the grafting yield was 
maximized after 12 h, with no further improvement even after 64 h. As the reaction 
proceeded, the accessibility of the remaining coupling sites on the substrate likely 
decreased, thus making further grafting reactions more difficult.  
When the reaction was carried out in DMSO the coupling rate was slower, but the 
grafting yield and the coupling efficiency were significantly improved after 64 h. Low 
grafting yields were observed in a DCM/DMF mixture, probably due to its lower polarity 
favoring side reactions in the activation process. DMSO therefore yielded the best results. 
Reactant stoichiometry optimization not only increased the grafting yield, but it also 
reduced the total number of side chains added in the reaction. The reactions carried out in 
DMSO at 25 ˚C for at least 36 h, using a slight excess of substrate (CO2H:NH2 ratio of 
1.25) were optimal. A 5:1 molar ratio of coupling agents (DIC/HOBt) to CO2H groups on 
the substrate also maximized the grafting yield and the coupling efficiency.  
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By utilizing the optimized reaction conditions mentioned above, namely by carrying 
out the reactions in DMSO at 25 ˚C for at least 36 h, using a 1.25:1 ratio of CO2H:NH2 and 
a 5:1 molar ratio of coupling agents (DIC/HOBt) to CO2H groups on the substrate, well-
defined (PDI < 1.04) G0 arborescent or comb-branched polypeptides were obtained with a 
grafting yield and coupling efficiency reaching 67% and 74%, respectively. These 
optimized reaction conditions were used to synthesize arborescent PBG of generations G1 
and G2 in the subsequent chapters of this Thesis. The PBG arborescent polypeptides 
constructed also served as intermediates in the preparation of unimolecular micelles useful 





    Unimolecular Micelles from 
Randomly Grafted Arborescent Copolymers with 
Different Core Branching Densities: Encapsulation of 














A series of amphiphilic arborescent copolymers of generations G1 and G2 with an 
arborescent poly(γ-benzyl L-glutamate) (PBG) core and poly(ethylene oxide) (PEO) chain 
segments in the shell, PBG-g-PEO, were synthesized and evaluated as drug delivery 
nanocarriers. The PBG building blocks were generated by ring-opening polymerization of 
γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-NCA) initiated with n-hexylamine. 
Partial or full deprotection of the benzyl ester groups followed by coupling with PBG 
chains yielded a comb-branched (arborescent polymer generation zero or G0) PBG 
structure. Additional cycles of deprotection and grafting yielded G1 and G2 arborescent 
polypeptides. Side chains of poly(ethylene oxide) were then randomly grafted onto the 
arborescent PBG substrates to produce amphiphilic arborescent copolymers. Control over 
the branching density of G0PBG was investigated by varying the length and the 
deprotection level of the linear PBG substrates used in their synthesis. Three G0PBG cores 
with different branching densities varying from a compact and dense to a loose and more 
porous structure were thus synthesized. The copolymers were characterized using 1H 
NMR, size exclusion chromatography (SEC), dynamic light scattering (DLS), transmission 
electron microscopy (TEM), and atomic force microscopy (AFM). These amphiphilic 
copolymers behaved like unimolecular micelles in aqueous solutions in most cases. It was 
demonstrated that these biocompatible copolymers can encapsulate hydrophobic drugs 
such as doxorubicin (DOX) within their hydrophobic core with a high efficiency. Sustained 
and pH-responsive DOX release was observed from the unimolecular micelles, which 




Amphiphilic block copolymer micelles have recently attracted much attention in 
biomedical fields such as for drug delivery.1-3 One of the most important characteristics of 
polymeric micelles in drug delivery applications is their ability to solubilize hydrophobic 
or poorly water soluble drugs within their core, and thus enhance their bioavailability.4 
Polymeric micelles obtained by the self-assembly of linear block copolymers are always at 
dynamic equilibrium with non-associated (unimer) polymer chains. The self-assembly of 
isolated polymer chains to form micelles only starts when a minimum concentration is 
reached, known as critical micelle concentration (CMC).5 As a consequence, when applied 
in vivo, polymeric micelles based on linear block copolymers face a difficulty related to 
their dilution in the body, which shifts the micellar equilibrium toward the unimer state and 
causes drug leaching, thus reducing the efficacy of drug delivery.6-9  
Amphiphilic dendritic polymer micelles are an interesting alternative to conventional 
amphiphilic block copolymer micelles, in that each micelle is formed by a single molecule 
with amphiphilic properties (unimolecular micelles), with a covalently bound core-shell 
morphology. In contrast to block copolymer micelles, unimolecular micelles are stable 
irrespective of their concentration or the solvency conditions.8,10-15 Due to these remarkable 
features, the past decade has witnessed a surge of interest in the synthesis and 
characterization of unimolecular micelles, particularly in relation to biomedical 
applications. To date, the polymers most widely investigated to form unimolecular micelles 
for various applications are dendrimers and hyperbranched polymers. Unfortunately 
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dendrimers are time-consuming and tedious to synthesize, while hyperbranched polymers 
are easier to synthesize but only with limited control over their structure.16-18 
In contrast to dendrimers and hyperbranched polymers, dendrigraft (arborescent) 
polymers are a subset of dendritic polymers derived from reactive polymer building blocks 
in successive grafting reactions rather than small molecule monomers.19,20 A schematic 
representation of the step-wise grafting procedure used for the synthesis of arborescent 
polymers is shown in Scheme 4.1. Due to the presence of a large number of coupling sites 
randomly distributed on the grafting substrates, a rapid increase in molecular weight is 
observed over successive arborescent polymer generations and high molecular weight 
species are obtained in a few steps, while narrow molecular weight distributions (Mw/Mn 
< 1.1) are maintained in most cases.21 Arborescent unimolecular micelles can be obtained 
by the addition of hydrophilic segments in the last grafting cycle. For example, arborescent 
polystyrene-graft-poly(2-vinylpyridine) (PS-g-P2VP) copolymers were synthesized by 
grafting poly(2-vinylpyridine) side chains onto arborescent PS substrates of different 
generations. These copolymers were freely soluble in acidic aqueous solutions, behaving 
like unimolecular micelles that were able to solubilize various polycyclic aromatic 
hydrocarbon probes within their hydrophobic core.22 In a subsequent study, the release 
properties of these systems loaded with indomethacin and lidocaine as model drugs were 
also investigated.23 Unfortunately, the arborescent PS-g-P2VP copolymers used in this 
investigation were not biocompatible and only water-soluble at low pH due to protonation 
of the P2VP side chains, and thus the conditions of these in vitro investigations were very 
different from real biological systems. The synthesis of fully biocompatible arborescent 
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polymers from poly(γ-benzyl L-glutamate) (PBG) side chains therefore represents a 
significant advancement in that area.24 We are now planning to investigate these materials 
as micellar drug delivery vehicles. 
 
Scheme 4.1. Generation-based synthesis of arborescent polymers. 
Structural variables such as the size and branching density of arborescent copolymers 
can be designed to meet specific requirements for various applications. For example, the 
properties of these materials can be tailored by adjusting the composition and the size of 
the side chains used in their core and corona. Since the core structure of dendritic micelles 
is expected to be a critical parameter controlling their drug solubilization ability, clarifying 
the relationship between the core structure of arborescent copolymers and micellar 
properties such as the drug loading capacity and release kinetics would be useful in 
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tailoring the properties of these materials for drug delivery applications. Our group 
previously reported the synthesis of arborescent PBG substrates grafted either randomly or 
at their chain ends with linear poly(ethylene oxide), polyglycidol, and poly(glutamic acid) 
to form a hydrophilic shell.25  
Despite the remarkable potential of arborescent micelles as drug nanocarriers, the use 
of fully biocompatible arborescent copolymers in drug delivery has yet to be explored. We 
herein expand the design and synthesis of biocompatible amphiphilic arborescent 
copolymers as drug nanocarriers. Arborescent copolymers with poly(γ-benzyl L-
glutamate) (PBG) cores of generations G1 and G2, derived from G0PBG substrates with 
different branching densities, and a shell of poly(ethylene oxide) (PEO) chain segments 
were examined. The effects of the PBG core branching density on the micellar size, drug 
loading capacity, drug loading efficiency, and drug release rate were investigated. The 
copolymers were characterized in solution by dynamic light scattering (DLS), 
proton nuclear magnetic resonance (1H NMR) and size exclusion chromatography (SEC) 
measurements, and in the solid state with transmission electron microscopy (TEM) and 
atomic force microscopy (AFM). The encapsulation and release properties were 
investigated by UV spectroscopy using doxorubicin (DOX) as a model hydrophobic drug. 
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4.3 Experimental Procedures 
4.3.1 Characterization and Sample Preparation 
4.3.1.1 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Proton nuclear magnetic resonance (1H NMR) spectroscopy was used to estimate the 
degree of polymerization of the linear poly(γ-benzyl L-glutamate) PBG chains, to 
determine the deprotection level of the PBG substrates, and to investigate the ability of 
randomly grafted arborescent copolymers to form micelles. The instrument used was a 
Bruker 300 MHz spectrometer. Fluorine nuclear magnetic resonance (19F NMR) 
spectroscopy was also performed on the Bruker 300 MHz instrument to determine the chain 
end primary amine functionality, fNH2, of the polymers used in the grafting reactions. 
4.3.1.2 Size Exclusion Chromatography (SEC) Analysis 
Analytical SEC was used for the characterization of the arborescent PBG substrates of 
generations G0-G2 and of the copolymers. The analytical SEC system consisted of a 
Viscotek GPCmax unit equipped with a VE 2001 GPC Solvent/Sample Module, a Viscotek 
double detector array equipped with refractive index and dual-angle light scattering 
detectors, and two Agilent Technologies PLgel 5 µm MIXED-C and PLgel 10 µm MIXED-
B organic mixed bed columns, with dimensions of 7.5 mm (ID) × 300 mm (L). The system 
was operated at a flow rate of 0.5 mL/min at 70 ˚C, using dimethyl sulfoxide (DMSO) with 
LiBr (0.05 M) as the mobile phase. Analysis of the chromatograms was performed with 
the OmniSEC 4.6.1 software package.  
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Preparative SEC was carried out on a system consisting of a Waters M45 HPLC pump, 
a 2-mL sample injection loop, a Waters R401 differential refractometer detector, and a 
Jordi Gel DVB 1000 Å 250 mm × 22 mm preparative SEC column. N,N-
Dimethylformamide (DMF) with 0.2 g/L LiCl was used as the mobile phase. The 
concentration of polymer injected was 25 mg/mL. The system was operated at a flow rate 
of 3 mL/min at room temperature (25 ˚C). 
4.3.1.3 Dynamic Light Scattering (DLS) Measurements 
Light scattering measurements were performed on a Zetasizer Nano ZS90 (Malvern 
Instruments) equipped with a 4 mW He–Ne laser operating at 633 nm and 25.0 ˚C, at a 
scattering angle of 90°. The polymers were dissolved in phosphate buffered saline (PBS), 
DMF, or water at least 12 h before analysis. The concentration of the solutions was around 
0.5 mg∙mL-1, 0.2 mg∙mL-1, and 0.1 mg∙mL-1 for the G0, G1 and G2 copolymers, 
respectively. All the solutions were filtered with either PTFE or cellulose acetate 
membrane filters having a nominal pore size of 0.45 μm prior to the measurements. Each 
sample was measured in triplicate. The light scattering data were analyzed with the 
Zetasizer 7.11 Software (Malvern Instruments). 
4.3.1.4 UV-visible (UV-vis) Spectroscopy 
Absorption spectra were obtained on a Cary 100 Bio UV-Vis spectrophotometer with 
a spectral bandwidth (SBW) of 2 nm, operated with the Cary Varian UV Scan Application 
(v3.001339). The absorption peak at 483 nm for doxorubicin was used to calculate the 
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doxorubicin loading in the DOX-polymer samples. Absorbance measurements were 
performed in the 200–800 nm range and baseline correction was applied for PBS. 
4.3.1.5 Transmission Electron Microscopy (TEM) 
The dendritic micelles were imaged with a Philips CM10 electron microscope operated 
at 60 kV accelerating voltage. The images were recorded with an Advance Microscopy 
Techniques 11 megapixel digital camera and the Image Capture Software Engine version 
5.42.558. The feature sizes and size distributions were measured with the open source 
processing program ImageJ (version 1.46r).26 Either automatic selection or manual analysis 
of the features was used, depending on the contrast and the resolution of the images. In 
either case, a minimum of 15 measurements were taken for each sample to provide 
adequate average size information. In some cases, contrast adjustment was necessary to 
improve visualization and help with measurement of the features. The samples for TEM 
measurements were prepared by the following method: one drop of solution (0.05 
mg∙mL-1) was cast onto a 300 mesh Formvar® carbon-coated copper TEM grid (Electron 
Microscopy Sciences, FCF300-Cu) placed onto filter paper and the excess solution was 
wicked off with filter paper. After 1 min, one drop of 2% (w/v) phosphotungstic acid was 
added to the grid and the excess staining solution was wicked off with filter paper. Finally 
the grid was transferred onto a new piece of filter paper in a Petri dish and left to dry 
overnight at room temperature. 
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4.3.1.6 Atomic Force Microscopy (AFM) 
Muscovite mica discs were adhered onto steel substrates using double-sided adhesive 
tape to allow securing of the sample on the magnetic spin coater. Immediately prior to film 
casting, a fresh surface was exposed by cleavage with a strip of Scotch® MultiTask tape. 
The polymer solutions were prepared at concentrations ranging from 0.01 to 0.05 mg.mL-1. 
A 20 μL aliquot of the solution was deposited on the mica substrate and spun at about 3000 
revolutions per minute (rpm) for 60 s under ambient conditions. Atomic force microscopy 
(AFM) images were recorded in the tapping mode on a Nanoscope III instrument (Digital 
Instruments, model MMAFM-2, scan stage J) housed in a NanoCube acoustic isolation 
cabinet and mounted on a Halcyonics Micro 40 vibration isolation table. The measurements 
were performed using Si probes (VistaProbes, T300) having a spring constant of 40 N/m, 
a resonance frequency of 300 kHz, and the following characteristics: length 125 μm, width 
40 μm, tip height 14 μm, and tip radius < 10 nm. The images were analyzed using the 
Nanoscope v 1.40 software. The scan rate was typically between 0.7 and 1.2 Hz, at a scan 
angle of 0°, acquiring 512 samples/line. 
4.3.2 Solvent and Reagent Purification 
Dimethyl sulfoxide and n-hexylamine were purified by stirring overnight with CaH2 
and distillation under reduced pressure. N,N’-Dimethylformamide serving in the polymer 
synthesis (DMF; Aldrich, >99%) was purified by distillation under reduced pressure. Ethyl 
acetate (Fisher, 99.9%) was distilled from LiAlH4 under nitrogen. γ-Benzyl L-glutamic 
acid (Bz-Glu; Bachem, >99%), diethyl ether (EMD Millipore OmniSolv), HBr solution 
(Aldrich, 33% in acetic acid), N,N’-diisopropylcarbodiimide (DIC; Aldrich, 99%), 1-ethyl-
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3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl; Aldrich, 98%), 1-
hydroxybenzotriazole (HOBt; Fluka, water content ca. 15% w/w), tetrahydrofuran (THF, 
EMD Millipore OmniSolv), methanol (EMD Millipore OmniSolv), triphosgene (Aldrich, 
98%), trifluoroacetic acid (TFA, Caledon, 99.9%), LiAlH4 (Aldrich, 95%), acetic 
anhydride (Caledon, 97%), deuterated DMSO (DMSO-d6, Cambridge isotopes, 99.9% D), 
deuterated H2O ( D2O; Aldrich, 99.9 atom % D) and triethylamine (TEA, EMD) were used 
as received from the suppliers. Doxorubicin hydrochloride (DOX·HCl) was obtained from 
Sigma-Aldrich (USA). Dialysis bags Spectra/Por® 7 (MWCO 3.5 kDa) were purchased 
from Spectrum Laboratories Inc. (USA). 
4.3.3 Synthesis 
4.3.3.1 Synthesis of γ-Benzyl L-Glutamic Acid N-Carboxyanhydride (Glu-NCA)  
The monomer was synthesized from γ-benzyl L-glutamic acid and triphosgene as 
described in the literature.27 γ-Benzyl L-glutamic acid (Bz-Glu) (10.0 g; 42.0 mmol) was 
dissolved in 300 mL of freshly distilled ethyl acetate in a 1-L round-bottomed flask fitted 
with a reflux condenser and a N2 bubbler. After heating to reflux, triphosgene (4.8 g, 16 
mmol) was added at once and refluxing was continued for 3.5 h longer. The flask was 
allowed to cool to room temperature, and then stored in a refrigerator (5 ˚C) for 2 h. The 
cold reaction mixture was transferred to a cold separatory funnel, washed with 100 mL of 
distilled water chilled to 0 ˚C, and then with 100 mL of chilled 0.5% aqueous NaHCO3 
solution. The ethyl acetate layer was dried over anhydrous MgSO4, filtered by gravity, and 
concentrated to 100–120 mL on a rotary evaporator. An equal volume of cold hexane was 
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then added to induce crystallization of the monomer. After chilling to -5 ˚C overnight, the 
monomer crystals were collected by filtration in a Schlenk funnel under N2. For further 
purification, in some cases, the monomer was recrystallized twice from n-hexane and ethyl 
acetate (n-hexane/ethyl acetate v/v: 2/1), to remove the last traces of remaining impurities. 
The product was dried under vacuum and stored under N2 in a freezer until used. Yield = 
9.7 g (88 %); 1H NMR (300 MHz, CDCl3): 7.55–7.22 (s, 5H), 6.72 (s, 1H), 5.09 (s, 2H), 
4.35–4.31 (t, 1H), 2.57–2.51 (t, 2H), 2.33–2.19 (m, 1H), 2.18–2.00 (m, 1H). 
4.3.3.2 Synthesis of Poly(γ-benzyl L-glutamate) PBG Serving as Side Chains 
A linear polymer serving as side chains was synthesized as described previously.24 
Briefly, Glu-NCA (8 g, 30.4 mmol) was dissolved in dry DMF (20 mL) at 0 ˚C. n-
Hexylamine (182 μL, 1.38 mmol, for a target Xn = 22) was then added to the monomer and 
the reaction was allowed to proceed for 2.5 days at 0 ˚C. The linear polymer was recovered 
by precipitation in cold methanol, centrifugation, and drying under vacuum overnight 
before characterization. Yield = 82%, Mn = 5,100, Mw/Mn = 1.09. 
1H NMR (300 MHz, 
DMSO-d6): Xn = 22.0, δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–4.88 (s, 2H), 4.09–3.87 (b, 
1H), 2.32–1.88 (b, 4H), 1.31–1.15 (b, 0.4H), 0.76–0.74 (s, 0.14H). 
4.3.3.3 Synthesis of Linear PBG Serving as Substrates 
Three linear PBG substrates with either 15, 30 or 68 repeating units were synthesized. 
The number of PBG repeating units was controlled by the amount of Glu-NCA and n-
hexylamine used in the reaction. The Glu-NCA (4 g, 15.2 mmol) was dissolved in dry DMF 
(10 mL) and n-hexylamine (134 μL, 1.01 mmol, 67 μL, 0.50 mmol and 29.5 μL, 0.22 mmol 
 
132 
for target Xn = 15, 30 and 68, respectively) was then added. The reaction was allowed to 
proceed at room temperature for 3, 4 and 5 h, respectively, before quenching with acetic 
anhydride (780 μL) to deactivate the terminal amine moiety. After 1 h the product was 
precipitated in cold methanol, centrifuged and dried under vacuum overnight before 
characterization. 
The different linear PBG substrates are identified in the form PBGx, where X denotes 
the experimental number of PBG repeating units in the chains. 
(PBG with target Xn = 15) Yield = 89%, Mw/Mn = 1.17. 
1H NMR (300 MHz, DMSO-
d6): δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–4.88 (s, 2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 
4H), 1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 0.20H). Xn = 15.0 (PBG15) 
(PBG with target Xn = 30) Yield = 90%, Mw/Mn = 1.18. 
1H NMR (300 MHz, DMSO-
d6): δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–4.88 (s, 2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 
4H), 1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 0.10H). Xn = 29.0 (PBG29) 
(PBG with target Xn = 68) Yield = 92%, Mw/Mn = 1.19. 
1H NMR (300 MHz, DMSO-
d6): δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–4.88 (s, 2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 
4H), 1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 0.05H). Xn = 65.0 (PBG65) 
4.3.3.4 Synthesis of Partially Deprotected Linear PBG Substrates 
A linear polymer PBG29 (3.05 g, 13.9 mmol Bz-Glu units) was dissolved in a mixture 
of TFA (33 mL) and 33% (w/w) HBr solution in acetic acid (0.88 mL, 4.17 mmol). The 
reaction was stirred for 3 hours at room temperature before the polymer was precipitated 
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in diethyl ether and recovered by suction filtration to give a product with 31% of free 
glutamic acid moieties. Yield = 64%. 
PBG29-CO2H.
 1H NMR (300 MHz, DMSO-d6): δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 5.01–
4.88 (s, 2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 4H), 1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 
0.1H). Xn = 29.0  
The partially deprotected linear PBG65 substrate was synthesized by the same procedure 
described above to give a product with 31% of free glutamic acid moieties. Yield = 68%. 
PBG65-CO2H. 
1H NMR (300 MHz, DMSO-d6): δ: 8.01 (b, 1H), 7.45–7.18 (s, 5H), 
5.01–4.88 (s, 2H), 4.09–3.87 (b, 1H), 2.32–1.88 (b, 4H), 1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 
0.05H). Xn = 65.0  
4.3.3.5 Synthesis of Fully Deprotected Linear PBG Substrate   
Sample PBG15 (2.90 g, 13.2 mmol Bz-Glu units) was dissolved in a mixture of TFA 
(30 mL) and 2.8 mL (13 mmol) of 33% (w/w) HBr solution in acetic acid. The reaction 
was allowed to stir for 3 h at room temperature before the polymer was precipitated in 
diethyl ether. After drying under vacuum the precipitate was dissolved in and dialyzed 
against distilled water, and subsequently freeze-dried, yielding a polymer with fully 
deprotected glutamic acid moieties as a white solid. Yield = 43%.  
PBG15-CO2H. 
1H NMR (300 MHz, DMSO-d6): δ: 8.01 (b, 1H), 4.09–3.87 (b, 1H), 
2.32–1.88 (b, 4H), 1.31–1.15 (b, 0.2H), 0.76–0.74 (s, 0.2H). Xn = 15.0 
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4.3.3.6 Synthesis of G0 Arborescent PBG 
In a typical coupling reaction used for the synthesis of G0PBG29 and G0BPG65, the 
partially (31 %) deprotected polymer serving as substrate (1.10 g, 1.78 mmol -CO2H) and 
the polymer serving as side chains (5.39 g, 1.05 mmol chains) were dissolved in 50 mL of 
dry DMSO. The peptide coupling reagents DIC (2.37 mL, 15.2 mmol) and HOBt (2.05 g, 
15.2 mmol) were then added to the reaction with TEA (0.73 mL, 5.2 mmol). The reaction 
was allowed to proceed for 36 h at room temperature before adding n-hexylamine (1.84 
mL, 18.2 mmol) to deactivate residual activated carboxylic acid sites. After 3 h the product 
was precipitated in cold methanol and recovered by suction filtration. Unreacted side 
chains were removed from the G0 crude polymer by preparative size exclusion 
chromatography (SEC). 
In a typical coupling reaction for G0PBG15, the fully deprotected polymer serving as 
substrate (0.14 g, 1.08 mmol -CO2H) and the polymer serving as side chains (5.07 g, 0.98 
mmol chains) were dissolved in 45 mL of dry DMSO. The peptide coupling reagents DIC 
(0.93 mL, 6.0 mmol) and HOBt (0.81 g, 6.0 mmol) were then added to the reaction with 
TEA (0.69 mL, 4.9 mmol). The reaction was allowed to proceed for 36 h at room 
temperature before adding n-hexylamine (0.72 mL, 7.2 mmol) to deactivate residual 
activated carboxylic acid sites. After 3 h the product was precipitated in cold methanol and 
recovered by suction filtration. Unreacted side chains were removed from the G0 crude 
polymer by preparative size exclusion chromatography (SEC). 
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4.3.3.7 Synthesis of G1 and G2 Arborescent PBG 
The G1 and G2 arborescent PBG substrates were synthesized as described in the 
previous chapter. Briefly, G0PBG (2.2 g, 10.0 mmol Bz-Glu units) was first partially 
deprotected by dissolution in a mixture of TFA (20 mL) and 0.64 mL (3.0 mmol) of 33% 
(w/w) HBr solution in acetic acid. The reaction was allowed to stir for 3 hours at room 
temperature before the polymer was recovered by precipitation in diethyl ether, suction 
filtration, and drying under vacuum. The product was recovered with 53% yield with 31 
mol % of free glutamic acid moieties. In a typical coupling reaction for the synthesis of 
G1PBG, the partially deprotected G0PBG substrate (0.3 g, 0.48 mmol -CO2H) and the 
polymer serving as side chains (2.27 g, 0.44 mmol chains) were dissolved in 15 mL of dry 
DMSO. The peptide coupling reagents DIC (0.42 mL, 2.7 mmol) and HOBt (0.36 g, 2.7 
mmol) were then added to the reaction with TEA (0.31 mL, 2.2 mmol). The reaction was 
allowed to proceed for 36 h at room temperature before adding n-hexylamine (0.32 mL, 
3.2 mmol) to deactivate residual carboxylic acid sites. After 3 h the product was recovered 
by precipitation in cold methanol, suction filtration, and drying under vacuum. Unreacted 
side chains were removed from the crude polymer by preparative SEC. The G2 arborescent 
PBG samples were synthesized and purified as described for the G1 sample. 
4.3.3.8 Quantification of Primary Amine Functionality Level by 19F NMR Analysis 
19F NMR spectroscopy was used to determine the chain end primary amine 
functionality level, fNH2, of the linear polymers used in the grafting reactions as described 
in the literature.28 The PBG sample (0.10 g, 1.72×10-5 mol chains) was first dissolved in 3 
mL of deuterated DMSO (DMSO-d6). A solution of 4-trifluoromethylbenzaldehyde 
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(TFBA, 0.0901 g, 5.17×10-4 mol) and benzotrifluoride (BTF, 0.0756 g, 6.16×10-4 mol) in 
2 g of DMSO-d6 was then prepared, and 0.1706 g of that reagent solution (4.563×10
-5 mol 
TFBA, 4.531×10-5 mol BTF) was added to the PBG solution which was stirred for 2 h 
before it was transferred to an NMR tube for analysis. 
4.3.3.9 Synthesis of Diphenylmethylpotassium 
Diphenylmethylpotassium (DPMK) was prepared as described in the literature.29  
Briefly, in a flame-dried 3-neck round-bottom flask (RBF) with a magnetic stirring bar, 
attached to a high-vacuum line, 150 mL of dry THF was introduced followed by potassium 
metal  (4.2 g, 107 mmol, 2 eq) cut into small pieces. Naphthalene (6.89 g, 53.7 mmol, 1 
eq) was added, at which point the solution turned dark green. After stirring for 30 min, 
diphenylmethane (18.1 mL, 107 mmol, 2 eq) was added to the flask with a syringe. All 
these additions were performed under nitrogen atmosphere. The reaction was allowed to 
proceed overnight to give a dark red DPMK solution. 
4.3.3.10 Determination of the Concentration of the DPMK Solution 
In a flame-dried 3-neck RBF with a magnetic stirring bar and purged with nitrogen, 
attached to a high-vacuum line, 30 mL of dry THF were introduced followed by a few 
drops of DPMK solution, until the solution retained a pale yellow coloration. Acetanilide 
(50 mg, 0.37 mmol) was then added to the solution, at which point the solution became 
colorless. The DPMK solution was then slowly added (0.75 mL) to obtain the same pale 
yellow color present initially. The concentration of DPMK was determined to be 0.49 M. 
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4.3.3.11 Ethylene Oxide Purification 
Ethylene oxide (EO) is very toxic in both its liquid and gas forms. Therefore it must be 
handled with special care in a well-ventilated fume hood. A vacuum manifold was 
connected to the EO tank line, and a thick-wall (double-thickness) ampoule with a PTFE 
stopcock, a magnetic stirring bar, and approximately 2 g of calcium hydride as drying 
agent. The apparatus was thoroughly flamed to remove adsorbed water before the manifold 
was sealed, the ampoule was cooled in liquid nitrogen, and EO was introduced slowly and 
condensed in the ampoule. The ampoule was then removed and mounted on a vacuum 
manifold with a RBF containing a magnetic stirring bar and another ampoule with a PTFE 
stopcock. The EO was degassed with three successive freeze-pump-thaw cycles. After 
closing the ampoule containing the EO the rest of the manifold was evacuated, flame-dried 
and purged with nitrogen. Then phenylmagnesium chloride solution (PhMgCl, 10 mL, 2.0 
M in THF) was added to the RBF. After removing the THF under vacuum the EO was 
recondensed to the RBF, stirred with the PhMgCl in an ice bath for 1 h, and slowly 
recondensed to the empty ampoule, which was subsequently removed and stored in the 
fume hood. 
4.3.3.12 Polymerization of EO 
Poly(ethylene oxide) (PEO) with a primary amine end group was synthesized using a 
vacuum manifold with a 5-neck RBF containing a magnetic stirring bar and the sealed 
ampoule containing the purified EO monomer (17.4 g, 0.395 mol). After the RBF was 
flame-dried under vacuum and purged with nitrogen, dry THF (200 mL) was added. The 
DPMK solution was introduced drop-wise through one neck until a faint yellow color 
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persisted, followed by 3-aminopropanol (0.138 mL, 1.75 mmol). Additional DPMK 
solution (4.7 mL, 2.3 mmol) was then added to deprotonate the alcohol. The EO monomer 
(17.4 g, 0.395 mol, for a target Xn = 226, Mn = 10000 g/mol) was added to the reaction, 
transferred to the ampoule and sealed carefully. The reaction was allowed to proceed for 9 
days at 45 ˚C in an oil bath, after which acidified methanol (0.5 mL, 1/10 v/v 
HCl/methanol) was added to the dark brown solution to terminate the reaction. The solution 
was concentrated by rotary evaporation and precipitated in diethyl ether. The brownish 
powder recovered by filtration was redissolved in methanol and precipitated again in 
diethyl ether. The polymer, recovered by suction filtration and drying under vacuum, was 
obtained as a white powder. Yield: 12.8 g (73%). SEC (THF): Mn
app = 10,100 g/mol, 
Mw/Mn = 1.12. 
1H NMR: (300 MHz, CDCl3): δ: 3.87-3.35 (m, 912H), 3.1 (br, 2H), 1.96 
(br, -OH), Xn = 228 (Mn = 10,100 g/mol). 
4.3.3.13 Synthesis of Arborescent Copolymers 
The arborescent copolymers were synthesized and purified similarly to the arborescent 
PBG samples. The synthesis of G1PBG15-g-PEO is described below as an example. The 
partially deprotected G1PBG15 substrate (30 mol % of free glutamic acid moieties, 0.040 
g, 0.063 mmol –CO2H) and the PEO serving as side chains (0.58 g, 0.057 mmol chains) 
were dissolved in 5 mL of dry DMSO. The peptide coupling reagents DIC (0.055 mL, 0.35 
mmol) and HOBt (0.047 g, 0.35 mmol) were then added to the reaction with TEA (0.040 
mL, 0.29 mmol) as a base. The reaction was allowed to proceed for 36 h at room 
temperature before adding n-hexylamine (0.042 mL, 0.42 mmol) to deactivate residual 
activated carboxylic acid sites. After 3 h the product was precipitated in cold methanol and 
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recovered by suction filtration. Unreacted side chains were removed from the G1PBG15-g-
PEO crude product by preparative size exclusion chromatography (SEC) in DMF and the 
sample was recovered by precipitation in cold diethyl ether, suction filtration, and drying 
under vacuum: Grafting yield = 27%, Mn =1.2×10
6, Mw/Mn = 1.07 (MALLS). 
4.3.3.14 Preparation of DOX-Loaded Unimolecular Micelles 
All the DOX-loaded micelles were prepared by dialysis. DOX·HCl was first neutralized 
with two equivalents of triethylamine (TEA) in DMSO to obtain the drug it its free base 
(hydrophobic) form. The arborescent copolymer (10 mg) was dissolved in 1 mL of DMSO 
and stirred for 2 hours. Then 0.5 mL of DOX solution in DMSO (4 mg/mL) was added to 
the micellar solution and the mixture was stirred overnight in the dark. The organic solvent 
and free drug were removed by dialysis (MWCO 3500) against deionized water (1 L) for 
24 h (the dialysis medium was changed three times) and the solution was either lyophilized 
in the dark or used directly for measurements. For the determination of the drug loading 
content (DLC) and the drug loading efficiency (DLE), the lyophilized DOX-loaded 
micelles were dissolved in deionized water and the absorbance was measured on a UV-Vis 
spectrometer at 483 nm. The DLC and DLE were calculated according to the following 
equations: 
DLC =
mass of drug in micelles 
mass of micelles and drug
× 100%                                                       (4.1) 
    
DLE =
mass of drug in micelles 
total mass of drug in feed
× 100%                                                     (4.2) 
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4.3.3.15 In Vitro Release of DOX 
To determine the release profiles of DOX, a 3 mg sample of the freeze-dried DOX-
loaded unimolecular micelles was suspended in 1 mL of phosphate buffered saline (release 
medium, 10 mM phosphate, 137 mM NaCl and 2.7 mM KCl, pH 7.4 or 5.5; the pH was 
adjusted by addition of 6 M HCl) and transferred into a dialysis bag (MWCO 3500). The 
release experiment was initiated by placing the sealed dialysis bag into 3 mL of release 
medium at the same pH and 37 ˚C, with constant shaking at 100 rpm. At selected time 
intervals, the release medium was completely withdrawn and replaced with 3 mL of fresh 
medium. The amount of DOX released was calculated based on the absorbance measured 
on a UV-Vis spectrometer at 483 nm and a molar extinction coefficient  = 10,240 
M-1·cm-1. The drug release studies were performed in triplicate for each sample. 
4.4 Results and Discussion 
4.4.1 Synthesis of Linear PBG Substrates 
The characteristics of arborescent copolymers can be tailored to meet specific 
requirements for different applications through variations in the synthetic procedure. For 
instance, the molecular weight of the linear substrate serving in the synthesis of the G0 
polymer, the functionalization level of the substrate, and the number of grafting cycles used 
in their synthesis can be varied. In the current investigation, the length and the deprotection 
level of the linear PBG substrate used in the synthesis of G0PBG were varied, while the 
length of the PBG side chains (core building blocks) had Mn  5000 g/mol in all cases. 
Linear PBG substrates with three different length were synthesized with Xn = 15, 29, and 
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65 as shown in Table 4.1. The number of benzyl glutamate repeating units was controlled 
by varying the ratio of monomer (Glu-NCA) to initiator (n-hexylamine) used in the 
polymerization reaction. Initially, linear PBG substrates were used with different lengths 
and the deprotection level of the substrates employed in the synthesis of G0PBG was varied 
with the hope that the shape of the molecules could be controlled. Unfortunately, the TEM 
and AFM images indicated that they were all spherical. This approach nevertheless allowed 
us to vary the branching density in the cores, which seemed to correlate very well with the 
release properties of the micelles, as discussed in Section 4.4.7.  
Table 4.1. Synthesis of linear PBG substrates with different molecular weights. 
Sample  Target Xn  
1





PBG15 15 15 3,600 3,880 1.11 
PBG29 30 29 6.600 6,900 1.10 
PBG65 68 65 14,500 15,700 1.12 
 
The different linear PBG substrates are identified in the form PBGx, where X denotes 
the experimental number of PBG repeating units in the chains. The arborescent G0PBG 
molecules obtained by coupling the amine-terminated PBG side chains with the different 
carboxyl-functionalized PBG substrates are likewise identified in the form G0PBGx, where 
X denotes the number of PBG repeating units that were used as substrate for the synthesis 
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of G0PBG. For example, G0PBG29 describes an arborescent polymer derived from the 
PBG substrate with Xn = 29. Similar sample notation is used for the G1 and G2 samples.   
All the PBG substrates used in this work were synthesized by the ring-opening 
polymerization of Glu-NCA in N,N-dimethylformamide (DMF) at 25 ˚C, using n-
hexylamine as initiator, and quenching with acetic anhydride to deactivate the terminal 
amine moiety as shown in Scheme 4.2. 
 
Scheme 4.2. Deactivation of the terminal amine moiety on the linear PBG 
substrates. 
As shown in Figure 4.1, the absolute values of Mn and Xn were determined from 
1H 
NMR analysis of the linear PBG samples, by comparing the integrated peak intensities for 
the benzylic methylene protons in the repeating units (4.9 ppm) and the terminal methyl 
group signal from the n-hexylamine initiator (0.77 ppm). For example, since the integrals 
for the peaks at 4.9 ppm and 0.77 ppm were 0.9 and 0.09, respectively, the Xn for PBG15 




Figure 4.1. Comparison of 1H NMR spectra for the different linear PBG samples. 
4.4.2 Deprotection of Linear PBG Substrates 
The branching functionality fn of arborescent polymer molecules can be varied through 
the functionalization (deprotection) level of the substrate. In the current investigation, only 
the deprotection level of the linear PBG substrate serving in the G0 polymer synthesis was 




Scheme 4.3. Partial and complete deprotection of the PBG substrates. 
The treatment of linear PBG with a mixture of HBr/TFA allowed the cleavage of a 
controlled fraction of benzyl ester protecting groups under mild reaction conditions, to 
generate coupling sites (carboxyl groups) for the grafting reaction. A target deprotection 
level of 31 % was used for PBG29 and PBG65, while 100 % deprotection was used for PBG15 
as shown in Table 4.2. The deprotection level was controlled by varying the molar ratio of 
HBr added with respect to the benzyl ester moieties. 
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Table 4.2. Deprotected linear PBG serving as substrates. 







H NMR deprotection 
level (%) 
PBG15 15 15 100 100 
PBG29 30 29 30 31 
PBG65 68 65 30 31 
 
The deprotection level of the PBG substrates was determined by 1H NMR analysis as 
described in Chapter 3 (Section 3.4.2). The 1H NMR spectra for partly deprotected PBG29 
and PBG65, and for fully deprotected PBG15 are shown in Figure 4.2. The ratio of integrated 
intensities for the benzylic methylene protons (2H at 4.9 ppm) of the remaining protected 
structural units to the methine protons (1H at 3.9 ppm) was used to determine the 
deprotection level of PBG29 and PBG65. For example, dividing the methylene protons 
integral (2.00/2H) by the methine protons integral (1.45/1H) gave a fraction of repeat units 
still protected of 0.69 or 69%. The corresponding deprotection level was therefore 31% for 
both PBG29 and PBG65 (Figure 4.2b and Figure 4.2c). The disappearance of the benzylic 
methylene (2H at 4.9 ppm) and phenyl protons (5H at 7.3 ppm) confirmed the complete 




Figure 4.2. 1H NMR spectra for (a) fully deprotected linear PBG15, (b) partially 
deprotected linear PBG29, and (c) partially deprotected linear PBG65. 
4.4.3 Synthesis of G0PBG with Different Branching Densities 
The synthesis of arborescent G0PBG from amine-terminated PBG side chains and 
carboxyl-functionalized PBG substrates of different lengths and deprotection levels was 
achieved using the optimized coupling reaction conditions determined in Chapter 3. The 
coupling reagents N,N′-diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole 
(HOBt) were used to activate the carboxyl groups. All the reactions were carried out in 
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DMSO at 25 ˚C, using a 5:1 molar ratio of coupling agents (DIC/HOBt) to CO2H groups 
on the substrate to maximize the grafting yield and the coupling efficiency. These 
optimized conditions were also subsequently used to synthesize the G1 and G2 arborescent 
PBG. The general coupling reaction for the synthesis of arborescent PBG is shown in 
Scheme 4.4, using a G0 polymer synthesis as an example. 
 
Scheme 4.4. Synthesis of a G0 polypeptide from PBG building blocks. 
Different chain lengths and deprotection levels for the linear PBG substrate were used 
in the synthesis of G0PBG, while the PBG side chains had Mn  5000 g/mol in all cases. 
Three well-defined (PDI  1.08) arborescent G0 (comb-branched) PBG were obtained in 
that manner: G0PBG15 from a PBG substrate with Xn = 15 and 100% deprotection, 
G0PBG29 from a PBG substrate with Xn = 29 and 31% deprotection, and G0PBG65 from a 
PBG substrate with Xn = 65 and 31% deprotection. The corresponding characterization data 
are summarized in Table 4.3. 
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Table 4.3. Characteristics of arborescent G0PBG with different structures. 
Sample 
Deprotection 
















G0PBG15 100 1.1 : 1 65400 1.04 76 80 12 0.80 
G0PBG29 31 1.7 : 1 35300 1.08 87 54 5.4 0.19 
G0PBG65 31 1.7 : 1 51000 1.06 89 36 7.1 0.11 
 
As shown in Table 4.3, the number-average branching functionality of the arborescent 
polypeptides, fn, defined as the number of side chains added in the grafting reaction, 
increased with the deprotection level since more coupling sites were available. However, 
despite the identical deprotection levels of PBG29 and PBG65, the branching functionality 
fn achieved for G0PBG29 was marginally lower. This may be due to increased steric 
crowding leading to less accessible carboxylic acid moieties in the shorter PBG29 substrate. 
The number-average branching density (bd), defined as the number of side chains added in 
the grafting reaction divided by the number of repeating units in the linear substrate, clearly 
increased as the chain length of the substrate decreased and the deprotection level 
increased. As a result, a compact and dense structure is expected for G0PBG15 (bd = 0.80), 
as opposed to a loose and more porous structure for G0PBG65 (bd = 0.11) and an 
intermediate (semi-compact) structure for G0PBG29 (bd = 0.19). 
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The synthesis of the arborescent G0PBG samples with different branching densities 
(porosities) is illustrated with their SEC elution curves in Figure 4.3. It is clear that the 
elution volume of the graft polymers decreased as the branching functionality increased, 
while the breadth of the peaks remained constant. These different G0PBG structures will 
be compared in terms of their influence, when incorporated in the hydrophobic cores, to 
yield water-dispersible unimolecular micelles and to encapsulate and control the release 
rate of the drug. 
 














   
Figure 4.3. SEC traces for G0 arborescent PBG samples. 
The G1 and G2 PBG arborescent substrates were synthesized and purified by the same 
method used for the G0 samples except that, in all cases, the deprotection level of the 
arborescent substrates used was  30%, and a 1:1.1 molar ratio of side chains (PBG-NH2) 
to CO2H groups was used to maximize the grafting yield and the coupling efficiency (Table 
4.4). The unreacted side chain material was removed from the crude polymer by 
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preparative size exclusion chromatography (SEC). The absolute molecular weight of the 
arborescent PBG was determined by SEC-MALLS analysis in DMSO. The molecular 
weight of the polymers increased with the generation number, while a low polydispersity 
index (PDI ≤ 1.09) was maintained. The branching functionality also increased over 
successive generations, as more coupling sites were available after each grafting cycle. 
Sample G1PBG15 showed the lowest Gy and Ce, which is attributed to the difficulty for the 
coupling sites to react in the compact and dense G0PBG15 substrate as a result of increased 
crowding. 







G1PBG15 240,000 1.07 31 39 35 
G1PBG29 200,000 1.06 54 66 32 
G1PBG65 260,000 1.09 53 60 42 
G2PBG15 1.2×10
6 1.09 50 59 192 
G2PBG29 1.0×10
6 1.08 47 57 156 
G2PBG65 1.4×10
6 1.05 56 64 228 
a Values from SEC-MALLS analysis in DMSO; b Grafting yield: fraction of side chains 
attached to the substrate;  c Coupling efficiency: fraction of coupling sites on the substrate 




4.4.4 Synthesis of Linear Amine-Terminated Poly(ethylene oxide) 
Poly(ethylene oxide) with a primary amine terminus was used as hydrophilic shell 
material to demonstrate the synthesis of water-dispersible arborescent copolymer micelles. 
The anionic polymerization of ethylene oxide with a bifunctional initiator, 3-
aminopropanol deprotonated with diphenylmethylpotassium (DPMK), was used to obtain 
linear PEO with a primary amine chain end as shown in Scheme 4.5. 
 
Scheme 4.5. Polymerization of ethylene oxide with 3-aminopropanol and DPMK. 
The 1H NMR spectrum obtained for the α-amino PEO sample synthesized is shown in 
Figure 4.4. The ratio of intensities for the -CH2- protons next to the terminal amine ( 3.1 
ppm) and the four protons in the repeat units ( 3.6 ppm) was used to determine the number-




Figure 4.4. 1H NMR spectrum for α-amino PEO in CDCl3. 
19F NMR analysis served to determine the amine functionality level of PEO (fNH2). The 
absence of primary amine end groups would lead to linear PEO chains being incapable of 
coupling with the substrate. A procedure developed by Ji et al.28 was used to determine the 
primary amine functionality level of the PEO side chains. The terminal amine was reacted 
with 4-trifluoromethylbenzaldehyde (TFBA) to produce imine functionalities at the chain 
end of the polymer as shown in Scheme 4.6. 19F NMR spectroscopy was then employed to 
observe the chemical shift of the fluorine atoms in the imine formed, to be compared with 




Scheme 4.6. Reaction of 4-trifluoromethylbenzaldehyde (TFBA) with the primary 
amines end group in the PEO side chains. 
The 19F NMR spectrum obtained for the linear PEO sample synthesized using the 3-
aminopropanol/DPMK initiator system is shown in Figure 4.5. An amine functionality 
level fNH2 > 94% was obtained by that method. A detailed discussion of the method used 
to obtain the fNH2 value by 
19F NMR analysis was provided in Chapter 3. 
 
Figure 4.5. 19F NMR spectrum for linear PEO synthesized using the 3-




4.4.5 Synthesis of Randomly Grafted Arborescent Copolymers 
Structural variables such as the size and the branching density (porosity) of arborescent 
copolymers can be designed to meet specific requirements for various applications. It was 
hypothesized that it should be possible to tailor the micellar properties of these materials 
by adjusting the length of the linear substrate used in the synthesis of the G0 polymer. 
Whitton and Gauthier previously reported the use of linear poly(ethylene oxide) with a 
molecular weight of 5000 (PEG110), grafted either randomly or at the end of the chains on 
arborescent PBG substrates to generate arborescent copolymer micelles.25 Unfortunately, 
the randomly grafted arborescent G1PBG-g-PEO110 copolymers obtained by that approach 
yielded large aggregated species in phosphate buffered saline (PBS), while G2PBG-g-
PEO110 and G3PBG-g-PEO110 were both insoluble. The corresponding end-grafted samples 
PBG-eg-PEO110 displayed better dispersibility in PBS than the randomly grafted systems, 
albeit a small population of aggregates still existed in these samples. These results were 
nevertheless useful in demonstrating that the solubility of arborescent copolymers could be 
controlled through variations in their structure and composition. Therefore we 
hypothesized that by randomly grafting longer hydrophilic PEO chains (Mn =10,000 
g/mol), the solubility of the copolymers in PBS would be enhanced to yield stable 
unimolecular micelles without aggregation. This would in turn affect the size and the 
properties of the micelles, and thereby provide control over the encapsulation and release 
behaviors of these unimolecular micelles.  
In the current investigation, we expanded this approach by designing amphiphilic 
arborescent copolymers having poly(ethylene oxide) (PEO) chain segments with Mn = 
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10,100 g/mol randomly grafted onto arborescent PBG substrates of generations G1 and G2 
with different G0PBG branching densities, to determine their influence on the dispersibility 
of the micelles in organic and aqueous environments, and on the encapsulation and release 
of a hydrophobic drug, doxorubicin. PBG of generations G1-G2 with three different 
G0PBG core branching densities were employed as substrates to generate a library of 
randomly grafted amphiphilic arborescent copolymers.  
The synthesis of amphiphilic arborescent copolymers from amine-terminated PEO 
chains and the randomly carboxyl-functionalized PBG substrates (PBG-rf-CO2H) with the 
different G0PBG cores was achieved using the optimized reaction conditions mentioned in 
Chapter 3. The coupling reagent N,N′-diisopropylcarbodiimide (DIC) and 1-
hydroxybenzotriazole (HOBt) as coupling additive were used to activate the carboxyl 
groups. All the reactions were carried out in DMSO at 25 ˚C, using a 5:1 molar ratio of 
coupling agents (DIC/HOBt) to CO2H groups on the substrate. The coupling of a randomly 
carboxyl-functionalized G1PBG substrate (G1PBG-rf-CO2H) with amine-terminated PEO 






Scheme 4.7. Schematic representation of the synthesis of a randomly carboxyl-
functionalized G1PBG substrate (G1PBG-rf-CO2H) and a G1PBG randomly grafted 
arborescent copolymer. 
The results obtained for grafting the different PBG substrates of generations G1 and G2 
with PEO side chains are summarized in Table 4.5. The absolute molecular weight of the 
substrates and the arborescent copolymers was determined by SEC-MALLS analysis in 
DMSO. In all cases, the molecular weight of the copolymers increased relatively to the 




Table 4.5. Characteristics of randomly grafted PBG-g-PEO arborescent 
copolymers. 
copolymer 












G1PBG15-g-PEO 240,000 31 27 1.2×10
6 1.07 96 80 
G1PBG29-g-PEO 200,000 31 27 1.0×10
6 1.09 80 80 
G1PBG65-g-PEO 260,000 33 29 1.5×10
6 1.08 124 82 
G2PBG15-g-PEO 1.2×10
6 31 13 3.4×106 1.08 220 65 
G2PBG29-g-PEO 1.0×10
6 32 15 3.2×106 1.09 220 69 
G2PBG65-g-PEO 1.4×10
6 30 13 3.9×106 1.06 250 64 
a Values from SEC-MALLS analysis in DMSO; b Mole fraction of carboxyl groups in the 
substrate; c Grafting yield: fraction of side chains attached to the substrate; d Branching 
functionality: number of branches added in the last grafting cycle; e PEO weight fraction, 
from the difference in Mn of the copolymer and the substrate. 
The grafting yield (Gy), defined as the fraction of linear chain segments becoming 
attached to the substrate, was determined from the weight fraction of each component in 
the copolymers, along with the known amounts of substrate and side chains used in each 
grafting reaction. The calculation of the grafting yield for sample G1PBG15-g-PEO is 
provided in Equation 4.3 as an example. In this reaction 0.59 g of PEO side chains and 0.04 
g of PBG substrate (corresponding to a NH2/CO2H ratio of 0.90) were used. Weight 
fractions for PEO and PBG of 0.80 and 0.20, respectively, were determined when 
comparing the molecular weights of the copolymer and the substrate. Multiplying the 
known mass of PBG used in the grafting reaction (0.04 g) by the weight fraction ratios 
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(0.8/0.2) yields a mass of 0.16 g PEO in the copolymer. Dividing this by the total mass 
used in the grafting reaction (0.59 g PEO), a grafting yield of 27% was obtained.25 
𝐺𝑦 =









= 0.27                               (4.3) 
Several factors could have contributed to the relatively low (13-29%) grafting yields in 
the synthesis of the amphiphilic arborescent copolymers. We assumed that partial 
deprotection of PBG would yield randomly distributed coupling sites within the substrates, 
but the deprotection of adjacent groups is also possible, which may lead to increased 
coupling site crowding. Some coupling sites are also necessarily located deeper within the 
PBG substrate, and thus less accessible in the grafting reaction. The grafting yield could 
therefore decline due to a combination of increased steric crowding and decreased 
accessibility of the carboxylic acid moieties. The grafting yield achieved for the G1PBG-
g-PEO copolymers was higher than for the G2PBG-g-PEO copolymers, which is also 
expected due to the increased rigidity of the PBG substrates of higher generations. 
The branching functionality fn, defined as the number of PEO side chains added, was 
determined by dividing the increase in molecular weight observed for the grafted 
copolymer by the molecular weight of the PEO side chains. A calculation for sample 
G1PBG15-g-PEO is provided in Equation 4.4 as an example. The weight fraction of PEO 
in the copolymers was determined by dividing the increase in molecular weight for the 









= 96   (4.4) 
All the copolymers synthesized were purified by preparative SEC. The SEC traces for 
the purified samples, corresponding to the data summarized in Table 4.5, are compared in 
Figure 4.6. As expected, a decrease in elution volume is observed as the generation number 
increases. Within each generation the elution volume decreased in the series PBG65-g-PEO 
< PBG15-g-PEO < PBG29-g-PEO. The PBG65-g-PEO showed the highest molecular weight, 
likely due to its more porous core structure minimizing steric crowding and facilitating the 
diffusion of the chains to the coupling sites in the grafting reaction. 
 
Figure 4.6. SEC traces for G1 (left) and G2 (right) arborescent copolymers. 
4.4.6 Properties of Randomly Grafted Arborescent Copolymer Micelles 
The different randomly grafted arborescent copolymers were evaluated for their 
potential to remain as unimolecular micelles in aqueous PBS solutions. The addition of 
hydrophilic PEO segments to the hydrophobic PBG core was proposed to stabilize the 






























micelles, without self-assembly typically observed for amphiphilic block copolymer 
micelles. The characteristics of the arborescent copolymers were evaluated by proton 
nuclear magnetic resonance (1H NMR) spectroscopy, dynamic light scattering (DLS), 
transmission electron microscopy (TEM), and atomic force microscopy (AFM) to 
investigate the effects of the dendritic core structure and the PEO shell on the micelle 
properties.  
The use of 1H NMR spectroscopy to investigate the formation of micellar structures is 
illustrated in Figure 4.7. Complete disappearance of the peaks characteristic for PBG such 
as the benzylic methylene (2H at 4.9 ppm) and phenyl protons (5H at 7.3 ppm) is observed 
in D2O, while these peaks are clearly visible in DMSO-d6, which confirms that the G2PBG-
g-PEO arborescent copolymer has a core–shell morphology in aqueous solutions with a 




Figure 4.7. 1H NMR spectra for G2PBG29-g-PEO in (a) D2O and (b) deuterated 
DMSO. 
The hydrodynamic diameter of the copolymers, determined by DLS in DMF (good 
solvent for PBG and PEO) and in aqueous PBS buffer (solvent selective for PEO) followed 
the expected trends for increasing generation numbers (Table 4.6). 
 
162 


















G1PBG15-g-PEO 16 ± 1 18 ± 1 21 ± 1 0.18 16 ± 1 19 ± 1 22 ± 1 0.41 
G1PBG29-g-PEO 15 ± 1 18 ± 1 22 ± 1 0.16 17± 2 22 ± 2 27 ± 2 0.50 
G1PBG65-g-PEO 18 ± 1 22 ± 1 26 ± 1 0.09 19 ± 2 23 ± 2 28 ± 2 0.43 
G2PBG15-g-PEO 33 ± 2 36 ± 2 43 ± 2 0.06 35 ± 2 40 ± 3 47 ± 2 0.28 
G2PBG29-g-PEO 32 ± 2 36 ± 2 42 ± 2 0.03 34 ± 1 40 ± 1 46 ± 2 0.26 
G2PBG65-g-PEO 37 ± 1 45 ± 1 58 ± 2 0.07 39 ± 1 47 ± 1 58 ± 2 0.17 
All experiments done in triplicate. The results are presented as the mean ± standard 
deviation. 
The good agreement for the hydrodynamic diameters obtained in DMF and in PBS 
confirms that the randomly grafted arborescent copolymers formed unimolecular micelles, 
with mean number-average diameters between 16-18 nm and 32-37 nm for the G1 and G2 
in DMF, respectively. As shown in Table 4.6, the unimolecular micelles are uniform in 
size since the values of the three average diameters (number, volume, and intensity) are 
similar. The copolymers should form unimolecular, non-aggregated solutions in DMF, a 
good solvent for both the PBG and PEO components. Analysis of the same copolymers in 
phosphate buffered saline (PBS) also yielded values for number-, volume-, and intensity-
average diameters similar to those obtained in DMF, which suggests that all the arborescent 
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copolymers formed unimolecular micelles. It is nonetheless well-known that these values 
represent differently weighted means of the size distributions, and indeed size distribution 
analysis (Figure 4.8) shows that all the G1PBG-g-PEO copolymers exhibit a small quantity 
(16-34%) of aggregated structures with a diameter of 70−160 nm in their intensity 
distributions, while no aggregation is detected in neither the number nor the volume 
distributions. Size distribution analysis of the G2PBG-g-PEO copolymers likewise yielded 
a small quantity (17-32%) of aggregated structures with a diameter of 160−230 nm in the 
intensity distributions, while no aggregation was detected in neither the number nor the 
volume distributions (Figure 4.9). These results indicate that even though the vast majority 
of randomly grafted arborescent copolymer molecules exist as stable, isolated 
unimolecular micelles, a minute amount of aggregation occurs that is only detectable in the 
intensity-weighted distributions. Arborescent copolymers of the same generation yielded 
similar hydrodynamic diameters by DLS analysis even though their core structure was 
different. For example, when comparing the micelles formed by G2PBG15-g-PEO and 
G2PBG65-g-PEO, there is only a 4 nm difference in the number-average diameter, 
confirming that the core only has a minor influence on the overall micelle size. Since the 
hydrophobic PBG cores should collapse to minimize their unfavorable interactions with 
the aqueous solution (as determined by NMR analysis) and the G1 and G2 cores have 
similar molecular weight in each series, their contribution to the overall size of the micelles 




Figure 4.8. Hydrodynamic diameter distributions for randomly grafted 
arborescent copolymers determined by DLS in DMF (left) and in PBS (right): (A) 
G1PBG15-g-PEO, (B) G1PBG29-g-PEO, and (C) G1PBG65-g-PEO. 
































































































































































Figure 4.9. Hydrodynamic diameter distributions for randomly grafted 
arborescent copolymers determined by DLS in DMF (left) and in PBS (right): (A) 
G2PBG15-g-PEO, (B) G2PBG29-g-PEO, and (C) G2PBG65-g-PEO. 
The number-average diameters from DLS may also be used for comparison with other 
measurements providing number-average results (e.g. TEM and AFM analysis). The 
morphology and size of the unimolecular micelles were investigated by TEM, after staining 
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with phosphotungstic acid on a carbon-coated copper grid (negative staining was used to 
improve the contrast of the micelles), as well as by AFM (Figures 4.10 for G1 copolymers, 
Figure 4.11 for G2 copolymers). It can be seen that the unimolecular micelles have a fairly 
uniform size distribution and a spherical shape in all cases. The average micelle diameter 
measured by TEM was 15 ± 2, 14 ± 3 and 16 ± 2 nm for G1PBG15-g-PEO, G1PBG29-g-
PEO and G1PBG65-g-PEO, respectively. In contrast, the average micelle diameter was 29 
± 3, 30 ± 2 and 35 ± 3 nm for G2PBG15-g-PEO, G2PBG29-g-PEO and G2PBG65-g-PEO, 
respectively. All the measurement were based on 15−30 particles within the same 
micrograph. The TEM measurements confirmed the trend seen in the DLS measurements 
in terms of increasing micelle size for higher generations. The diameter of these 
unimolecular micelles appears to be within the ideal size range for therapeutic nanocarriers 
to be used in cancer treatment.30  The size of the micelles measured by TEM was somewhat 
smaller than by DLS analysis. Because TEM yields the diameter of the dry, somewhat 
flattened micelles on the TEM grid surface, while DLS measures their hydrodynamic 
(solvated) diameter, discrepancies are to be expected between these methods. The results 




Figure 4.10. TEM (left) and AFM phase scan (right) for randomly grafted 





Figure 4.11. TEM (left) and AFM phase scan (right) for randomly grafted 




4.4.7 Drug Loading and Micelle Characterization  
Since the arborescent PBG-g-PEO copolymers have a hydrophobic PBG core and a 
hydrophilic PEG shell, these amphiphilic molecules could serve as nanocarriers to 
physically encapsulate hydrophobic guest molecules through hydrophobic interactions 
(Scheme 4.8). 
 
Scheme 4.8. Schematic representation of the encapsulation and release of DOX in 
the hydrophobic PBG core of G2PBG-g-PEO through hydrophobic interactions. 
The ability to load the hydrophobic core of these unimolecular micelles with guest 
molecules was investigated to determine whether the differences in their core structure 
affected their ability to encapsulate and control the rate of release of the hydrophobic drug. 
Doxorubicin (DOX), an anticancer drug, was selected as a model drug to assess drug 
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loading and release in vitro. DOX·HCl was treated with triethylamine before encapsulation 
to obtain DOX in its free base (more hydrophobic) form. DOX was encapsulated within 
the hydrophobic core of G1PBG-g-PEO and G2PBG-g-PEO by a dialysis method. It was 
indeed determined that hydrophobic DOX could be solubilized in the amphiphilic 
arborescent copolymers, as shown in Figure 4.12. For example, the successful 
encapsulation of DOX within the hydrophobic core of G2PBG-g-PEO is indicated by the 
enhanced absorption around 490 nm of the DOX-loaded micellar solutions (G2PBG-g-
PEO/DOX) as compared to the empty micelles (G2PBG-g-PEO). The encapsulation of 
DOX specifically within the hydrophobic core of the micelles is also suggested by the blue 
shift in the maximum absorption for G2PBG-g-PEO/DOX as compared to free DOX in 
PBS (λmax = 483 nm), which is attributed to the hydrophobic microenvironment created by 
the PBG core of G2PBG-g-PEO.31 































Figure 4.12. UV Absorption of free DOX, G1 (left) and free DOX, G2 (right) 
arborescent copolymers in PBS. 
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The existence of hydrophobic interactions was further confirmed by 1H NMR analysis 
of the G2PBG15-g-PEO/DOX unimolecular micelles in D2O (Figure 4.13). The complete 
disappearance of both the PBG and DOX signals for G2PBG15-g-PEO/DOX in D2O 
(Figure 4.13c) in comparison to the characteristic signals observed of free DOX in D2O at 
the same overall DOX concentration (Figure 4.13a) clearly confirms the restricted mobility 
of both the PBG and DOX components within the core of G2PBG15-g-PEO. This again 
confirms the solubilization of DOX within the core of the micelles in aqueous solutions, 




Figure 4.13. 1H NMR spectra for (a) DOX in D2O, (b) G2PBG29-g-PEO in D2O and 
(c) G2PBG29-g-PEO/DOX in D2O. The insets show the appearance of the (1) DOX, (2) 
G2PBG29-g-PEO, and (3) G2PBG29-g-PEO/DOX samples in D2O. 
The drug loading content (DLC) determined for the micelles ranged from 7.1–10.8 
wt%, and the drug loading efficiency (DLE) from 42–65% for the different G1PBG and 
G2PBG copolymers (Table 4.7). Both the drug loading content (DLC) and the drug loading 
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efficiency (DLE) clearly increased with the generation number of the copolymers. 
However, for the same generation, the minor variations observed do not seem to correlate 
with parameters such as differences in branching density among the samples. Sample 
G2PBG15-g-PEO/DOX nevertheless has slightly higher values of DLC (10.8%) and DLE 
(65%) as compared to the two other arborescent copolymers. Common sense dictates that 
larger particles should be capable of loading more drug. However it can be seen that, 
despite the lower molecular weight of G2PBG15-g-PEO and its lower hydrodynamic 
diameter relatively to G2PBG65-g-PEO, it has slightly higher DLC and DLE values. This 
could be related to the denser core of G2PBG15-g-PEO micelles creating a more 
hydrophobic microenvironment for the drug. The size of all six DOX-loaded and empty 
micelles in PBS is compared in Table 4.7. It can be seen that for each arborescent 
copolymer, the size measured by DLS before and after drug loading is almost identical. 
Given that for a 10% drug loading, the diameter of a micelle is only expected to increase 




Table 4.7. Characterization of DOX-loaded unimolecular micelles. 
Copolymer 






   PDI 
  DLC     
(wt%) 
   DLE 
  (%) 
G1PBG15-g-PEO/DOX 16 0.41  17 0.38 8.3 ± 0.3 50 ± 2 
G1PBG29-g-PEO/DOX 17 0.51  17 0.54 7.1 ± 0.2 42 ± 3 
G1PBG65-g-PEO/DOX 19 0.43  20 0.44 7.4 ± 0.2 44 ± 4 
G2PBG15-g-PEO/DOX 35 0.28  37 0.49   10.8 ± 0.2 65 ± 3 
G2PBG29-g-PEO/DOX 34 0.26  35 0.51   10.1 ± 0.2 60 ± 3 
G2PBG65-g-PEO/DOX 39 0.17  41 0.47   10.3 ± 0.3 62 ± 3 
The data represent the mean ± standard deviation (n = 3). 
As shown in Table 4.7, the drug loading content (DLC) and the drug loading efficiency 
(DLE) increased with the generation number of the copolymers, due to the higher PBG 
content of G2PBG-eg-PEO/DOX relatively to G1PBG-eg-PEO/DOX. The following 
release experiments mainly focused on G2PBG-eg-PEO/DOX systems, which had the 
highest DLC and DLE.  
4.4.8 In Vitro Drug Release Kinetics 
An in vitro drug release study was conducted using a dialysis method at 37 ˚C, in 
phosphate buffered saline (PBS) and at different pH values (7.4 and 5.5). The slightly 
acidic environment (pH 5.5) was used to simulate the pH of endosomal or lysosomal 
microenvironments. As shown in Figure 4.14, the results clearly demonstrate that the pH 
affected the DOX release rate from all three DOX-loaded unimolecular micelles 
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investigated. The release rate of DOX-loaded micelles was clearly slower at pH 7.4, with 
total release after 50 h reaching 12, 14.4 and 19.7 % for G2PBG15-g-PEO/DOX (Figure 
4.14a), G2PBG29-g-PEO/DOX (Figure 4.14b) and G2PBG65-g-PEO/DOX (Figure 4.14c), 
respectively, as compared with 17.7, 21.6 and 25.6% at pH 5.5. The relatively slower 
release at pH 7.4 is attributed to stronger hydrophobic interactions between the core of the 
nanocarriers and DOX. These results demonstrate that the DOX-loaded unimolecular 
micelles exhibit pH-dependent in vitro release behavior, whereby faster release of DOX 
takes place in an acidic environment (e.g., in endosomes/lysosomes) than at physiological 
pH (e.g., the bloodstream). The protonation of DOX in the acidic environment would also 
lead to higher aqueous solubility for DOX, since this would weaken the hydrophobic 
interactions between the DOX and the core of the micelles, and thus enhance DOX 
release.32,33 This pH-dependent drug release behavior is highly desirable for drug delivery 
applications, as it should greatly increase the efficacy of cancer therapy while minimizing 
undesirable side effects.34 For comparison, the releasing profile of free DOX is also 
presented (Figure 4.14e). Sustained release was observed for all the DOX-loaded micelles, 












































































































































Figure 4.14. In vitro DOX release profiles for (a) G2PBG15-g-PEO/DOX, (b) 
G2PBG29-g-PEO/DOX, (c) G2PBG65-g-PEO/DOX, (d) G1PBG29-g-PEO/DOX 
unimolecular micelles and (e) free DOX in PBS (pH 7.4 and 5.5) at 37 ˚C. 
The drug release mechanism from unimolecular arborescent micelles is expected to be 
passive diffusion. It is generally recognized that the smaller the mean particle diameter, the 
shorter the diffusion path for drug release, and thereby the faster the release rate. The 
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release rate of DOX at both pH was indeed slower for all the G2PBG-g-PEO/DOX systems 
as compared to G1PBG29-g-PEO/DOX.  For example, the total amount of drug released 
from G2PBG29-g-PEO/DOX (Figure 4.14b) after 50 h reached 14.4 and 21.6 % at pH 7.4 
and at pH 5.5, respectively, as compared with 30.5 and 34.9% from G1PBG29-g-PEO/DOX 
(Figure 4.14d). This is obviously a consequence of the larger hydrodynamic diameter of 
G2PBG-g-PEO/DOX relatively to G1PBG-g-PEO/DOX, which increases the diffusion 
path for drug release, thus reducing the drug release rate. However since the G2PBG 
micelles used in the current investigation all had comparable diameters, no correlation 
between the micelle diameter and the release rate was attempted. Another parameter that 
might influence the release rate of the drug is structural rigidity, i.e. the branching density 
(bd). As pointed out in Section 4.4.3, the branching density increased in the series G2PBG65 
< G2PBG29 < G2PBG15. Interestingly, the amount of drug released after 50 h was inversely 
related to the branching density of the PBG cores, namely G2PBG15 < G2PBG29 < 
G2PBG65. The significant differences in release rate observed within this series of micelles 
is attributed to their different core bd. Very compact and dense cores (G2PBG15, bd = 0.80) 
would indeed be expected to prevent the diffusion of the drug molecules out of the core 
more strongly, thus resulting in slower release. In contrast, a more porous core structure 
(e.g., G2PBG65, bd = 0.11) should facilitate the diffusion process. The results obtained 
therefore strongly suggest that the release rate of DOX can be controlled through variations 
in the branching density of the core for the randomly grafted arborescent copolymers.  
An investigation of drug release over an extended time period (up to 30 days) was also 
carried out (Figure 4.15). It revealed that in all cases, the DOX release profiles displayed a 
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biphasic release pattern at both low and high pH, with an initial burst release followed by 
sustained release of the drug. At neutral pH (7.4) for example, 7% of the loaded DOX was 
released from G2PBG65-g-PEO/DOX over the first 6 h, and only 19.7% after 50 h. Due to 
the random grafting of the PEO chains onto the PBG substrate, the burst release is attributed 
to the drug solubilized in the interfacial region of the micelles, which can diffuse more 
easily and faster into the release medium. The sustained release behavior of the 
unimolecular micelles again correlates with the branching density, with a larger cumulative 
release observed for the micelles with the lowest branching density (G2PBG65-g-
PEO/DOX). Even after one month the release of DOX from the micelles was incomplete 
(Figure 4.15). This could be due in part to strong hydrophobic interactions between the 
PBG core and the DOX molecules, which was indeed confirmed by analysis of the micelles 
left in the dialysis bag. A significant amount of DOX may also be physically trapped deeper 
within the hydrophobic PBG core of the micelles, which would make its diffusion out of 
the highly dense and branched PBG core more difficult. Such a hydrophobic environment 
can prevent the protonation of DOX, and thus decrease the diffusion capability of DOX. A 
similar explanation was suggested by Gauthier et al.23 for the incomplete release of 
indomethacin from highly branched arborescent polystyrene-g-poly(2-vinylpyridine) 
copolymers, serving as non-biocompatible model systems with a structure similar to the 
























































































Figure 4.15. In vitro DOX release profiles over a 30-day period for (a) G2PBG15-g-
PEO/DOX, (b) G2PBG29-g-PEO/DOX and (c) G2PBG65-g-PEO/DOX in PBS (pH 7.4 
and 5.5) at 37 ˚C. 
4.5 Conclusions 
A library of water-soluble amphiphilic arborescent copolymers PBG-g-PEO was 
successfully prepared. Poly(γ-benzyl L-glutamate) cores were generated by ring-opening 
polymerization of γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-NCA) initiated with 
n-hexylamine. Cleavage of a fraction of the benzyl ester groups, and coupling with PBG 
chains to obtain a comb-branched (G0) PBG structure. Additional cycles of partial 
deprotection and grafting yielded G1 and G2 arborescent polypeptides. The PBG substrates 
serving as cores for the synthesis of amphiphilic arborescent copolymers also had randomly 
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distributed carboxylic acid functionalities. Side chains of poly(ethylene oxide) were 
grafted onto these functionalized arborescent PBG substrates to produce amphiphilic 
arborescent copolymers. Their aqueous solution behavior revealed that the copolymers 
existed mostly as unimolecular (non-aggregated) micellar species. An encapsulation study 
demonstrated that these well-defined, biocompatible copolymers could efficiently 
encapsulate hydrophobic DOX. Sustained, pH-responsive release of the encapsulated drug 
was observed.  
The ability of these unimolecular micelles to encapsulate and release DOX was 
correlated with the generation number of the copolymers and the branching density (bd) of 
the hydrophobic cores. Both the DLC and the DLE clearly increased with the generation 
number of the copolymers. For each generation, slightly higher values of DLE and DLC 
were obtained for the micelles with a denser core structure (G1PBG15 and G2PBG15), with 
a DLE of about 50% and 65%, respectively, and a DLC of about 8.3% and 10.8%, 
respectively. Both the DLE and DLC decreased slightly as the grafting density of the cores 
decreased. The release profiles indicated that the drug release rate could be controlled 
through the generation number of the copolymers and by modulating the grafting density, 
and thereby the porosity of the cores. Micelles with highly branched cores (G2PBG15) 
reduced the diffusion rate of the drug, while a lower branching density (G2PBG65) 
facilitated the diffusion process. The versatile encapsulation and release properties of these 
unimolecular micelles show that they could be useful as nanocarriers for a broad range of 




    Influence of the Core Branching 
Density on Drug Release from Arborescent Poly(γ-






Amphiphilic dendritic copolymers of arborescent poly(γ-benzyl L-glutamate) of 
generations G1 and G2, grafted at their chain ends with poly(ethylene oxide) segments 
(PBG-eg-PEO) were synthesized, characterized and evaluated as nanocarriers for 
doxorubicin (DOX). The copolymers were designed with hydrophobic PBG cores having 
three different branching densities and were characterized using 1H NMR spectroscopy, 
size exclusion chromatography (SEC), transmission electron microscopy (TEM) and 
atomic force microscopy (AFM). Dynamic light scattering (DLS) measurements revealed 
that these amphiphilic molecules behaved like unimolecular micelles without significant 
aggregation in aqueous media such as phosphate buffered saline (PBS), with diameters in 
the 13-29 nm range depending on the generation number and the core structure. Efficient 
encapsulation of DOX by these unimolecular micelles was demonstrated, with drug 
loading capacities of up to 11.2 wt%, drug loading efficiencies of up to 67%, and pH-
responsive sustained drug release as determined by UV spectroscopy. The generation 
number of the copolymers and the branching density of the dendritic PBG core were found 
to influence the encapsulation and release properties of the micelles. Given the tailorable 
characteristics, good water dispersibility and biocompatibility of amphiphilic arborescent 
copolymers, these should be useful as robust nanocarriers for a broad range of therapeutic 





Over the past two decades many new drug delivery systems have been developed to 
enhance the aqueous solubility of drugs, increase their circulation time in the bloodstream, 
and thereby increase their therapeutic efficacy.1 Among different nanocarriers used for 
controlled drug delivery, polymeric micelles (e.g. amphiphilic block copolymer micelles, 
unimolecular micelles and cross-linked micelles) with tunable properties have shown great 
potential due to their excellent characteristics that brought them to the front line in the 
development of drug delivery systems.2,3  
A considerable amount of research has been devoted to the design of polymeric 
micelles of different types, sizes, morphologies and stabilities for drug delivery 
applications. Among these, micelles formed by amphiphilic block copolymers were found 
very attractive due to their ability to solubilize hydrophobic or poorly water soluble drugs 
within their core, and thus enhance drug bioavailability.4 Although the stability of 
amphiphilic block copolymer micelles has been improved significantly over the last few 
years, they are still sensitive to solvent composition and other parameters such as the 
concentration and temperature in many cases. For instance, once self-assembled micelles 
are injected into the body, they may dissociate due to dilution and lead to rapid release of 
physically encapsulated drugs, which reduces the efficacy of the treatment.5 These 
unfavorable issues can be resolved by stabilizing polymeric micelles via crosslinking, 
either in the core or the corona, or by constructing unimolecular structures that are stable 
regardless of their environment.6-8 Certain types of amphiphilic dendritic copolymers with 
covalently bonded core and shell components can behave like unimolecular micelles. In 
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contrast to conventional amphiphilic block copolymers forming micelles by aggregation 
only above their critical micelle concentration (CMC), dendritic unimolecular micelles do 
not dissociate upon dilution and show excellent colloidal stability in aqueous media, 
regardless of their concentration, while their size and morphology can be precisely 
controlled.9 Dendritic polymers, defined as macromolecules with a tree-like multi-level 
branched architecture, can be divided into three main classes depending on the specific 
characteristics of their architecture: dendrimers, hyperbranched polymers, and dendrigraft 
polymers.10-13 Due to their remarkable features, such as a compact globular topology with 
internal cavities and the presence of functional groups useful to fulfill different tasks 
simultaneously, amphiphilic dendritic polymers may be useful to replace block copolymers 
in drug delivery applications.14,15 Among the three dendritic polymer classes, dendrigraft 
(or arborescent) polymers provide a good compromise between monodispersed 
dendrimers, generated by a tedious synthetic process, and highly polydisperse 
hyperbranched polymers obtained in one-step reactions. Dendrigraft polymers are typically 
obtained in a generation-based scheme analogous to dendrimers, but with cycles of 
polymerization and grafting reactions. The use of polymeric chain segments rather than 
small molecules as building blocks leads to very rapid growth, such that high molecular 
weights are obtained in only a few steps for these systems, while maintaining fairly narrow 
molecular weight distributions (Mw/Mn < 1.1).
16,17  
Amphiphilic arborescent copolymers can be synthesized by adding hydrophilic 
segments in the last grafting cycle. With proper design, these copolymers may behave like 
unimolecular micelles for which the size and porosity can be tailored via variations in the 
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length of the side chains and the grafting density. Whitton and Gauthier recently reported 
the synthesis of arborescent PBG substrates grafted either randomly or at their chain ends 
with poly(ethylene oxide) segments, to be evaluated as micellar species.18 Unfortunately 
these copolymers formed a significant amount of large aggregated species in aqueous 
media, and their drug encapsulation and release properties were not explored.  
This investigation focuses on the synthesis of arborescent poly(γ-benzyl L-glutamate) 
end-grafted with poly(ethylene oxide) segments (PBG-eg-PEO) designed to avoid 
aggregation, and their application as nanocarriers for doxorubicin (DOX) as a model 
hydrophobic drug. Micelles derived from PBG cores of generations G1 and G2 and three 
different branching densities were compared to determine the influence of these parameters 
on their dispersibility in aqueous media, and on the encapsulation and release of the 
hydrophobic drug. 
5.3 Experimental Procedures 
5.3.1 Characterization and Sample Preparation 
5.3.1.1 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Proton nuclear magnetic resonance (1H NMR) spectroscopy served to estimate the 
degree of polymerization of the linear PBG chains, to determine the deprotection level of 
the PBG substrates, and to investigate the ability of randomly grafted arborescent 
copolymers to form micelles. The instrument used was a Bruker 300 MHz spectrometer. 
Fluorine nuclear magnetic resonance (19F NMR) spectroscopy was also performed on the 
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Bruker 300 MHz instrument to determine the chain end primary amine functionality, fNH2, 
of the polymers used in the grafting reactions. 
5.3.1.2 Size Exclusion Chromatography (SEC) Analysis 
Analytical SEC was used for the characterization of the arborescent PBG substrates of 
generations G0-G2 and of the arborescent copolymers. The analytical SEC system was a 
Viscotek GPCmax unit equipped with a VE 2001 GPC Solvent/Sample Module, a Viscotek 
double detector array with refractive index and dual-angle light scattering detectors, and 
two Agilent Technologies PLgel 5 µm MIXED-C and PLgel 10 µm MIXED-B organic 
mixed bed columns, with dimensions of 7.5 mm (ID) × 300 mm (L). The system was 
operated at a flow rate of 0.5 mL/min at 70 ˚C, using dimethyl sulfoxide (DMSO) with 
LiBr (0.05 M) as the mobile phase. Analysis of the chromatograms was performed with 
the OmniSEC 4.6.1 software package. 
Preparative SEC was carried out on a system consisting of a Waters M45 HPLC pump, 
a 2-mL sample injection loop, a Waters R401 differential refractometer detector, and a 
Jordi Gel DVB 1000 Å 250 mm × 22 mm preparative SEC column. N,N-
Dimethylformamide (DMF) with 0.2 g/L LiCl served as the mobile phase. The 
concentration of the polymer solution injected was 25 mg/mL. The system was operated at 
a flow rate of 3 mL/min at room temperature (25 ˚C). 
5.3.1.3 Dynamic Light Scattering (DLS) Measurements 
Light scattering measurements were performed on a Zetasizer Nano ZS90 (Malvern 
Instruments) equipped with a 4 mW He–Ne laser operating at 633 nm and 25.0 ˚C, at a 
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scattering angle of 90°. The polymers were dispersed in phosphate buffered saline (PBS), 
DMF or water for at least 12 h before analysis. The concentration of the solutions was 
around 0.5 mg∙mL-1, 0.2 mg∙mL-1 and 0.1 mg∙mL-1 for the G0, G1 and G2 copolymers, 
respectively. All the solutions were filtered with either PTFE or cellulose acetate 
membrane filters having a nominal pore size of 0.45 μm prior to the measurements. The 
light scattering data were analyzed with the Zetasizer 7.11 Software (Malvern Instruments). 
Each sample was measured in triplicate. 
5.3.1.4 UV-visible (UV-vis) Spectroscopy 
Absorption spectra were obtained on a Cary 100 Bio UV-Vis spectrophotometer with 
a spectral bandwidth (SBW) of 2 nm, operated with the Cary Varian UV Scan Application 
(v3.001339). The absorption peak at 483 nm was used to calculate the doxorubicin loading 
in the DOX-polymer samples. Absorbance measurements were performed in the 200–800 
nm range and baseline correction was applied for PBS. 
5.3.1.5 Transmission Electron Microscopy (TEM) 
The dendritic micelles were imaged with a Philips CM10 electron microscope operated 
at 60 kV accelerating voltage. The images were recorded with an Advance Microscopy 
Techniques 11 megapixel digital camera and the Image Capture Software Engine version 
5.42.558. The feature sizes and size distributions were measured with the open source 
processing program ImageJ (version 1.46r).19 Either automatic selection or manual analysis 
of the features was used, depending on the contrast and the resolution of the images. In 
either case, a minimum of 15 measurements were taken for each sample to provide 
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adequate average size information. In some cases, contrast adjustment was necessary to 
improve visualization and help with the measurement of the features. The samples for TEM 
measurements were prepared by the following method: one drop of solution (0.05 
mg∙mL-1) was cast onto a 300 mesh Formvar® carbon-coated copper TEM grid (Electron 
Microscopy Sciences, FCF300-Cu) placed onto filter paper and excess solution was wicked 
off with filter paper. After 1 min, one drop of 2% (w/v) phosphotungstic acid was added to 
the grid and the excess staining solution was wicked off with filter paper. Finally the grid 
was transferred onto a new piece of filter paper in a Petri dish and left to dry overnight at 
room temperature. 
5.3.1.6 Atomic Force Microscopy (AFM) 
Muscovite mica discs were adhered onto steel substrates using double-sided adhesive 
tape to secure the sample to the magnetic spin coater. Immediately prior to film casting, a 
fresh surface was exposed by cleavage with a strip of Scotch® MultiTask tape. The 
polymer solutions were prepared at concentrations ranging from 0.01 to 0.05 mg·mL-1. A 
20 μL aliquot of the solution was deposited on the mica substrate and spun at about 3000 
revolutions per minute (rpm) for 60 s under ambient conditions. Atomic force microscopy 
(AFM) images were recorded in the tapping mode on a Nanoscope III instrument (Digital 
Instruments, model MMAFM-2, scan stage J) housed in a NanoCube acoustic isolation 
cabinet and mounted on a Halcyonics Micro 40 vibration isolation table. The measurements 
were performed using Si probes (VistaProbes, T300) having a spring constant of 40 N/m, 
a resonance frequency of 300 kHz, and the following characteristics: length 125 μm, width 
40 μm, tip height 14 μm, and tip radius < 10 nm. The images were analyzed using the 
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Nanoscope v 1.40 software. The scan rate was typically between 0.7 and 1.2 Hz, at a scan 
angle of 0°, acquiring 512 samples/line. 
5.3.2 Solvent and Reagent Purification 
Dimethyl sulfoxide and n-hexylamine were purified by stirring overnight with CaH2 
and distillation under reduced pressure. N,N’-Dimethylformamide serving in the polymer 
synthesis (DMF; Aldrich, >99%) was purified by distillation under reduced pressure. Ethyl 
acetate (Fisher, 99.9%) was distilled from LiAlH4 under nitrogen. γ-Benzyl L-glutamic 
acid (Bz-Glu; Bachem, >99%), diethyl ether (EMD Millipore OmniSolv), HBr solution 
(Aldrich, 33% in acetic acid), N,N’-diisopropylcarbodiimide (DIC; Aldrich, 99%), 
triphosgene (Aldrich, 98%), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC·HCl; Aldrich, 98%), LiAlH4 (Aldrich, 95%), 1-hydroxybenzotriazole 
(HOBt; Fluka, water content ca. 15% w/w), tetrahydrofuran (THF, EMD Millipore 
OmniSolv), methanol (EMD Millipore OmniSolv), trifluoroacetic acid (TFA, Caledon, 
99.9%), acetic anhydride (Caledon, 97%), deuterated DMSO (DMSO-d6, Cambridge 
isotopes, 99.9% D), deuterated water (D2O; Aldrich, 99.9 atom % D) and triethylamine 
(TEA, EMD) were used as received from the suppliers. Doxorubicin hydrochloride 
(DOX·HCl) was obtained from Sigma-Aldrich (USA). Dialysis bags Spectra/Por® 7 
(MWCO 3.5 kDa) were purchased from Spectrum Laboratories Inc. (USA). 
5.3.3 Synthesis 
The synthesis of the monomer γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-
NCA), the PBG linear side chains, the linear PBG substrates with different lengths, the 
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partially and fully deprotected linear PBG substrates, the partially deprotected arborescent 
PBG cores of generations 0 (G0) and generation 1 (G1), linear poly(ethylene oxide) (PEO), 
and their characterization were accomplished according to the procedures described in 
Chapter 4. 
The different linear PBG substrates are identified in the form PBGx, where X denotes 
the experimental number of PBG repeating units in the chains. The arborescent G0PBG 
molecules obtained by coupling the amine-terminated PBG side chains with the different 
carboxyl-functionalized PBG substrates are likewise identified as G0PBGx,  where X 
denote the number of PBG repeating units that were used as substrate for the construction 
of G0PBG. For example, G0PBG29 describes arborescent G0PBG derived from the PBG 
substrate with 29 repeating units. Similar sample notation is also used for the G1 and G2 
samples. 
Linear PBG substrates with different molecular weights and deprotection levels were 
used in the synthesis of arborescent G0PBG, while the PBG side chains (core building 
blocks) used in the subsequent reactions had Mn  5000 g/mol. The three linear PBG 
substrates used had an increasing number of PBG repeating units (Xn = 15, 29 and 65, 
identified as PBG15, PBG29 and PBG65, respectively). Their deprotection level also varied 
from 31% (PBG29 and PBG65) to 100% (PBG15) of free glutamic acid moieties. 
5.3.3.1 Synthesis of Glu(OtBu)2-Poly(γ-benzyl L-glutamate) [(tBuO)2-PBG)] 
Linear (tBuO)2-PBG serving as side chains for the last grafting cycle of the arborescent 
PBG core syntheses was obtained as described previously.18 Briefly, γ-benzyl L-glutamic 
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acid N-carboxyanhydride (Glu-NCA; 9.2 g, 35.0 mmol) was dissolved in dry DMF (23 
mL) at 40 ˚C. The tert-butyl diester of glutamic acid H-Glu(OtBu)-OtBu·HCl (414 mg, 
1.39 mmol, for a target Xn = 25) was dissolved in dry DMF (2 mL), added as initiator to 
the monomer, and the reaction was allowed to proceed for 7 d at 40 ˚C. The reaction was 
cooled to room temperature and triethylamine (0.25 mL, 1.84 mmol) was added. After 5 
min the linear polymer was recovered by precipitation in cold methanol, centrifugation and 
drying under vacuum overnight before characterization. Yield = 68%, Mw/Mn = 1.17. 
1H 
NMR (300 MHz, DMSO-d6): δ: 8.01-7.7 (b, 1H), 7.26–7.20 (s, 5H), 5.01–4.88 (s, 2H), 
4.30–3.85 (b, 1H), 2.30–1.68 (b, 4H), 1.31 (s, 0.75H), Xn = 24.0. 
5.3.3.2 Synthesis of Chain End-Functionalized G1 and G2 Arborescent PBG Substrates 
The chain end-functionalized arborescent PBG substrates were obtained by grafting 
glutamic acid-functionalized PBG linear chains in the last grafting cycle as described 
previously.18  For example, the G1 polymer was synthesized from the partially deprotected 
G0PBG substrate (0.27 g, 0.438 mmol -CO2H) and (OtBu)2-PBG side chains (2.22 g, 0.398 
mmol chains), dissolved in 22 mL of dry DMSO. The peptide coupling reagents DIC (0.377 
mL, 2.41 mmol) and HOBt (0.325 g, 2.41 mmol) were then added to the reaction with TEA 
(0.28 mL, 1.99 mmol) as a base. The reaction was allowed to proceed for 36 h at room 
temperature before adding n-hexylamine (0.29 mL, 2.89 mmol), to deactivate residual 
activated carboxylic acid sites. After 3 h the product was precipitated in cold methanol and 
recovered by suction filtration. The product was dissolved in DMF, purified by preparative 
SEC, precipitated in methanol, recovered by suction filtration, and dried under vacuum 
 
192 
overnight before characterization. The G2 arborescent polymer was synthesized and 
purified as described for the G1 sample. 
Mw/Mn = 1.07 (MALLS). 
1H NMR (300 MHz, DMSO-d6) δ: 8.01-7.7 (b, 1H), 7.26–
7.20 (s, 5H), 5.01–4.88 (s, 2H), 4.30–3.85 (b, 1H), 2.30–1.68 (b, 4H), 1.31 (s, 18H). 
5.3.3.3 Deprotection of Chain End-Functionalized Arborescent PBG Substrates 
The tert-butyl ester protecting groups were selectively removed to generate coupling 
sites only at the chain ends for further grafting reactions. As an example, the arborescent 
G1PBG substrate (0.3 g) was dissolved in trifluoroacetic acid (3 mL). After 10 min the 
polymer was precipitated in methanol, recovered by suction filtration, and dried under 
vacuum overnight before characterization. Yield: 0.23 g (77%). 1H NMR (300 MHz, 
DMSO-d6) δ: 8.01-7.7 (b, 1H), 7.26–7.20 (s, 5H), 5.01–4.88 (s, 2H), 4.30–3.85 (b, 1H), 
2.30–1.68 (b, 4H). 
5.3.3.4 Synthesis of Arborescent Copolymers 
All the arborescent copolymers were synthesized and purified similarly to the reaction 
described for the arborescent PBG samples. The synthesis of G1PBG15-eg-PEO is 
described below as an example. The deprotected chain end-functionalized arborescent 
G1PBG15 substrate (0.120 g, 0.051 mmol -CO2H) and the PEO serving as side chains (0.46 
g, 0.046 mmol chains) were dissolved in 5 mL of dry DMSO. The peptide coupling 
reagents DIC (0.044 mL, 0.281 mmol) and HOBt (0.038 g, 0.281 mmol) were then added 
to the reaction with TEA (0.030 mL, 0.233 mmol) as a base. The reaction was allowed to 
proceed for 36 h at room temperature before adding n-hexylamine (0.034 mL, 0.338 mmol) 
 
193 
to deactivate residual activated carboxylic acid sites. After 3 h the product was precipitated 
in cold methanol and recovered by suction filtration. Unreacted PEO was removed from 
the G1PBG15-eg-PEO crude polymer by preparative size exclusion chromatography (SEC) 
in DMF and the sample was recovered by precipitation in cold diethyl ether, suction 
filtration, and drying under vacuum. Grafting yield: 70%, Mn = 890,000, Mw/Mn = 1.06 
(MALLS). 
5.3.3.5 Preparation of DOX-loaded Unimolecular Micelles 
DOX·HCl (2 mg) was first dissolved in 0.5 mL of DMSO and neutralized with two 
equivalents of TEA (4 μL) to obtain the drug in its free base (hydrophobic) form. The 
arborescent copolymer (10 mg) was dissolved in 1 mL of DMSO and stirred for 2 hours. 
Then the DOX solution was added and the mixture was stirred overnight in the dark. The 
organic solvent and the free drug were removed by dialysis (MWCO 3500) against 
deionized water (1 L) for 24 h with three changes of the dialysis medium, and the resulting 
solution was either lyophilized in the dark or used directly for the subsequent 
measurements. For the determination of the drug loading content (DLC) and the drug 
loading efficiency (DLE), the lyophilized DOX-loaded micelles (3 mg) were dissolved in 
deionized water and the absorbance was measured on a UV-Vis spectrometer at 483 nm. 
The DLC and DLE were calculated according to the following equations: 
DLC =
mass of drug in micelles 
mass of micelles and drug
× 100%                                                                     (5.1) 
DLE =
mass of drug in micelles 
total mass of drug in feed
× 100%                                                                    (5.2) 
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5.3.3.6 In Vitro DOX Release 
To determine the DOX release profiles, a 3 mg sample of freeze-dried DOX-loaded 
micelles was dispersed in 1 mL of phosphate buffered saline (release medium, 10 mM 
phosphate, 137 mM NaCl and 2.7 mM KCl, pH 7.4 or 5.5; the pH was adjusted to 5.5 by 
addition of 6 M HCl) and transferred to a dialysis bag (MWCO 3500). The release 
experiment was initiated by placing the sealed dialysis bag into 3 mL of release medium at 
the same pH and 37 ˚C, with constant shaking at 100 rpm. At selected time intervals, the 
release medium was completely withdrawn and replaced with 3 mL of fresh medium. The 
amount of DOX released was calculated based on the absorbance measured on a UV-Vis 
spectrometer at 483 nm and a calibration curve. The drug release studies were performed 
in triplicate for each sample. 
5.4 Results and Discussion 
The structure of arborescent copolymers can be tailored to construct unimolecular 
micelles for various applications, and particularly for drug delivery. For example, the 
branching density (porosity) of the molecules can be varied by adjusting the length of the 
chains and the functionalization (deprotection) level in the arborescent PBG substrates, 
while their overall size and branching functionality can be controlled by using substrates 
of different generations. Linear PBG substrates with different molecular weights and 
deprotection levels were used in the current investigation for the synthesis of arborescent 
G0PBG, while the PBG side chains used in the subsequent reactions all had Mn  5000 
g/mol. The three linear PBG substrates used had an increasing number of PBG repeating 
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units (Xn = 15, 29 and 65, identified as PBG15, PBG29 and PBG65, respectively). The 
number of PBG units was controlled by varying the ratio of monomer (γ-benzyl L-glutamic 
acid N-carboxyanhydride, Glu-NCA) to initiator (n-hexylamine) used in the 
polymerization reaction. Their deprotection level also varied from 31 mol% (PBG29 and 
PBG65) to 100 mol% (PBG15) of free glutamic acid moieties. As a result, three well-defined 
(PDI < 1.09) comb-branched or arborescent G0PBG were obtained, but with a structure 
varying from compact and dense for G0PBG15, to a loose and more porous structure for 
G0PBG65, and an intermediate (semi-compact) structure for G0PBG29. The different 
substrate lengths and deprotection levels of linear PBG were used initially in the synthesis 
of G0PBG in the hope that the topology (shape) of the molecules could be varied from 
spherical to rod-like, but TEM and AFM imaging indicated that all the molecules were 
spherical. This approach nevertheless allowed variations in the branching density 
(porosity) for the cores, which seems to correlate well with the release properties of the 
molecules as discussed in Section 5.4.5. A detailed discussion of the synthesis of these 
linear PBG substrates and the arborescent G0PBG serving as hydrophobic core 
components for the synthesis of arborescent copolymers was provided in Chapter 4, and 
hence will not be discussed further here. 
The characterization data for the linear PBG and arborescent G0PBG substrates are 
provided in Tables 5.1 and 5.2, respectively. As seen in Table 5.2, the number-average 
branching density (bd), defined as the number of side chains added in the grafting reaction 
divided by the number of repeating units on the linear chain substrate, increased as the 
chain length of the substrate decreased. G0PBG15 had the highest branching density (bd = 
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0.80) among the three PBG substrates, and therefore should have a more compact and 
dense core structure. In contrast, G0PBG65 had the lowest branching density (bd = 0.11) 
and should have a more porous core structure (G2PBG65), while G2PBG29-eg-PEO/DOX, 
with bd = 0.19) is in-between. 
Table 5.1. Characteristics of linear PBG substrates. 
Sample Target Xn Xn(NMR) Mn(NMR) Mnapp(SEC)  PDI 
PBG15 15 15 3,600 3,880 1.11 
PBG29 30 29 6,600 6,900 1.10 
PBG65 68 65 14,500 15,700 1.12 











(g/mol) PDI fn bd 
G0PBG15 100 1.1 : 1 65400 1.04 12 0.80 
G0PBG29 31 1.7 : 1 35300 1.08 5.4 0.19 
G0PBG65 31 1.7 : 1 51000 1.06 7.1 0.11 
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5.4.1 Synthesis of Linear (tBuO)2-PBG 
Linear PBG with two tert-butyl ester protecting groups at one chain end, (tBuO)2-PBG, 
was obtained by the ring-opening polymerization of Glu-NCA initiated by the HCl salt of 
glutamic acid di-tert-butyl ester.18 The polymerization was carried out in DMF at 40 ˚C for 
7 days (Scheme 5.1).  
 
Scheme 5.1. Polymerization of γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-
NCA) using Glu(OtBu)2·HCl as initiator. 
The number-average degree of polymerization (Xn) of the (tBuO)2-PBG sample was 
determined by 1H NMR analysis as shown in Figure 5.1, by comparing the integrated peak 
intensities for the benzylic methylene protons in the repeating units (2H at 4.9 ppm) and 
the protons of the tert-butyl ester groups in the initiator fragment (18H at 1.3 ppm). The 
polymerization initiated by Glu(OtBu)2·HCl yielded PBG with Xn = 24, in good agreement 




Figure 5.1. 1H NMR spectrum for linear PBG with two tert-butyl ester protecting 
groups at one chain end (tBuO)2-PBG. 
5.4.2 Synthesis of Arborescent PBG Substrates with Carboxylic Acid Chain 
Ends 
The PBG arborescent substrates serving as cores for the amphiphilic copolymer 
micelles were synthesized as described previously.18 Three different PBG cores of 
generations G1 and G2 were employed as substrates to generate a library of chain end-
grafted copolymers to be evaluated as nanocarriers for doxorubicin (DOX). 
The chain end-functionalized substrates were obtained by grafting (tBuO)2-PBG onto 
randomly deprotected arborescent PBG substrates of generations G0 and G1 as described 
in Chapter 3. The deprotection level of the arborescent PBG substrates was ca. 30%, and a 
1 : 1.1 molar ratio of side chains NH2 chain ends to CO2H groups on the substrate was used 
to maximize the grafting yield and the coupling efficiency (Table 5.3). The unreacted side 
chains were removed from the crude polymer by preparative size exclusion 
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chromatography (SEC). The absolute molecular weight of the arborescent PBG samples 
was determined by SEC-MALLS analysis in DMSO. The molecular weight and the 
branching functionality (fn) of the polymers increased with the generation number as 
expected, while maintaining a low polydispersity index (PDI ≤ 1.09). The lower grafting 
yield (Gy) and coupling efficiency (Ce) observed for sample G1PBG15 are attributed to the 
dense structure of the G0PBG15 substrate, making it difficult for the linear side chains to 
diffuse to the coupling sites. 
Table 5.3. Characteristics of chain end-functionalized generation G1 and G2 







G1PBG15 220,000 1.09 27 31 28 
G1PBG29 210,000 1.07 53 64 31 
G1PBG65 270,000 1.09 48 56 39 
G2PBG15 1.2×106 1.08 51 57 171 
G2PBG29 970,000 1.06 39 48 137 
G2PBG65 1.3×106 1.07 43 50 185 
a Values from SEC-MALLS analysis in DMSO; b Grafting yield: fraction of side chains 
attached to the substrate;  c Coupling efficiency: fraction of coupling sites on the substrate 
consumed in the reaction; d Branching functionality: number of branches added in the last 
grafting cycle. 
The arborescent PBG substrates with tert-butyl ester-protected carboxylic acid groups 
at the chain end were then dissolved in trifluoroacetic acid (TFA), to selectively cleave the 
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tert-butyl ester protecting groups and generate two carboxylic acid groups at each chain 
end (PBG-ef-(CO2H)2). These chain end-functionalized arborescent PBG samples served 
as substrates in a subsequent grafting reaction with amine-terminated PEO chains to obtain 
the chain end-grafted amphiphilic arborescent copolymers PBG-end-grafted-PEO (PBG-
eg-PEO) as shown in Scheme 5.2. 
 
Scheme 5.2. Schematic representation of the synthesis of chain end carboxyl-
functionalized G1PBG substrate (G1PBG-ef-(CO2H)2) and the chain end-grafted 
arborescent copolymer G1PBG-eg-PEO. 
The mole fraction of tert-butyl ester groups in the arborescent substrates was 
determined by 1H NMR analysis, as shown in Figure 5.2c, by comparing the integrated 
peak intensities for the methine protons in the repeating units (1H at 3.9 ppm) and the 
protons of the tert-butyl ester groups in the initiator fragment (18H at 1.3 ppm). A 
calculation of the mole fraction of tert-butyl ester groups before deprotection of the G1 
PBG sample, G1PBG15-ef-(tBuO)2, is provided in Equation 5.3 as an example. 
𝑓𝑡𝐵𝑢 =





= 0.045 × 2 = 0.09                        (5.3) 
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1H NMR analysis was also used to confirm that complete deprotection of the tert-butyl 
ester groups was achieved before grafting PEO onto the PBG substrate. The complete 
disappearance of the tert-butyl protons at 1.3 ppm confirmed their complete removal 
(Figure 5.2b). 
 
Figure 5.2. 1H NMR spectra for G1PBG15-ef-(tBuO)2 (a) before and (b) after 




The results obtained when coupling the six different G1 and G2 chain end-
functionalized PBG-ef-(CO2H)2 substrates with PEO side chains to obtain the 
corresponding arborescent PBG-end-grafted-PEO (PBG-eg-PEO) copolymers are 
summarized in Table 5.4. The absolute molecular weight of the substrates and the 
arborescent copolymers was determined by SEC-MALLS analysis in DMSO. In all cases, 
the molecular weight of the copolymers increased with respect to the PBG substrates while 
maintaining a low polydispersity index (PDI ≤ 1.09). 
Table 5.4. Characteristics of chain end-grafted PBG-eg-PEO arborescent 
copolymers. 
copolymer 











G1PBG15-eg-PEO 220,000 9 70 890,000 1.06 67 75 
G1PBG29-eg-PEO 210,000 8 68 760,000 1.09 55 72 
G1PBG65-eg-PEO 270,000 9 63 1.0×106 1.05 73 73 
G2PBG15-eg-PEO 1.2×106 9 24 2.4×106 1.05 120 50 
G2PBG29-eg-PEO 970,000 9 31 2.3×106 1.09 133 57 
G2PBG65-eg-PEO 1.3×106 7 20 2.2×106 1.07 90 40 
a Values from SEC-MALLS analysis in DMSO; b Mole fraction of carboxyl groups in the 
substrate; c Grafting yield: fraction of side chains attached to the substrate; d Branching 
functionality: number of branches added in the last grafting cycle; e PEO weight fraction 
from the difference in Mn of the copolymer and the substrate. 
 
203 
The grafting yield (Gy), defined as the fraction of linear chain segments becoming 
attached to the substrate, was calculated by the same method described in Chapter 4 for the 
randomly grafted systems. While a lower functionality level of CO2H coupling sites was 
achieved for the chain end-functionalized PBG substrates (7–9 mol %) in comparison to 
the randomly functionalized PBG substrates (30–33 mol %), higher grafting yields were 
obtained under the same reaction conditions. For example, the PEO grafting yield for chain 
end grafting was 70, 68 and 63, for G1PBG15-eg-PEO, G1PBG29-eg-PEO and G1PBG65-
eg-PEO, respectively, significantly higher than for the randomly grafted systems (27, 24 
and 29 for G1PBG15-g-PEO, G1PBG29-g-PEO and G1PBG65-g-PEO, respectively, as 
provided in Chapter 4, Table 4.4). This can be explained by the better accessibility of the 
coupling sites in the chain end-functionalized PBG substrates in comparison to the 
randomly functionalized analogues. Despite the better accessibility of the coupling sites in 
the chain end-functionalized PBG substrates, arborescent copolymers with lower molar 
masses were obtained for the G1 and G2 polymers with different PBG core structures 
relatively to the randomly functionalized analogues. This means that a lower number of 
hydrophilic PEO segments were added in the last grafting cycle, and thus a lower branching 
functionality fn was achieved. This is obviously a consequence of the lower functionality 
level of the chain end-functionalized PBG substrates.  
The SEC traces obtained for the purified samples are compared in Figure 5.3, and the 
analysis results are summarized in Table 5.4. A decrease in elution volume is observed as 
the generation number increases. The elution volume increases in the G1 polymer series as 
G1PBG65-eg-PEO < G1PBG15-eg-PEO < G1PBG29-eg-PEO, while for the G2 series it 
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increases as G2PBG15-eg-PEO < G2PBG29-eg-PEO < G2PBG65-eg-PEO; the variations in 
absolute Mn within each series (Table 5.4) are small however, with average values of ca. 
(9  1)×105 g/mol and (2.3  0.1)×106 g/mol for the G1 and G2 copolymers, respectively. 





























Figure 5.3. SEC traces for G1 (left) and G2 (right) arborescent copolymers. 
5.4.3 Properties of Chain End-Grafted Arborescent Copolymer Micelles 
Since the coupling sites for the chain end-functionalized PBG substrates are located 
closer to the periphery of the molecules, a better defined crew-cut core-shell morphology 
is expected for the amphiphilic copolymers. Consequently, the hydrophilic PEO shell 
should be able to shield the hydrophobic PBG core from intermolecular hydrophobic 
interactions and the aqueous environment more efficiently, leading to stable unimolecular 
micelles free of aggregation. The chain end-grafted arborescent copolymers were 
investigated using dynamic light scattering (DLS), transmission electron microscopy 
(TEM), and atomic force microscopy (AFM) measurements, to investigate the influence of 
the dendritic core structure on the micelle properties. The hydrodynamic diameter 
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determined by DLS followed the expected increasing trend from G1 to G2 molecules 
(Table 5.5). The addition of hydrophilic PEO segments strictly at the chain ends of the 
arborescent hydrophobic PBG core clearly facilitated the formation of unimolecular 
micelles without aggregates in aqueous solutions, in contrast to the randomly grafted 
copolymers investigated in Chapter 4. 


















G1PBG15-eg-PEO 11 ± 1 15 ± 1 17 ± 1 0.08 13 ± 2 17 ± 2 26 ± 2 0.19 
G1PBG29-eg-PEO 12 ± 1 13 ± 1 15 ± 1 0.10 14 ± 2 17 ± 2 22 ± 2 0.31 
G1PBG65-eg-PEO 14 ± 2 16 ± 2 18 ± 2 0.12 14± 2 16 ± 2 19 ± 3 0.27 
G2PBG15-eg-PEO 25 ± 2 27 ± 2 32 ± 2 0.04 29 ± 1 33 ± 1 37 ± 1 0.19 
G2PBG29-eg-PEO 25 ± 1 29 ± 1 35 ± 1 0.05 26 ± 1 31 ± 3 39 ± 1 0.27 
G2PBG65-eg-PEO 21 ± 1 23 ± 1 29 ± 1 0.09 22 ± 1 27 ± 1 31 ± 1 0.23 
All experiments were carried out in triplicate, and the results are presented as the mean ± 
standard deviation for three measurements. 
The good agreement in the hydrodynamic diameter of the copolymers determined by 
DLS analysis in both DMF (a good solvent for the core and shell component) and PBS 
solution (an aqueous environment, selective for the PEO shell) indeed suggests that 
unimolecular micelles were obtained with number-average mean diameters of 11-14 nm 
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and 21-29 nm for the G1 and G2 molecules, respectively (Table 5.5). Similar trends were 
also observed for the volume- and intensity-average diameters. The average hydrodynamic 
diameter of the end-grafted samples is clearly smaller than for the randomly grafted 
samples investigated in Chapter 4. 
Size distribution analysis of the DLS results for the G1PBG-eg-PEO copolymers 
confirmed that the chain end-grafted copolymers formed exclusively stable unimolecular 
species without aggregation in DMF. Analysis of the same copolymers in phosphate 
buffered saline (PBS) solution yielded similar results, with number-average diameters 
comparable to those obtained in DMF in most cases. Interestingly, the G1PBG-eg-PEO 
copolymers also yielded a small amount (1−3 intensity %) of aggregates with a diameter 
around 5000 nm in the intensity distributions, while no aggregation was detected in the 
number nor in the volume distributions (Figure 5.4). This could be due to insignificant 
aggregation in the samples. The DLS measurements on all the G2PBG-eg-PEO samples 
yielded no detectable amounts of aggregates in DMF nor in PBS, as shown in Figure 5.5. 
The absence of significant amounts of aggregates in these systems clearly shows that the 
better defined crew-cut core-shell morphology of the chain end-grafted arborescent 
copolymers is a key factor in the formation of unimolecular micelles. In spite of the 
different hydrophobic G0PBG core structures used in the synthesis of the chain end-grafted 
G2 copolymers only small changes in hydrodynamic diameter were obtained, as 
determined by DLS analysis. This is attributed to the collapse of the hydrophobic PBG 
cores to minimize their exposure to the aqueous environment (as determined by 1H NMR 
analysis), leading to a comparable contribution to the overall size of the micelles. 
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Figure 5.4. Hydrodynamic diameter distributions of the arborescent copolymers 
determined by DLS in DMF (left) and in PBS solution (right): (A) G1PBG15-eg-PEO, 
(B) G1PBG29-eg-PEO, and (C) G1PBG65-eg-PEO. 
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Figure 5.5. Hydrodynamic diameter distributions of the arborescent copolymers 
determined by DLS in DMF (left) and in PBS solution (right): (A) G2PBG15-eg-PEO, 
(B) G2PBG29-eg-PEO, and (C) G2PBG65-eg-PEO. 
The formation of micelles with a collapsed core structure was further confirmed by 1H 
NMR spectroscopy as shown in Figure 5.6. For example, the analysis of G2PBG15-eg-PEO 
in D2O yielded no resonances for the phenyl (5H at 7.3) and benzylic methylene protons 
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(2H at 4.9 ppm), while these signals were present in DMSO-d6, a good solvent for both the 
PBG core and PEO sides chains, indicating that the G2PBG core was collapsed in D2O. 
 
Figure 5.6. 1H NMR spectra for G2PBG15-eg-PEO in (a) D2O and (b) deuterated 
DMSO. 
Further analysis of the chain end-grafted copolymers by TEM (after staining with 
phosphotungstic acid) and by AFM revealed that all the samples had a uniform size 
distribution and a spherical shape (Figures 5.7 for G1 copolymers, Figure 5.8 for G2 
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copolymers). The average diameter measured by TEM for the G1 copolymers was 10 ± 2, 
10 ± 3, and 13 ± 3 nm for G1PBG15-eg-PEO, G1PBG29-eg-PEO, and G1PBG65-eg-PEO, 
respectively. For the G2 copolymers, the average diameter was 23 ± 3, 21 ± 5, and 18 ± 4 
nm for G2PBG15-eg-PEO, G2PBG29-eg-PEO, and G2PBG65-eg-PEO, respectively. The 
TEM measurements therefore confirm the trends observed by DLS of increasing micelle 
size with the generation number, but the diameter is smaller because the TEM analysis was 
performed in the dry state. Although it was expected that the different PBG linear substrates 
would yield micelles with different shapes, only spherical micelles were observed in both 
the AFM and TEM images (Figure 5.7 and Figure 5.8) for all the samples. While the exact 
reason for this is unknown, several factors may have contributed to the similar shape of the 
micelles including the branched structure of the copolymers, solvent effects and 




Figure 5.7. TEM (left) and AFM phase (right) images for chain end-grafted 





Figure 5.8. TEM (left) and AFM phase (right) images for chain end-grafted 




5.4.4 Drug Loading and Micelle Characterization 
The arborescent copolymers synthesized consist of an amphiphilic core–shell 
morphology with a hydrophobic arborescent poly(γ-benzyl L-glutamate) (PBG) core, 
creating a favorable microenvironment for the encapsulation of hydrophobic drugs via 
physical entrapment, and a hydrophilic shell of poly(ethylene oxide) (PEO) making these 
copolymers water-soluble (Scheme 5.3).  
 
Scheme 5.3. Schematic representation of the encapsulation and release of DOX in 
the hydrophobic PBG core of G2PBG-eg-PEO through hydrophobic interactions. 
In contrast to amphiphilic block copolymer micelles, unimolecular micelles are stable 
irrespective of their concentration or the solvency conditions used. Unimolecular micelles 
do not dissociate upon dilution in the human body, and thus should lead to more controlled 
drug release and increased treatment efficacy. To evaluate the encapsulation and release 
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properties of the synthesized arborescent copolymers, doxorubicin (DOX) was used as a 
model hydrophobic drug. The influence of differences in core structure on the ability to 
encapsulate and control the release of the hydrophobic drug was investigated. 
To this end the hydrophilic doxorubicin hydrochloride (DOX·HCl) form of the drug 
was neutralized with two equivalents of triethylamine (TEA), to obtain the more 
hydrophobic DOX free base before encapsulation. The encapsulation study confirmed that, 
following purification by dialysis as described in Section 5.3.3.5, DOX could be 
solubilized in aqueous solutions of amphiphilic arborescent copolymers of generations G1 
and G2. For example, the encapsulation of DOX within the hydrophobic core of G2PBG-
eg-PEO yielded enhanced absorption around 490 nm for G2PBG-eg-PEO/DOX as 
compared to the blank micelles (Figure 5.9). The UV–vis spectra exhibited a bathochromic 
shift for the encapsulated drug (λmax = 490 nm) as compared to free DOX (λmax = 483 nm), 
attributed to hydrophobic interactions with the PBG core, which confirms successful DOX 
encapsulation within the micelles. 

























Figure 5.9. UV Absorption of free DOX, G1 (left) and free DOX, G2 (right) 
arborescent copolymers in PBS. 
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1H NMR spectroscopy was also used to confirm the encapsulation of DOX as shown in 
Figure 5.10, by the complete disappearance of the PBG and DOX signals for G2PBG15-eg-
PEO/DOX in D2O (Figure 5.10c), in comparison to the signal observed for free DOX in 
D2O at the same overall concentration of 2 mg/mL (Figure 5.10a), indicating restricted 
mobility of the hydrophobic PBG core and the DOX molecules entrapped within the core 




Figure 5.10. 1H NMR spectra for (a) DOX in D2O, (b) G2PBG15-eg-PEO in D2O and 
(c) G2PBG15-eg-PEO/DOX in D2O. The spectra show the appearance of the DOX 
signals upon encapsulation in G2PBG15-eg-PEO. 
The physical encapsulation of hydrophobic drugs in micelles is mainly driven by 
hydrophobic interactions between the drug and the core of the micelles. By increasing the 
PBG content from a G1PBG to a G2PBG substrate in the synthesis of the unimolecular 
micelles, it should be possible to load more DOX in the micelles. Indeed, the DOX loading 
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capacity of the arborescent copolymers was higher for all the G2PBG-eg-PEO/DOX 
samples as compared to the G1PBG-eg-PEO/DOX systems (Table 5.6). For example, 
sample G2PBG15-eg-PEO/DOX had higher values of DLC (11.2%) and DLE (67%) as 
compared to sample G1PBG15-eg-PEO/DOX, with DLC and DLE values of 7.9% and 47%, 
respectively. This is attributed to the higher PBG content of G2PBG-eg-PEO/DOX 
relatively to G1PBG-eg-PEO/DOX, allowing for more DOX molecules to be physically 
encapsulated within the PBG core through hydrophobic interactions. Moreover, the  DOX 
loading capacity of the arborescent copolymers varied slightly within the series G2PBG15-
g-PEO/DOX, G2PBG65-g-PEO/DOX, G2PBG29-g-PEO/DOX from 11.2 wt% to 10.4 wt% 
and 9.7 wt%, respectively. While these variations are minor, they could be related to 
variations in core size as seen in Table 5.6. Increasing the core size led to increased 
hydrophobicity for the G2PBG substrate for the synthesis of the unimolecular micelles, 




Table 5.6. Characterization of DOX-loaded unimolecular micelles. 
Copolymer 
















- - 13 0.19 14 0.41 7.9 ± 0.3 47 ± 4 
G1PBG29-eg-
PEO/DOX 
- - 14 0.31 14 0.32 7.5 ± 0.2 45 ± 4 
G1PBG65-eg-
PEO/DOX 
- - 14 0.27 15 0.35 8.1 ± 0.2 49 ± 5 
G2PBG15-eg-
PEO/DOX 
14 0.18 29 0.19 31 0.28 11.2 ± 0.3 67 ± 4 
G2PBG29-eg-
PEO/DOX 
10 0.05 26 0.27 27 0.27 9.7 ± 0.2 58 ± 3 
G2PBG65-eg-
PEO/DOX 
12 0.04 22 0.23 24 0.29 10.4 ± 0.3 62 ± 4 
Data represent the mean ± standard deviation (n = 3). 
Examining the drug loading efficiency (DLE) to further investigate whether differences 
in core-shell morphology between the chain end-grafted and randomly grafted arborescent 
copolymers (Chapter 4)  affect their ability to encapsulate the hydrophobic DOX, it was 
found that the DLE of all the arborescent copolymers with similar cores did not differ 
significantly. For example the end-grafted arborescent copolymers G2PBG15-eg-PEO 
encapsulated DOX with a DLE of 67%, while the randomly grafted arborescent 
copolymers G2PBG15-g-PEO had a DLE of 65%. The end-grafted copolymer had an 
insignificantly larger DLE, while its molar mass and hydrodynamic diameter were 
significantly lower (2.4×106 g.mol-1, 29 nm, respectively) than for its randomly grafted 
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counterpart (3.4×106 g.mol-1, 35 nm, respectively), which is attributed to the similarity of 
the core size and hydrophobicity in both copolymers. Similar trends were also observed for 
the other copolymers. These results further confirm that the branching density (bd) of the 
hydrophobic core, and thus the core size and the hydrophobicity of the unimolecular 
micelles, is the main factor affecting their drug loading capacity rather than the overall size 
of the micelles. 
The size of the DOX-loaded micelles in PBS was also investigated by DLS and found 
to be only slightly larger than the corresponding blank micelles (Table 5.6). For instance, 
the number-average diameter of G2PBG15-eg-PEO increased from 29 to 31 nm upon 
loading with DOX. This size increase is of course small and close to the error limits of the 
DLS technique (ca.  1 nm), but is nevertheless consistent with the presence of entrapped 
DOX molecules. The following release experiments mainly focused on the G2PBG-eg-
PEO/DOX systems, which had the highest DLC and DLE. 
5.4.5 In Vitro Drug Release Kinetics 
The in vitro drug release properties of the DOX-loaded micelles were investigated by 
dialysis at 37 ˚C in phosphate-buffered saline (PBS) at pH 7.4 (normal physiological 
conditions) and 5.5 (to mimic tumor cell environments). The release profile for the DOX-
loaded micelles at the different pH are compared with the release profile for free DOX in 
Figure 5.11. It is clear that the pH significantly affected the release kinetics of DOX from 
all three DOX-loaded micelle systems. At pH 7.4 the DOX release was slower, with a 
cumulative release after 50 hours of only 14.5, 16.5 and 20.4% for G2PBG15-eg-PEO/DOX 
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(Figure 5.11a), G2PBG29-eg-PEO/DOX (Figure 5.11b), and G2PBG65-eg-PEO/DOX 
(Figure 5.11c), respectively. However at pH 5.5, the cumulative release under the same 
conditions increased to 27.8, 28.6 and 39.4% for G2PBG15-eg-PEO/DOX, G2PBG29-eg-
PEO/DOX, and G2PBG65-eg-PEO/DOX, respectively. These results confirm that the 
DOX-loaded micelles show pH-dependent drug release profiles. This is presumably due to 
the protonation of DOX under acidic conditions, which increases its solubility and 
accelerates the diffusion rate of DOX. As a result, the hydrophobic interactions between 
DOX and the core of the micelles are weakened.23,24 Such pH-dependent release behavior 
of DOX was pointed out to be highly beneficial in drug delivery for cancer therapy, as it 
would favor the release of DOX in cancer cells while limiting release in the blood stream.25 
As shown in Figure 5.11d, the release rate of DOX at both pH was faster for the G1PBG29-
eg-PEO/DOX system than for G2PBG29-eg-PEO/DOX. For example, the total amount of 
drug released from G1PBG29-eg-PEO/DOX after 50 h reached 33.2 and 50.4 % at pH 7.4 
and at pH 5.5, respectively, as compared with 16.5 and 28.6% for G2PBG29-eg-PEO/DOX 
(Figure 4.11b). This is attributed to the smaller hydrodynamic diameter of G1PBG29-eg-
PEO/DOX relatively to G2PBG29-eg-PEO/DOX, decreasing the diffusion path for drug 
release and thus increasing the drug release rate. The release profile observed for free DOX 
is also provided in Figure 5.11e for comparison. The burst release of DOX is very obvious 




































































































































Figure 5.11. In vitro DOX release profiles from (a) G2PBG15-eg-PEO/DOX, (b) 
G2PBG29-eg-PEO/DOX, (c) G2PBG65-eg-PEO/DOX, (d) G1PBG29-eg-PEO/DOX 
unimolecular micelles and (e) free DOX in PBS (pH 7.4 and 5.5) at 37 ˚C. 
As shown in Figure 5.11, faster DOX release was observed from G2PBG65-eg-
PEO/DOX as compared to the other two DOX-loaded micelles, which could be attributed 
to two factors. The most probable explanation for the difference is the micelle size. Since 
the drug release in these systems should be diffusion-controlled, faster drug release is 
expected from micelles with a smaller hydrodynamic diameter due to the shorter diffusion 
 
222 
path for drug release. G2PBG65-eg-PEO/DOX has indeed the smallest hydrodynamic 
diameter (24 nm) and the fastest DOX release rate as compared to the other two DOX-
loaded unimolecular micelles (31 and 27 nm for G2PBG15-eg-PEO/DOX and G2PBG29-
eg-PEO/DOX, respectively). Another reason could be differences in core branching 
densities (bd) among the micelles. G2PBG65-eg-PEO/DOX has the lowest branching 
density (bd = 0.11) among the three PBG core substrates, and therefore should have a more 
porous core structure allowing water molecules to penetrate more easily into it. 
Consequently the protonation rate of DOX should increase, resulting in its faster release. 
In contrast, G2PBG15-eg-PEO/DOX has the highest branching density (bd = 0.80) and a 
more compact core structure (G2PBG15), while G2PBG29-eg-PEO/DOX has an 
intermediate branching density (bd = 0.19) which correlates with slower DOX release. 
All the DOX-loaded micelles displayed a biphasic DOX release pattern at both pH, 
characterized by an initial burst release followed by slower and sustained release of the 
drug. The burst release could be due to DOX adsorbed in the interfacial core-shell region 
of the micelles, which can diffuse faster into the release medium. In all cases, the release 
profiles showed incomplete DOX release from the micelles even after one month, as shown 
in Figure 5.12, which is attributed to the dense and branched hydrophobic PBG core 






























































































Figure 5.12. In vitro DOX release profiles over 30 days from (a) G2PBG15-eg-
PEO/DOX, (b) G2PBG29-eg-PEO/DOX and (c) G2PBG65-eg-PEO/DOX micelles in 
PBS (pH 7.4 and 5.5) at 37 ˚C. 
All the DOX-loaded chain end-grafted arborescent copolymers exhibited faster DOX 
release rates in comparison with their randomly grafted counterparts (Chapter 4), as shown 
in Figure 5.13. The faster release rates observed in the current investigation are attributed 
to the smaller size and the unimolecular nature of the end-grafted copolymer micelles. The 
release rate of DOX was clearly influenced by the pH for both systems, but the chain end-
grafted copolymers displayed enhanced pH responsiveness as compared to the randomly 
grafted systems. Since the chain end-grafted copolymers are expected to have a better-
defined core-shell morphology, the hydrophilic PEO chains in the shell should be able to 
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shield the hydrophobic PBG core and the DOX from the aqueous environment more 


























































































Figure 5.13. In vitro DOX release profiles from (a) G2PBG15-eg-PEO/DOX and 
G2PBG15-g-PEO/DOX, (b) G2PBG29-eg-PEO/DOX and G2PBG29-g-PEO/DOX, (c) 
G2PBG65-eg-PEO/DOX and G2PBG65-g-PEO/DOX unimolecular micelles in PBS 
(pH 7.4 and 5.5) at 37 ˚C. 
The results obtained therefore demonstrate the advantages of using chain end-grafted 
arborescent copolymers in comparison to randomly grafted copolymers as nanocarriers for 
drug delivery: The end-grafted copolymers formed either insignificant (G1) or 
 
225 
undetectable (G2) amounts of aggregates in aqueous solutions, exhibited more sharply pH-
dependent drug release profiles, but also a similar drug loading capacity for DOX even 
though their hydrodynamic diameter was smaller than their randomly grafted analogues. 
5.5 Conclusions 
In this study, a series of well-defined amphiphilic arborescent copolymers of 
generations G1 and G2 with three different poly(γ-benzyl L-glutamate) (G0PBG) core 
branching densities (bd) were successfully synthesized and evaluated as drug delivery 
nanocarriers. The copolymers were obtained by end-grafting arborescent poly(γ-benzyl L-
glutamate) (PBG) cores with different structures, of generations G1 and G2, with 
poly(ethylene oxide) (PEO) chain segments. These copolymers were characterized in 
solution by DLS, 1H NMR and SEC-MALLS measurements, as well as by TEM and AFM 
in the dry state. All the copolymers investigated formed spherical unimolecular micelles 
with dimensions tailorable from 13 to 29 nm, depending on their generation number and 
core structure. The encapsulation ability of these unimolecular micelles was evaluated 
using doxorubicin (DOX) as a model hydrophobic drug, and drug loading contents of up 
to 11.2 wt% with pH-responsive sustainable drug release were observed by UV-vis 
spectroscopy.  
Both the drug loading content (DLC) and the drug loading efficiency (DLE) increased 
with the generation number of the copolymers, due to the increase in PBG content from 
G1PBG to G2PBG in the micelles. The branching density of the dendritic G0PBG core 
was only found to have a minor influence on the overall unimolecular micelle diameter, 
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but it affected the drug loading content, the drug loading efficiency, and the drug release 
rate more significantly. Increasing the branching density of the G0PBG core, by increasing 
the deprotection level of the substrate, led to a larger core diameter and increased 
hydrophobicity for the G2BPG substrate for the synthesis of the unimolecular micelles, 
which enhanced their loading capacity for DOX. The release rate of DOX was also affected 
by the generation number and the hydrophobic core structure for the arborescent 
copolymers. Increasing the hydrodynamic diameter of the copolymers, by increasing the 
generation number, increased the diffusion path for drug release, thus reducing the drug 
release rate. In addition, the micelles with a denser core structure (G2PBG15) exhibited the 
slowest release rate, while those with a more porous core structure (G2PBG65) exhibited 
the fastest DOX release rate.  
Considering their controllable molecular structure, good water solubility and drug 
loading capacity, and the desirable pH-dependent controlled release characteristics 
observed, unimolecular micelles based on amphiphilic arborescent copolymers appear to 
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Dendritic graft copolymers of generations G1 and G2, in the form of arborescent 
poly(γ-benzyl L-glutamate) grafted at their chain ends with poly(ethylene oxide) segments 
(PBG-eg-PEO), and the corresponding deprotected poly(L-glutamic acid)-eg-
poly(ethylene oxide) (PGA-eg-PEO), were synthesized and evaluated as nanocarriers for 
the anticancer drug doxorubicin (DOX). These micelles had a spherical topology and a 
uniform size, with average diameters of 15 and 29 nm for G1PBG-eg-PEO and G2PBG-
eg-PEO, respectively. Three different strategies were examined to load DOX in these 
carriers. The hydrophobic form of DOX could be physically entrapped within the poly(γ-
benzyl L-glutamate) core. Doxorubicin hydrochloride (DOX·HCl) was also successfully 
loaded in the hydrophilic core of arborescent PGA-eg-PEO via either electrostatic 
interactions or conjugation through a pH-sensitive hydrazone bond. While a good drug 
loading capacity (7.6-14.1 wt%) was achieved in all cases, electrostatic interactions yielded 
the highest drug loading efficiency 66 and 83% for G1PGA-eg-PEO and G2PGA-eg-PEO, 
respectively. All the systems exhibited sustained and pH-sensitive drug release behavior, 
with a drug release rate increasing from physiological (pH 7.4) to acidic (pH 5.5) 
conditions. The hydrazone bond-conjugated systems had the best overall pH-responsive 
behavior however, due to the stability of the hydrazone bond at physiological pH 
eliminating burst release of the drug. The arborescent polymeric micelles would be useful 





Cancer is a group of more than 100 diseases characterized by the uncontrolled growth 
and spread of abnormal cells.1 It is a leading cause of death worldwide, and chemotherapy 
remains one of the most effective methods for the treatment of cancer. Chemotherapy 
conventionally involves the use of small molecule drugs such as doxorubicin (DOX) to 
destroy rapidly dividing cancer cells via damage to their RNA or DNA. DOX is widely 
used in chemotherapy to treat many types of cancer that has spread such as lung, bladder 
and breast cancer.2 Unfortunately, its therapeutic potential is limited by its cytotoxicity 
which lacks specificity to cancer cells, causing serious damage to healthy cells. One 
approach to reduce the side effects of DOX as well as to enhance its therapeutic 
effectiveness is to develop drug delivery systems. In recent years, various drug delivery 
systems have been developed with different designs for that purpose such as polymeric 
micelles, nanoparticles, dendrimers, liposomes and carbon nanotubes.3 Such systems 
increase the solubility limit and action time of drugs, and most importantly facilitate their 
accumulation in tumors through the enhanced permeability and retention (EPR) effect.4,5 
Among the many drug delivery systems investigated, polymer micelles based on 
amphiphilic diblock or triblock copolymers have attracted significant attention for 
biomedical applications due to their unique core-shell structure that can be used to 
encapsulate drugs within their hydrophobic core.6-8 Unfortunately, self-assembled 
nanocarriers can become unstable and disassemble into free polymeric chains when 
subjected to pH or temperature variations, or upon dilution below their critical micelle 
concentration (CMC) in the bloodstream. In contrast, amphiphilic dendritic copolymers 
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can behave like unimolecular micelles and provide excellent in vivo stability irrespective 
of their surroundings, due to their covalently bonded core-shell structure.9-12 
Dendritic polymers are a versatile class of macromolecules characterized by a highly 
branched tree-like architecture, incorporating multiple branching levels resulting from 
coupling reactions of either small molecule monomers (hyperbranched polymers and 
dendrimers) or macromolecular building blocks (dendrigraft polymers).13-16 In aqueous 
media, amphiphilic dendritic polymers may either exist as unimolecular micelles or form 
multimolecular aggregates useful for a number of applications such as drug delivery.9 Due 
to the vast array of architectures that can be obtained, dendrigraft (arborescent) polymers 
are an interesting alternative in the design of unimolecular micelles.17-19 In contrast to the 
other dendritic polymer families, high molecular weight arborescent polymers can be 
obtained in relatively few steps, while maintaining fairly narrow molecular weight 
distributions (Mw/Mn < 1.1).
20 Furthermore, the properties of unimolecular arborescent 
micelles can be fine-tuned to suit certain needs, for example through the introduction of 
functional groups to attach drugs, imaging agents or targeting moieties, which makes them 
highly suited as nanocarriers for drug delivery. 
Ideally, drug nanocarriers should not only solubilize hydrophobic anticancer drugs, but 
also protect them from inactivation in the biological milieu and from fast clearance 
processes (e.g. via urinary excretion). They should also possess functional groups to attach 
the drugs, and most of all, be biocompatible. There are certain requirements which the 
nanocarriers must meet to improve the efficacy of cancer therapy. These include a high 
drug loading efficiency, controlled drug release characteristics, and in vivo stability. 
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Polypeptides such as poly(glutamic acid), poly(L-lysine) and poly(aspartic acid) have 
attracted much interest as building blocks to construct nanostructures for biological 
applications, due to their remarkable characteristics including but not limited to good 
biocompatibility, biodegradability, economics, and the presence of versatile functional 
groups such as hydroxyl, carboxyl and amino groups that can serve for chemical 
modification.21 In addition to these features making them excellent materials for drug 
delivery applications, polypeptides have the ability to form well-defined secondary 
structures (α-helices and β-sheets) contributing to their self-assembly, which leads to novel 
nanostructured materials. Poly(ethylene glycol) (PEG, also referred to as poly(ethylene 
oxide) or PEO), is the polymer most widely used to coat nanoparticulate carriers and 
minimize their interactions with components of biological fluids such as plasma proteins, 
and to avoid their recognition by the mononuclear phagocytic system (MPS) and 
subsequent clearance by the kidneys. In addition, PEG provides protection for cargoes that 
are sensitive to particular environments and prolongs the circulation time of polymeric 
micelles in the bloodstream.22’
23 As a result, various amphiphilic copolymers of different 
architectures, composed of hydrophobic polypeptide and hydrophilic PEG segments, have 
been studied for drug delivery applications.24-26 
Three main strategies can be employed to load drugs into polymeric micelle cores: (i) 
physical entrapment, (ii) electrostatic interactions, and (iii) covalent conjugation. 
Depending on the polymer structure and the nature of the drug, each strategy has distinct 
advantages and disadvantages. In the literature, different types of PEO- or PEG-
polypeptide copolymers such as poly(ethylene oxide)-b-poly(γ-benzyl L-glutamate) (PEO-
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b-PBLG) diblock copolymers, PBLG-b-PEO-b-PBLG triblock copolymers, 
and  poly(ethylene glycol)-b-poly(β-benzyl L-aspartate) block copolymers (PEG-b-PBLA) 
have been reported to encapsulate DOX via physical entrapment.27,28 Hydrophilic 
DOX·HCl was also loaded via electrostatic interactions in poly(ethylene glycol)-b-poly(L-
glutamic acid) (PEG-b-PLG) and poly(ethylene glycol)-b-poly(L-glutamic acid-co-L-
phenylalanine) (PEG-b-P(Glu-co-Phe)).29,30 Examples of the covalent conjugation of DOX 
to the hydrophobic segments of amphiphilic block copolymers include poly(ethylene 
glycol)-b-poly(β-benzyl L-aspartate) and the amphiphilic hyperbranched block copolymer 
Boltorn® H40-poly(β-benzyl L-aspartate)-b-poly(ethylene glycol) via pH-sensitive 
hydrazone linkages.31,32 However despite the precise structure, controlled and high degree 
of size uniformity that could be achieved for unimolecular micelles constructed from 
arborescent polymer substrates,33 their use as biocompatible drug nanocarriers through 
physical entrapment, electrostatic interactions, or covalent conjugation with drugs has yet 
to be explored.  
The aim of this study was to load DOX into arborescent copolymer micelles by different 
strategies, so as to compare them in terms of loading efficiency, loading capacity, and drug 
release profiles. We report herein the synthesis of biocompatible arborescent polymeric 
micelles with poly(γ-benzyl L-glutamate) (PBG) and poly(ethylene oxide) segments. The 
arborescent poly(γ-benzyl L-glutamate) substrates were synthesized by ring-opening 
polymerization of γ-benzyl L-glutamic acid N-carboxyanhydride initiated with n-
hexylamine, and successive grafting reactions via standard peptide coupling techniques. 
Amphiphilic unimolecular micelles of poly(benzyl L-glutamate)-eg-poly(ethylene oxide) 
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copolymers were obtained by grafting hydrophilic side chains of poly(ethylene oxide) at 
the end of the PBG chains on the hydrophobic arborescent substrates. The synthesized 
polymers were characterized by 1H NMR spectroscopy, gel permeation chromatography 
(GPC), atomic force microscopy (AFM), dynamic light scattering (DLS), and transmission 
electron microscopy (TEM).  
The encapsulation and release properties of these nanocarriers were investigated using 
doxorubicin (DOX) as a model anticancer drug, which was effectively encapsulated via 
three different methods. The hydrophobic form of DOX was physically entrapped within 
the core of the poly(γ-benzyl L-glutamate)-eg-poly(ethylene oxide) micelles. The 
nomenclature used to identify these samples is PBG-eg-PEO/DOX. Doxorubicin 
hydrochloride (DOX·HCl) was also loaded into the hydrophilic (deprotected) arborescent 
poly(L-glutamic acid)-eg-poly(ethylene oxide) copolymers via electrostatic interactions 
(PGA-eg-PEO-DOX). The conjugation of doxorubicin with poly(L-glutamic acid)-eg-
poly(ethylene oxide) micelles via pH-sensitive hydrazone bonds was also achieved (PGA-
eg-PEO-Hyd-DOX). 
6.3 Experimental Procedures 
6.3.1 Characterization and Sample Preparation 
6.3.1.1 Nuclear Magnetic Resonance Spectroscopy 
Proton nuclear magnetic resonance (1H NMR) spectroscopy was used to estimate the 
degree of polymerization of linear poly(γ-benzyl L-glutamate) and to determine the 
 
234 
deprotection level of the PBG grafting substrates. The instrument used was a Bruker 300 
MHz spectrometer. The concentration of the samples for the analysis ranged from 3–15 
mg/mL and depending on the sample concentration, either 16 or 128 scans were used. 
6.3.1.2 Size Exclusion Chromatography (SEC) Analysis 
Analytical SEC served for the characterization of the arborescent PBG substrates of 
generations G0-G2 and of the copolymers. The analytical SEC system used was a Viscotek 
GPCmax unit with a VE 2001 GPC Solvent/Sample Module, a Viscotek double detector 
array with refractive index and dual-angle light scattering detectors, and two Agilent PLgel 
5 µm MIXED-C and PLgel 10 µm MIXED-B organic mixed bed columns with dimensions 
of 7.5 mm (ID) × 300 mm (L). The system was operated at a flow rate of 0.5 mL/min at 
70 ˚C, using dimethyl sulfoxide (DMSO) with LiBr (0.05 M) as the mobile phase. Data 
analysis was performed with the OmniSEC 4.6.1 software package. 
Preparative SEC was carried out on a system consisting of a Waters M45 HPLC pump, 
a 2-mL sample injection loop, a Waters R401 differential refractometer detector, and a 
Jordi Gel DVB 1000 Å 250 mm × 22 mm preparative SEC column. N,N-
Dimethylformamide (DMF) with 0.2 g/L LiCl was used as the mobile phase at a flow rate 
of 3 mL/min at room temperature. The concentration of polymer solution injected was 25 
mg/mL. 
6.3.1.3 Polymer Characterization  
All the characterization techniques were previously described in Chapter 5. Briefly, 
light scattering measurements were performed on a Zetasizer Nano ZS90 (Malvern 
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Instruments) equipped with a 4 mW He–Ne laser operating at 633 nm and 25.0 ˚C, at a 
scattering angle of 90°. The samples were dissolved in phosphate buffered saline (PBS), 
DMF, or water at least 12 h before analysis. 
Absorption spectra were obtained on a Cary 100 Bio UV-Vis spectrophotometer with 
a spectral bandwidth (SBW) of 2 nm, operated with the Cary Varian UV Scan Application 
(v3.001339). The absorption peak at 483 nm for doxorubicin and a molar extinction 
coefficient  = 10,240 M-1·cm-1 were used to calculate the doxorubicin loading in the 
polymer samples. 
The dendritic micelles were imaged with a Philips CM10 electron microscope operated 
at 60 kV acceleration voltage. The feature sizes and size distributions were measured with 
the open source processing program ImageJ (version 1.46r).34 Samples for the TEM 
measurements were prepared by the following method: One drop of solution (0.05 
mg∙mL-1) was cast onto a 300-mesh Formvar® carbon-coated copper TEM grid placed on 
filter paper and the excess solution was wicked off with filter paper. After 1 min, one drop 
of 2% (w/v) phosphotungstic acid was added to the grid and the excess staining solution 
was wicked off with filter paper. Finally, the grid was transferred onto a new piece of filter 
paper in a Petri dish and left to dry overnight at room temperature. 
The Atomic Force Microscopy images were recorded in the tapping mode on a 
Nanoscope III instrument (Digital Instruments, model MMAFM-2, scan stage J). The 
polymer solutions were prepared at concentrations ranging from 0.01 to 0.05 mg.mL-1. A 
20 μL aliquot of solution was deposited on the mica substrate and spun at about 3000 
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revolutions per minute (rpm) for 60 s under ambient conditions. The images were analyzed 
using the Nanoscope v 1.40 software. The scan rate was typically between 0.7 and 1.2 Hz, 
at a scan angle of 0°, acquiring 512 samples/line. 
6.3.2 Solvent and Reagent Purification 
Dimethyl sulfoxide and n-hexylamine were purified by stirring overnight with CaH2 
and distillation under reduced pressure. N,N-Dimethylformamide serving in the polymer 
synthesis (DMF; Aldrich, >99%) was purified by distillation under reduced pressure. 
Anhydrous hydrazine was prepared by decomposition of hydrazine cyanurate using a 
procedure described elsewhere.35 Ethyl acetate (Fisher, 99.9%) was distilled from LiAlH4 
under nitrogen. γ-Benzyl L-glutamic acid (Bz-Glu; Bachem, >99%), diethyl ether (EMD 
Millipore OmniSolv), HBr solution (Aldrich, 33% in acetic acid), 1-hydroxybenzotriazole 
(HOBt; Fluka, water content ca. 15% w/w), N,N’-diisopropylcarbodiimide (DIC; Aldrich, 
99%), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl; 
Aldrich, 98%), tetrahydrofuran (THF, EMD Millipore OmniSolv), methanol (EMD 
Millipore OmniSolv), triphosgene (Aldrich, 98%), trifluoroacetic acid (TFA, Caledon, 
99.9%), LiAlH4 (Aldrich, 95%), acetic anhydride (Caledon, 97%), deuterated DMSO 
(DMSO-d6, Cambridge isotopes, 99.9% D), deuterated H2O ( D2O; Aldrich, 99.9 atom % 
D) and triethylamine (TEA, EMD) were used as received from the suppliers. Doxorubicin 
hydrochloride (DOX·HCl) was obtained from Sigma-Aldrich (USA). Dialysis bags 





The synthesis of the monomer γ-benzyl L-glutamic acid N-carboxyanhydride (Glu-
NCA), the PBG side chains, the PBG substrates, the partially deprotected arborescent 
poly(γ-benzyl L-glutamate) (PBG) cores of generations 0 (G0) and generation 1 (G1), 
linear poly(ethylene oxide), and arborescent PBG substrates of generations G1 and G2 
functionalized with carboxyl groups at their chain ends was accomplished as described in 
Chapter 4. 
6.3.3.1 Synthesis of Arborescent Poly(γ-benzyl L-glutamate)-eg-Poly(ethylene oxide) 
Copolymers (PBG-eg-PEO) 
The procedure used for the synthesis of the chain end PEO-grafted arborescent 
copolymers was as described in Chapter 5, except that the reactions were carried out on a 
3-fold larger scale. The synthesis of G1PBG-eg-PEO is described below as an example. 
The carboxyl chain end-functionalized arborescent G1PBG substrate (0.350 g, 0.132 
mmol) and the PEO-NH2 serving as side chains (1.210 g, 0.119 mmol) were dissolved in 
15 mL of dry DMSO. The peptide coupling reagents DIC (0.103 mL, 0.670 mmol) and 
HOBt (0.089 g, 0.670 mmol) were then added, with TEA (0.071 mL, 0.532 mmol) as a 
base. The reaction was allowed to proceed for 36 h at room temperature before adding n-
hexylamine (0.803 mL, 0.791 mmol), to deactivate residual activated carboxylic acid sites. 
After 3 h the product was precipitated in cold methanol and recovered by suction filtration. 
Unreacted PEO-NH2 was removed from the G1PBG-eg-PEO crude polymer by preparative 
size exclusion chromatography (SEC) in DMF and the sample was recovered by 
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precipitation in cold diethyl ether, suction filtration, and drying under vacuum. Grafting 
yield = 70%, 230 mg, Mn = 790,000, Mw/Mn = 1.07 (MALLS). 
6.3.3.2 Preparation of Arborescent Poly(γ-benzyl L-glutamate)-eg-Poly(ethylene 
oxide)/DOX (PBG-eg-PEO/DOX) 
The physical entrapment of DOX into the hydrophobic core of PBG-eg-PEO was 
achieved for both generations of arborescent copolymers as follows: DOX·HCl was first 
neutralized with two equivalents of triethylamine (TEA) in DMSO to obtain the DOX free 
base (more hydrophobic) form. The arborescent copolymer (10.0 mg) was dissolved in 1.0 
mL of DMSO which was stirred for 2 hours. Then 0.5 mL of DOX solution (in DMSO) at 
a concentration of 4.0 mg/mL was added to the polymer solution and the mixture was 
stirred overnight in the dark. The organic solvent and free drug were removed by dialysis 
(MWCO 3500) against deionized water (1 L) for 24 h (with three changes in the dialysis 
medium) before lyophilization in the dark to obtain the product, (PBG-eg-PEO/DOX). 
6.3.3.3 Synthesis of Arborescent Poly(L-glutamic acid)-eg-Poly(ethylene oxide) 
Copolymers (PGA-eg-PEO) 
The arborescent copolymers (PGA-eg-PEO) of generation G1 and G2 were synthesized 
and purified by the procedure described above, with an additional acidolysis step to 
deprotect the PBG core. The synthesis of G1PGA-eg-PEO is described below as an 
example. Briefly, the arborescent G1PBG-eg-PEO copolymer (90 mg, 0.41 mmol Bz-Glu 
units) was dissolved in a mixture of TFA (1.50 mL) to which 0.12 mL of 33% (w/w) HBr 
solution in acetic acid was added. The reaction was stirred for 3 hours at room temperature 
before the polymer was precipitated in diethyl ether. After drying under vacuum, the 
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precipitate was dialyzed against distilled water and freeze-dried, yielding a product with 
100% deprotected glutamic acid moieties as a white solid. Yield = 29 mg. 
6.3.3.4 Preparation of Arborescent Poly(L-glutamic acid)-eg-Poly(ethylene oxide)-DOX 
(PGA-eg-PEO-DOX) 
The encapsulation of DOX into the hydrophilic core of PGA-eg-PEO via electrostatic 
interactions was achieved for both generations as follows: The arborescent copolymer (5.0 
mg) was dissolved in 4.0 mL of deionized water and stirred for 10 min, and then the pH 
was adjusted to 7.4 with a few drops of 0.1 M NaOH. An aqueous solution of DOX·HCl 
(1.0 mL, 1 mg/mL) was added dropwise to the polymer solution and the mixture was stirred 
overnight in the dark. Excess drug was removed by dialysis (MWCO 3500) against 
deionized water (1 L) for 24 h (with three changes in the dialysis medium) before 
lyophilization in the dark to obtain the product, (PGA-eg-PEO-DOX). 
6.3.3.5 Synthesis of Arborescent Poly(L-glutamate-hydrazide)-eg-Poly(ethylene oxide) 
Copolymers (PGA-eg-PEO-Hyd) 
The benzyl ester group of the arborescent PBG-eg-PEO copolymers was substituted 
with a hydrazide (Hyd) functionality by an ester-amide exchange reaction as described 
previously.36,37 For example, G1PBG-eg-PEO (83 mg, 0.39 mmol) was dissolved in 15 mL 
of anhydrous DMF, and anhydrous hydrazine (15.0 mg, 0.47 mmol) was added to the 
polymer solution under nitrogen atmosphere. The reaction was allowed to proceed for 
24 h at 40 ˚C. The polymer was purified by dialysis against 0.25% ammonia solution for 
48 h, and freeze-drying to obtain the product, G1PGA-eg-PEO-Hyd. The derivative 
G2PGA-eg-PEO-Hyd was synthesized by the same procedure. 
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In an attempt to reduce the hazards associated with preparing, handling and storing the 
anhydrous form of hydrazine, the benzyl ester group of the arborescent PBG-eg-PEO 
copolymers were also substituted with hydrazide (Hyd) functionalities using a hydrazine 
solution in THF. In this method, G1PBG-eg-PEO (28 mg, 0.13 mmol) was dissolved in 5 
mL of anhydrous DMF, and hydrazine solution in THF (4 mL, 1.0 M) was added to the 
polymer solution under nitrogen atmosphere. The reaction was allowed to proceed for 6 
days at 40 ˚C. The polymer was purified by dialysis against 0.25% ammonia solution for 
48 h, and freeze-dried to obtain the product, G1PGA-eg-PEO-Hyd. While the 1H NMR 
analysis confirmed complete disappearance of the peaks characteristic for PBG such as the 
benzylic methylene (2H at 4.9 ppm) and phenyl protons (5H at 7.3 ppm), FTIR analysis of 
the product was not attempted. Further investigation is needed to verify the lack of 
degradation or chain cleavage reactions under these conditions. Due to insufficient 
materials being available, DOX was only conjugated to the hydrazide groups of both 
generations of PGA-eg-PEO-Hyd obtained by the first method (using anhydrous 
hydrazine). 
6.3.3.6 Synthesis of Arborescent Poly(L-glutamate-hydrazide-doxorubicin)-eg-
Poly(ethylene oxide) Copolymers (PGA-eg-PEO-Hyd-DOX)  
To conjugate DOX to the arborescent copolymer, G1PGA-eg-PEO-Hyd (20.0 mg, 
3.45×10-3 mmol –hydrazide units) was dissolved in 3.00 mL of DMF, and an excess of 
DOX·HCl (4.00 mg, 6.90×10-3 mmol) was added. The solution was stirred at room 
temperature for 24 h in the dark. The product was then purified by dialysis against methanol 
for 24 h, dialysis against deionized water for 48 h to completely remove free DOX, and 
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freeze-drying to obtain the product, G1PGA-eg-PEO-Hyd-DOX. G2PGA-eg-PEO-Hyd-
DOX was obtained by the same method. 
6.3.3.7 Determination of the Drug Loading Content (DLC) and Drug Loading 
Efficiency (DLE) 
For the determination of the drug loading content (DLC) and drug loading efficiency 
(DLE), the lyophilized DOX-loaded unimolecular micelles powder was dissolved in 
deionized water and the absorbance at 490 nm was measured with a UV-Vis spectrometer. 
The DLC and DLE were calculated according to the following equations: 
DLC =
mass of drug in micelles 
mass of micelles and drug
× 100%                                                           (6.1) 
DLE =
mass of drug in micelles 
total mass of drug in feed
× 100%                                                           (6.2) 
6.3.3.8 In Vitro Release of DOX 
In a typical experiment to determine the DOX release profiles, 3.0 mg of the freeze-
dried DOX-loaded unimolecular micelles powder was dispersed in 1.0 mL of phosphate 
buffered saline (PBS) for 20 min (release medium; 10 mM phosphate, 137 mM NaCl and 
2.7 mM KCl, pH 7.4 and 5.5; the pH was adjusted to by the addition of 6 M HCl) and 
transferred into a dialysis bag (MWCO 3500). The release experiment was initiated by 
placing the sealed dialysis bag into 3.0 mL of release medium at 37 ˚C with constant 
shaking at 100 rpm (New Brunswick Scientific Innova 4000 Incubator Shaker). At selected 
time intervals, all the release medium was withdrawn and the same volume of fresh 
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medium was added. The amount of DOX released was calculated using the molar 
extinction coefficient of DOX at 483 nm,  = 10,240 M-1·cm-1, and the absorbance of the 
DOX solution. The drug release studies were performed in triplicate for each sample. 
6.4 Results and Discussion 
6.4.1 Synthesis and Characterization of Arborescent Poly(γ-benzyl L-
glutamate)-eg-Poly(ethylene oxide) Copolymers (PBG-eg-PEO) 
Amphiphilic dendritic copolymers with distinct core and shell phases that are 
covalently bound have recently attracted much attention for drug delivery due to their 
excellent in vivo stability. In the current investigation, arborescent PBG substrates of 
generations G1 and G2 serving as cores for the construction of amphiphilic copolymers 
were synthesized with carboxylic acid termini using standard peptide coupling techniques 
as described in Chapter 5. The synthesis of the chain end-functionalized arborescent PBG 
substrates, and their subsequent coupling with amine-terminated PEO chains is represented 
in Scheme 6.1, using G1PBG-eg-PEO as an example. In this case, two carboxylic acid 
functional groups were generated at the end of each chain of the arborescent G1PBG 
substrate (G1PBG-ef-(CO2H)2) using trifluoroacetic acid (TFA) to deprotect the tert-butyl 
ester groups at the chain end, before coupling with the amine-terminated PEO chains to 





Scheme 6.1. Schematic representation of the synthesis of a chain end carboxyl-
functionalized G1PBG substrate (G1PBG-ef-(CO2H)2) and the copolymer G1PBG-
eg-PEO. 
The synthesis of the G1PBG-ef-(CO2H)2 substrate was confirmed by 
1H NMR analysis 
of the purified polymers, as shown in Figure 6.1. For the G0PBG substrate (Figure 6.1a), 
the peaks at 7.3 and 5.0 ppm are ascribed to the protons of the benzyl and methylene groups 
of the PBG chains. Grafting linear PBG with two tert-butyl ester protecting groups at the 
chain ends (tBuO)2-PBG onto the randomly deprotected arborescent G0PBG substrate 
yielded arborescent PBG with the tert-butyl ester protecting groups at the periphery of 
generation G1 molecule (G1PBG-ef-(tBuO)2). The grafting reaction was carried out in dry 
DMSO at room temperature, in the presence of DIC and HOBt to activate the carboxylic 
groups on the G0PBG substrate. In the 1H NMR spectrum of G1PBG-ef-(tBuO)2 (Figure 
6.1b), an additional peak is observed at 1.3 ppm due to the (18H) protons of the tert-butyl 
ester groups in the grafted PBG-(tBuO)2 chains. This clearly confirms the formation of 
arborescent G1PBG-ef-(tBuO)2. Similar spectra were obtained for the synthesis of 
G2PBG-ef-(tBuO)2. Deprotection of the tert-butyl ester protecting groups before the 
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grafting reaction of PEO was likewise confirmed by 1H NMR analysis, by the complete 
disappearance of the tert-butyl protons at 1.3 ppm (Figure 6.1c). 
The core–shell amphiphilic arborescent PBG-eg-PEO copolymers were obtained by 
coupling amine-terminated PEO chains with the arborescent PBG core substrates (PBG-
ef-(CO2H)2). The 
1H NMR spectrum obtained for copolymer G1PBG-eg-PEO, after 
complete removal of unreacted PEO-NH2 chains, is provided in Figure 6.1d. The large 
peak from 3.60-3.72 ppm is assigned to the methylene protons of the PEO chains. These 
results indicate the successful formation of the amphiphilic arborescent PBG-eg-PEO 




Figure 6.1. 1H NMR spectra for (a) G0PBG, G1PBG-ef-(tBuO)2 sample before (b) 
and after deprotection (c) of the tert-butyl ester protecting groups, and (d) G1PBG-
eg-PEO in DMSO-d6. 
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The results obtained upon grafting the PBG-ef-(CO2H)2 substrates of generations G1 
and G2 with amine-terminated PEO chains are summarized in Table 6.1. The absolute 
molecular weights of the substrates and the arborescent copolymers were determined by 
SEC-MALLS analysis in DMSO. The molecular weight of the copolymers increased 
relatively to the corresponding PBG substrates, while a low polydispersity index was 
maintained (PDI ≤ 1.08). 
Table 6.1. Characteristics of chain end-grafted PBG-eg-PEO arborescent 
copolymers. 
copolymer 
PBG Substrate Graft Copolymer 
Mn (g/mol) 








G1PBG-eg-PEO 220,000 8 70 790,000 1.07 57 29 
G2PBG-eg-PEO 1.0×106 9 35 2.4×106 1.08 140 42 
a Mole fraction of carboxyl groups in the PBG-ef-(CO2H)2 substrate; 
b Grafting yield: 
fraction of side chains attached to the substrate; c Branching functionality: number of 
branches added in the last grafting cycle; d PBG weight fraction from the difference in Mn 
of the copolymer and the substrate. 
The arborescent G1PBG-eg-PEO and G2PBG-eg-PEO copolymers were expected to 
behave like unimolecular micelles in aqueous solutions because of their amphiphilic 
character and their globular topology. The hydrophilic PEO chains formed a shell 
stabilizing the micelles, whereas PBG constituted the hydrophobic core. The characteristics 
of the arborescent copolymer were evaluated by size exclusion chromatography (SEC), 
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dynamic light scattering (DLS), transmission electron microscopy (TEM), and atomic 
force microscopy (AFM) as shown in Figure 6.2 for G1PBG-eg-PEO, and Figure 6.3 for 
G2PBG-eg-PEO. 
The hydrodynamic diameter of the arborescent copolymers is consistent with the 
formation of unimolecular micelles, as the number-average diameter in phosphate buffered 
saline (PBS) is 15 and 29 nm for the G1 and G2, respectively, and comparable to the 
diameter measured in DMF (14 and 27 nm for the G1 and G2 copolymers, respectively) 
which is a good solvent for both the PEO and PBG components. As shown in Figures 6.2 
and 6.3, the micelles are uniform in size, with a single size population and similar values 
for the number, volume, and intensity DLS distributions, and the absence of a second 
(aggregated) size population even in the intensity-weighted distributions. 
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Figure 6.2. Characterization of G1PBG-eg-PEO: (a) SEC trace, (b) DLS intensity 
distributions, (c) TEM image, and AFM (d) phase scan. 
The size and morphology of the unimolecular micelles were further evaluated by TEM 
and AFM imaging (Figure 6.2 for the G1 copolymer, Figure 6.3 for the G2 copolymer). 
The TEM and AFM images likewise indicated that the size distribution of the micelles was 




Table 6.2. The average diameters of arborescent PBG-eg-PEO copolymers by 
different techniques. 
copolymer 
DLS TEM AFM 
Dh, number Dh, volume Dh, intensity PDI Dh Dh 
G1PBG-eg-PEO 15 ± 2 18 ± 2 22 ± 2 0.25 13 ± 3 13 ± 2 
G2PBG-eg-PEO 29 ± 2 33 ± 2 41 ± 3 0.29 22 ± 3 26 ± 3 
 
These measurements confirmed the trends seen in the DLS measurement, such as the 
increase in micelle size with the generation number. The small difference in the average 
size determined by DLS, TEM and AFM analysis can be explained by shrinkage of the 
micelles during TEM and AFM sample preparation. 
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Figure 6.3. Characterization of G2PBG-eg-PEO: (a) SEC trace, (b) DLS intensity 
distributions, (c) TEM image, and AFM (d) phase scan. 
Given the size range of the G1PBG-eg-PEO and G2PBG-eg-PEO micelles determined 
by DLS analysis, they should be suitable as nanocarriers for drug delivery through passive 
tumor targeting via the enhanced permeability and retention effect. The size of these 
micelles (diameter below 50 nm) should minimize clearance by filtration in the spleen, but 
should also be large enough (diameter greater than 5.0 nm) to prevent fast renal clearance. 
This, again, gives the unimolecular micelles a better chance of accumulation in the tumor 
and thus to increase their overall therapeutic efficacy.38  
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6.4.2 Encapsulation via Physical Entrapment 
In contrast to dendrimer-based amphiphilic copolymers, arborescent copolymers are 
obtained as high molecular weight materials with a larger core, in fewer synthetic steps, 
which makes them very attractive as nanocarriers for drug encapsulation. The PBG 
segments in the arborescent core, and the PEO segments in the shell should endow 
arborescent copolymers with both good biocompatibility and biodegradability.24 
The ability of these unimolecular micelles to encapsulate hydrophobic guest molecules 
within their hydrophobic core was investigated using doxorubicin (DOX) as a model 
anticancer drug. While three different encapsulation strategies were explored for DOX, 
simple physical entrapment via hydrophobic interactions between DOX and the PBG core 
was first considered. To this end, the hydrophilic doxorubicin hydrochloride (DOX·HCl ) 
was neutralized with triethylamine (TEA) to obtain the more hydrophobic free base DOX 





Scheme 6.2. Schematic representation of the encapsulation and release of DOX in 
G2PBG-eg-PEO/DOX through hydrophobic interactions. 
UV-vis analysis confirmed that hydrophobic DOX could indeed be solubilized in the 
amphiphilic arborescent PBG-eg-PEO copolymers of both generations, as indicated by the 
enhanced absorption around 490 nm for the DOX-loaded micellar solutions as compared 
to the empty micelles (Figure 6.4). The red-orange coloration of the PBG-eg-PEO/DOX 
dispersions also provided direct visual evidence for the encapsulation of DOX into PBG-
eg-PEO (Figure 6.4). 
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Figure 6.4. UV absorption spectra for DOX·HCl, PBG-eg-PEO, G1PBG-eg-
PEO/DOX and G2PBG-eg-PEO/DOX in PBS. The inset shows the appearance of PBS 
solutions of DOX·HCl, PBG-eg-PEO and PBG-eg-PEO/DOX. 
The amount of drug encapsulated into G1PBG-eg-PEO and G2PBG-eg-PEO micelles 
was quantified by UV-visible spectrometry (Table 6.3). Both the drug loading content 
(DLC) and the drug loading efficiency (DLE) were slightly higher for G2PBG-eg-
PEO/DOX than for G1PBG-eg-PEO/DOX, due to the higher PBG content of G2PBG-eg-
PEO/DOX relatively to G1PBG-eg-PEO/DOX. 









PDI DLC (wt%) DLE (%) 
G1PBG-eg-PEO/DOX 15 0.22 18 0.35 7.6 ± 0.2 40 ± 3 
G2PBG-eg-PEO/DOX 29 0.26 34 0.37 9.5 ± 0.2 47 ± 4 
Data represent the mean ± standard deviation (n = 3). 
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The encapsulation results clearly show that the DLC and DLE increased with the PBG 
content of the micelles. Such a difference suggests that the hydrophobic interactions 
between the drug and the core of the micelles is the main driving force for physical 
entrapment. The size of the DOX-loaded micelles and the empty micelles in PBS is also 
compared in Table 6.3. The small (3-5 nm) size increase observed upon drug loading is 
consistent with the modest DLC of the micelles (less than 10% by weight). 
6.4.3 Encapsulation via Electrostatic Interactions 
The DOX-loaded arborescent copolymers, poly(L-glutamic acid)-eg-poly(ethylene 
oxide)-DOX (PGA-eg-PEO-DOX), of generations G1 and G2 were prepared as shown in 
Scheme 6.3. The G1PGA-eg-PEO and G2PGA-eg-PEO copolymers were first synthesized 
to allow DOX loading via electrostatic interactions between the carboxylic acid groups of 




Scheme 6.3. Schematic representation of the encapsulation and release of DOX·HCl 
in the hydrophilic PGA core of G2PGA-eg-PEO via electrostatic interactions. 
The arborescent G1PGA-eg-PEO and G2PGA-eg-PEO copolymers were prepared by 
complete deprotection of the benzyl ester groups of G1PBG-eg-PEO and G1PBG-eg-PEO, 
respectively, using 33% (w/w) HBr solution in acetic acid. The synthesis of arborescent 




Scheme 6.4. Synthesis of arborescent G1PGA-eg-PEO copolymer. 
1H NMR spectra for copolymers G1PBG-eg-PEO and G1PGA-eg-PEO are shown in 
Figure 6.5. The disappearance of the benzylic methylene protons (2H at 4.9 ppm) and 
phenyl protons (5H at 7.3 ppm) confirms the complete deprotection of the γ-benzyl groups 





Figure 6.5. 1H NMR spectra for (a) PBG-eg-PEO and (d) PGA-eg-PEO in DMSO-
d6. 
The hydrophilic doxorubicin hydrochloride (DOX·HCl), which is a weak amphipathic 
base (pKa = 8.2),39 can be loaded into anionic polymers such as poly(L-glutamic acid) 
(PGA) through electrostatic interactions in aqueous media. The electrostatic interactions 
make the use of organic solvents unnecessary, which is a significant advantage when 
compared to the physical entrapment strategy. This is also important because organic 
solvents are not only toxic, but they may accelerate the decomposition of drugs.40 Since 
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DOX·HCl is a weak amphipathic base, most of the amino groups in the sugar moiety are 
protonated under normal physiological conditions. DOX·HCl was loaded into the PGA-
eg-PEO copolymers of both generations by first converting the carboxylic acid moieties of 
PGA-eg-PEO to carboxylates by adjusting the pH with NaOH. Aqueous solutions of the 
copolymer and the drug were combined and stirred overnight at a pK below the pKa of 
DOX, and then free drug was removed by dialysis. The encapsulation of cationic DOX 
within the anionic arborescent PGA core was investigated by UV-Vis spectrometry, using 
the maximum absorbance of free DOX at 483 nm; the empty micelles showed no 
significant absorption around that wavelength (Figure 6.6). After DOX was loaded the 
colorless PGA-eg-PEO solution became orange (PGA-eg-PEO-DOX), indicating the 
successful encapsulation of DOX. 













Figure 6.6. UV absorption spectra for DOX·HCl, PGA-eg-PEO, G1PGA-eg-PEO-
DOX and G2PGA-eg-PEO-DOX in PBS. The inset shows the appearance of PBS 
solutions of DOX·HCl, PGA-eg-PEO and PGA-eg-PEO-DOX. 
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The DLC and DLE determined by spectrophotometry, listed in Table 6.4, increased 
with the generation number of the copolymers. Electrostatic interactions therefore allowed 
more DOX·HCl to be loaded into the unimolecular micelles, similarly to the physical 
entrapment approach examined previously. The DLC were 11 and 14 wt%, and the 
corresponding DLE were 66 and 83% for G1PGA-eg-PEO-DOX and G2PGA-eg-PEO-
DOX, respectively. This is likely because the arborescent copolymers of the higher 
generation number have a higher PBG content (42% by weight) and thus a larger number 
of coupling sites (carboxyl groups) available for DOX·HCl to bind. 









PDI DLC (wt%) DLE (%) 
G1PGA-eg-PEO-DOX 17 0.48 16 0.29 11.2 ± 0.4 66 ± 5 
G2PGA-eg-PEO-DOX 34 0.60 32 0.35 14.1 ± 0.3 83 ± 4 
Data represent the mean ± standard deviation (n = 3). 
Using the drug loading efficiency (DLE) for comparison of the physical and 
electrostatic entrapment strategies used to prepare the drug-loaded micelles, it is clear that 
a higher DLE was achieved with the second strategy. For example, G2PGA-eg-PEO-DOX 
had a DLE of 83%, while a DLE of 47% was achieved for G2PBG-eg-PEO/DOX.  
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The higher DLC and DLE achieved with the electrostatic interaction strategy is mainly 
attributed to ionic bonding between the cationic DOX·HCl and the carboxylic acid groups 
in the core of nanocarriers, although other contributions due to hydrophobic interactions or 
hydrogen bonding cannot be excluded. Under normal physiological conditions (pH 7.4) the 
carboxylic acid groups of PGA-eg-PEO (pKa = 5.6)41 should be deprotonated, forming 
anionic carboxylates, while most of the amino groups in the sugar moiety of DOX (pKa = 
8.3) should be protonated, forming cationic ammonium groups. This is the main reason for 
postulating that electrostatic interactions should dominate between the DOX and PGA 
components. 
6.4.4 Encapsulation via pH-Sensitive Hydrazone Bond Conjugation 
As mentioned earlier, three main strategies can be employed to load drugs into 
polymeric micelles: (i) physical entrapment, (ii) electrostatic interactions, and (iii) covalent 
conjugation. The first two strategies are simple, but are unlikely to ensure optimal control 
over the drug release rate because the drug is not covalently attached to the nanocarrier. 
The latter strategy, in contrast, provides the option of enhanced stimuli-responsive drug 
release, which should increase the therapeutic efficiency and reduce toxicity by ensuring 
drug release at a target site. Different stimuli have been considered for that purpose 
including sensitivity to specific enzymes, pH, temperature, and light.42 For instance, the 
pH around tumor tissues tends to be lower (5.4 to 6.5) relatively to physiological pH (7.4).43 
Therefore, much attention has been paid to polymer−drug conjugates with acid-cleavable 
bonds such as hydrazone derivatives.31 
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In the current investigation, we also constructed pH-sensitive copolymers in which 
DOX was conjugated to the core of the micelles via a cleavable hydrazone bond (samples 
denoted as PGA-eg-PEO-Hyd-DOX). The influence of covalent drug conjugation on the 
drug loading capacity and the drug release rate was investigated and compared with the 
analogous PBG-eg-PEO/DOX and PGA-eg-PEO-DOX systems. A schematic illustration 
of the formation of pH-sensitive micelles is presented in Scheme 6.5. 
 
Scheme 6.5. Formation of pH-sensitive PGA-eg-PEO-Hyd-DOX micelles. 
As shown in Scheme 6.5, the benzyl groups of PBG-eg-PEO were substituted with 
hydrazide groups by an ester-amide exchange aminolysis reaction to obtain PGA-eg-PEO-
Hyd. The DOX was then conjugated to the hydrazide groups of PGA-eg-PEO-Hyd to 
obtain the final product, PGA-eg-PEO-Hyd-DOX.36,37  
The PBG-eg-PEO, PGA-eg-PEO-Hyd and PGA-eg-PEO-Hyd-DOX arborescent 
copolymers were characterized by 1H NMR spectroscopy as shown in Figure 6.7. As 
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observed for PGA-eg-PEO-Hyd (Figure 6.7b), the disappearance of the benzylic methylene 
protons (2H at 4.9 ppm) and phenyl protons (5H at 7.3 ppm) confirms that the benzyl esters 
residues were replaced completely with hydrazide groups. A new signal (2H at 4.4 ppm) 
corresponds to the amino protons in the hydrazide group, further confirming the successful 
synthesis of PGA-eg-PEO-Hyd. In addition to the peaks characteristic for PEO, the 
conjugation of DOX onto PGA-eg-PEO-Hyd was confirmed by the appearance of aromatic 
protons for DOX at 7.95 and 7.69 ppm, and its methyl groups at 1.16 and at 4.00 ppm. The 
disappearance of the hydrazide protons of PGA-eg-PEO-Hyd (2H at 4.4 ppm) in the 
spectrum of the final product (Figure 6.7c) also indicates the depletion of hydrazide groups 




Figure 6.7. 1H NMR spectra for (a) PBG-eg-PEO, (b) PGA-eg-PEO-Hyd and (c) 
PGA-eg-PEO-Hyd-DOX in DMSO-d6. 
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This result was further verified by comparing the FTIR spectra for the PBG-eg-PEO 
and PGA-eg-PEO-Hyd arborescent copolymers before and after reaction with hydrazine 
and DOX, respectively (Figure 6.8). After the reaction with hydrazine a new peak, 
attributed to the stretching vibrations of amino (NH2) groups, was detected around 1465 
cm-1 (Figure 6.8c). The disappearance of the ester C=O stretch vibration (1735 cm-1) also 
indicated the complete removal of the benzyl ester groups in the PBG core and the 
conjugation of the hydrazide (Figure 6.8b). The disappearance in Figure 6.8d of the peak 
at 1730 cm-1 for the carbonyl stretching of free DOX (Figure 6.8a) is also consistent with 
the formation of a hydrazone bond between the ketone and hydrazine (PGA-eg-PEO-Hyd-
DOX). Finally the intensity of the peak at 1465 cm-1 decreased, which suggests partial 
consumption of NH2 in the formation of hydrazone bonds. These results clearly confirm 






Figure 6.8. FT-IR spectra for (a) free DOX, (b) PBG-eg-PEO, (c) PGA-eg-PEO-
Hyd and (d) PGA-eg-PEO-Hyd-DOX. 
The UV-vis absorption spectra for DOX·HCl, PGA-eg-PEO-Hyd, and PGA-eg-PEO-
Hyd-DOX of both generations are compared in Figure 6.9. Successful conjugation is 
indicated by the enhanced absorption around 490 nm of the DOX-loaded micellar solutions 
(G1PGA-eg-PEO-Hyd-DOX and G2PGA-eg-PEO-Hyd-DOX) as compared to the empty 
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micelles PGA-eg-PEO-Hyd. As before, the PGA-eg-PEO-Hyd solutions were colorless but 
became red-orange after DOX conjugation (PGA-eg-PEO-Hyd-DOX), as seen in the inset 
of Figure 6.9. 













Figure 6.9. UV absorption spectra for DOX·HCl, PGA-eg-PEO-Hyd, G1PGA-eg-
PEO-Hyd-DOX and G2PGA-eg-PEO-Hyd-DOX in PBS. The inset shows the 
appearance of PBS solutions of DOX·HCl, PGA-eg-PEO-Hyd and PGA-eg-PEO-
Hyd-DOX. 
The amount of drug covalently conjugated to the G1PGA-eg-PEO-Hyd and G2PGA-
eg-PEO-Hyd micelles was determined by UV-Visible spectrometry (Table 6.5). The DLC 
were determined to be 7.7 and 10.3 wt%, and the corresponding DLE were 46 and 62% for 
G1PGA-eg-PEO-Hyd-DOX and G2PGA-eg-PEO-Hyd-DOX, respectively. Similarly to 
the two previous systems, G2PGA-eg-PEO-Hyd-DOX had higher values of DLC and DLE 
as compared to G1PGA-eg-PEO-Hyd-DOX. This is due to the higher PBG content (42% 
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by weight) and therefore, a large number of coupling sites (hydrazide groups) available for 
conjugation on the relatively larger G2PGA-eg-PEO-Hyd-DOX micelle. 
Table 6.5. Characterization of unimolecular micelles loaded via pH-sensitive 












G1PGA-eg-PEO-Hyd-DOX 15 0.22 17 0.38 7.7 ± 0.4 46 ± 5 
G2PGA-eg-PEO-Hyd-DOX 29 0.26 35 0.34 10.0 ± 0.3 62 ± 4 
Data represent the mean ± standard deviation (n = 3). 
6.4.5 In Vitro Drug Release Study 
To demonstrate the influence of DOX encapsulation via electrostatic interactions 
(PGA-eg-PEO-DOX), covalent conjugation (PGA-eg-PEO-Hyd-DOX) and physical 
entrapment (PBG-eg-PEO/DOX) on the drug release rate from the unimolecular micelles, 
an in vitro drug release study was conducted by dialysis at 37 ˚C. The drug release profile 
was assessed under both simulated physiological conditions (PBS, pH 7.4) and acidic 
conditions (PBS, pH 5.5), corresponding to the endosomal and lysosomal 
microenvironments, respectively. For all the systems investigated, the DOX release rate 
was affected by the pH, with slower DOX release at pH 7.4. For G1PBG-eg-PEO/DOX 
and G2PBG-eg-PEO/DOX (Figure 6.10a), the total release after 50 h reached 30 and 17.5 
%, respectively, as compared with 48 and 26% at pH 5.5. As before, the faster release at 
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pH 5.5 is attributed to the protonation of DOX in the acidic environment increasing its 
aqueous solubility.44,45 While G2PBG-eg-PEO/DOX had a higher DLC and DLE than 
G1PBG-eg-PEO/DOX, the release rate of DOX at both pH was much slower for G2PBG-
eg-PEO/DOX as compared to G1PBG-eg-PEO/DOX. This is attributed to the larger 
hydrodynamic diameter of G2PBG-eg-PEO/DOX relatively to G1PBG-eg-PEO/DOX, 
increasing the diffusion path for drug release, and thus reducing the drug release rate. 
Another parameter that might influence the release rate of the drug is the PBG content for 
the arborescent copolymers. As pointed out in Table 6.1, the PBG content increased with 
generation number. The micelles with a higher PBG content (G2PBG-eg-PEO/DOX, 42% 
by weight) exhibited slower release rate, while those with a lower PBG content (G1PBG-
eg-PEO/DOX, 29% by weight) exhibited the faster DOX release rate. 
In an attempt to achieve better control over the DOX release rate, the PGA-eg-PEO-
DOX samples were prepared in which DOX was loaded via electrostatic interactions. The 
in vitro drug release profiles for both generations of PGA-eg-PEO-DOX in PBS at different 
pH at 37 ˚C are compared in Figure 6.10b. The total amount of drug released after 50 h at 
pH 7.4 reached 13 and 27 % for G1PGA-eg-PEO-DOX and G2PGA-eg-PEO-DOX, 
respectively, as compared with 56 and 38% at pH 5.5. As discussed earlier, since 
electrostatic interactions exist between DOX and the carboxylic acid groups of the 
copolymers at pH 7.4, the release rate should be decreased. However at pH 5.5 most of the 
carboxyl groups should be protonated, which would weaken the electrostatic interactions 
between PGA-eg-PEO and DOX, and thereby accelerate drug release.  
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The release rate of DOX from PGA-eg-PEO-DOX was clearly influenced by pH for 
both generations, but G1PGA-eg-PEO-DOX displayed better defined pH-responsive 
behavior as compared to G2PGA-eg-PEO-DOX. For example, approximately four times 
the amount of loaded DOX was released from G1PGA-eg-PEO-DOX after 50 h at pH 5.5 
in comparison to pH 7.4, while only a small incremental amount of DOX was released 
from G2PGA-eg-PEO-DOX at pH 5.5 vs. pH 7.4. The relatively low pH responsiveness of 
G2PGA-eg-PEO-DOX is attributed to the larger size of its hydrophobic core. DOX bonded 
to the core of the micelles via electrostatic interactions should be nevertheless more 
sensitive to changes in pH. Such electrostatic interactions will be weakened under acidic 
conditions, and thus increase the DOX release rate. This also explains why the difference 
in release rate of DOX from G1PGA-eg-PEO-DOX is larger at the different pH as 























































































































Figure 6.10. In vitro DOX release profiles from (a) PBG-eg-PEO/DOX, (b) PGA-eg-
PEO-DOX, (c) PGA-eg-PEO-Hyd-DOX micelles, and (d) free DOX in PBS (pH 7.4 
and 5.5) at 37 ˚C. 
To combine the sustained release characteristics of the above two systems and reduce 
the occurrence of burst (premature) DOX release, pH-sensitive arborescent copolymers 
(PGA-eg-PEO-Hyd-DOX), in which the DOX was covalently conjugated to the core of the 
micelles via a cleavable hydrazone bond, were also synthesized. Since the hydrazone 
linkage between DOX and the copolymers is subject to hydrolysis under acidic conditions, 
the DOX release rate should increase in acidic environments (e.g. the tumor extracellular 
environment) and may provide a system with better pH-responsive behavior. The results 
indeed clearly show that both generations of PGA-eg-PEO-Hyd-DOX were very stable at 
pH 7.4, but exhibited much faster DOX release at pH 5.5. At pH 7.4 after 50 h, for example, 
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only 7 and 5% of the total drug was released from G1PGA-eg-PEO-Hyd-DOX and 
G2PGA-eg-PEO-Hyd-DOX, respectively, as compared with 57 and 42% at pH 5.5. This 
suggests that the hydrazone linkage would remain stable in the bloodstream and thereby 
eliminate burst drug release, while controlling the DOX release rate from PGA-eg-PEO-
Hyd-DOX once exposed to the acidic environment of the endosomal intracellular 
compartments (Figure 6.10c). Furthermore, similarly to the PBG-eg-PEO/DOX systems, 
the release rate of DOX from PGA-eg-PEO-Hyd-DOX at pH 5.5 decreased for the G2 
copolymer, while the release rate of DOX from PGA-eg-PEO-Hyd-DOX at pH 7.4 
remained relatively unaffected. This pH-dependent release behavior is highly desirable for 
drug delivery applications, as it should greatly increase the efficacy of cancer therapy while 
minimizing undesirable side effects. For comparison, the release profiles for free DOX are 
also presented (Figure 6.10d). Sustained release was observed for all the DOX-loaded 
micelles, in contrast to the sharp burst release seen for free DOX in the absence of the 
copolymers. 
6.5 Conclusions 
Amphiphilic arborescent copolymers of generations G1 and G2 with poly(γ-benzyl L-
glutamate) (PBG) in the core and poly(ethylene oxide) (PEO) chain segments in the shell 
were synthesized and evaluated as nanocarriers for drug delivery applications. The 
copolymers were characterized using 1H NMR, DLS, SEC-MALLS, TEM and AFM 
measurements. These results demonstrated that these copolymers formed exclusively 
stable, non-aggregated (unimolecular) micelles. The size distribution of these micelles was 
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narrow, with average diameters of ca. 15 and 29 nm for G1PBG-eg-PEO and G2PBG-eg-
PEO, respectively. 
Three different strategies were used to load DOX into these unimolecular micelles. The 
hydrophobic form of DOX was physically entrapped within the core of the micelles to 
obtain G1PBG-eg-PEO/DOX and G2PBG-eg-PEO/DOX, with a DLE of 40 and 47%, 
respectively. Physical entrapment was easy to achieve, but the DOX release profiles 
showed an initial burst which is undesirable for controlled release. In the second strategy, 
DOX·HCl was loaded into the hydrophilic G1PGA-eg-PEO and G2PGA-eg-PEO 
copolymers via electrostatic interactions between the cationic DOX and the anionic 
nanocarriers to obtain G1PGA-eg-PEO-DOX and G2PGA-eg-PEO-DOX, with a DLE of 
up to 66 and 83%, respectively. This strategy yielded the highest drug loading capacity for 
both generations. The use of electrostatic interactions also avoided the use of organic 
solvents, which is a significant advantage when compared to physical entrapment. The 
release rate of DOX from PGA-eg-PEO-DOX was clearly influenced by pH for both 
generations, but G1PGA-eg-PEO-DOX showed better-defined pH-responsive behavior as 
compared to G2PGA-eg-PEO-DOX. Finally, to further reduce initial burst (premature) 
DOX release, the DOX was covalently conjugated to the core of G1PBG-eg-PEO and 
G2PBG-eg-PEO via an acid-cleavable hydrazone bond to obtain G1PGA-eg-PEO-DOX 
and G2PGA-eg-PEO-DOX, with a DLE of 46 and 62%, respectively. The conjugated 
system had an intermediate drug loading capacity as compared to the other systems, but 
displayed the best pH-sensitive release profile. The PGA-eg-PEO-Hyd-DOX system 
therefore has obvious advantages over the other two systems, namely enhanced pH-
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sensitivity and sustained drug release behavior. This sustained and pH-sensitive release 
behavior is very promising for drug delivery applications, as it would facilitate maintaining 
an adequate drug concentration for longer times and thus improve patient compliance, 
while the pH-sensitive release behavior should minimize undesirable side effects and 




 Concluding Remarks and 




7.1 Original Contributions to Knowledge 
The main goals of this Ph.D. research work were to synthesize amphiphilic arborescent 
copolymers designed to serve as nanocarriers for drug delivery applications, to study their 
aqueous solution behavior, and for the first time, to investigate the ability of these 
biocompatible copolymers to encapsulate and control the release rate of a hydrophobic 
drug (doxorubicin) in aqueous media. Previously, Whitton and Gauthier reported the use 
of linear poly(ethylene oxide) with a molecular weight of 5000 (PEG110), grafted either 
randomly or at the end of the chains on arborescent PBG substrates, to generate arborescent 
copolymer micelles. Unfortunately, the randomly grafted arborescent G1PBG-g-PEO110 
copolymers obtained by that approach yielded large aggregated species in phosphate 
buffered saline (PBS), while G2PBG-g-PEO110 and G3PBG-g-PEO110 were both insoluble. 
The corresponding end-grafted samples PBG-eg-PEO110 displayed better dispersibility in 
PBS than the randomly grafted systems, albeit a small population of aggregates still existed 
in these samples. In the current investigation, we expanded this approach by designing 
amphiphilic arborescent copolymers having poly(ethylene oxide) (PEO) chain segments 
with Mn = 10,100 g/mol grafted onto arborescent PBG substrates of generations G1 and 
G2 with different G0PBG branching densities, to determine their influence on the 
dispersibility of the micelles in organic and aqueous environments, and on the 
encapsulation and release of a hydrophobic drug, doxorubicin. The poly(γ-benzyl L-
glutamate) building blocks were generated by ring-opening polymerization of γ-benzyl L-
glutamic acid N-carboxyanhydride (Glu-NCA) initiated with n-hexylamine. Partial or full 
deprotection of the benzyl ester groups followed by coupling with PBG chains yielded a 
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comb-branched (arborescent polymer generation zero or G0) PBG structure. Additional 
cycles of deprotection and grafting yielded G1 and G2 arborescent polypeptides. It was 
demonstrated that the efficiency of the polypeptide coupling reactions used to synthesize 
arborescent polypeptides could be optimized beyond the conditions previously used by 
varying the solvent, temperature, reaction time, and reactant stoichiometry used. Utilizing 
the optimized reaction conditions, namely reactions carried out in DMSO at 25 ˚C for at 
least 36 h, using a 1.1:1 ratio of CO2H:NH2 and 5:1 molar ratio of coupling agents 
(DIC/HOBt) to CO2H groups on the substrate, well-defined (PDI < 1.04) G0 arborescent 
or comb-branched polypeptides were obtained with a grafting yield and coupling efficiency 
reaching 67% and 74%, respectively. These optimized reaction conditions were also used 
to synthesize arborescent PBG of the upper generations (G1–G2). 
Two classes of amphiphilic arborescent copolymers, namely randomly grafted 
arborescent poly(γ-benzyl L-glutamate)-g-poly(ethylene oxide) (PBG-g-PEO) and chain 
end-grafted arborescent poly(γ-benzyl L-glutamate)-eg-poly(ethylene oxide) (PBG-eg-
PEO) were then synthesized. For each series of compounds, the influence of the generation 
number and the branching density of the G0PBG substrate on unimolecular micelle 
properties such as the drug loading capacity and the release kinetics was investigated. 
Consequently, for each system, three G0PBG cores with different branching densities 
varying from a compact and dense to a loose and more porous structure were synthesized 
as the molecular weight of the linear substrate was varied. All the amphiphilic arborescent 
copolymers provided opportunities to tailor their dimensions, from 13 to 39 nm, by the 
generation number and the branching density of the G0PBG cores. The size distribution of 
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these unimolecular micelles was found to be quite uniform. The aqueous solution behavior 
for all PBG-g-PEO revealed that these amphiphilic copolymers behave like unimolecular 
micelles in many cases, whereas all PBG-eg-PEO formed spontaneously stable 
unimolecular micelles with insignificant amounts of aggregation, if any. An encapsulation 
study demonstrated that these well-defined, biocompatible copolymers could efficiently 
physically encapsulate the hydrophobic (free base) form of DOX. Sustained, pH-
responsive release of the encapsulated drug was observed.  
The ability of these unimolecular micelles to encapsulate and release DOX correlated 
with the generation number of the copolymers and the branching density of the 
hydrophobic cores in each system. Both the drug loading content (DLC) and the drug 
loading efficiency (DLE) increased with the generation number of the copolymers as a 
result of increasing the PBG content in the micelles. For each generation, slightly higher 
values of DLC and DLE were obtained for the micelles with a denser core structure. Both 
the DLE and DLC decreased slightly as the grafting density of the cores decreased. The 
release profiles indicated that the drug release rate could be modulated through the 
generation number of the copolymers as well as by controlling the grafting density, and 
thereby the porosity of the cores. Increasing the hydrodynamic diameter of the copolymers, 
by increasing the generation number, increased the diffusion path for drug release, and thus 
reduced the drug release rate. In addition, micelles with highly branched cores reduced the 
diffusion rate of the drug, while a lower branching density facilitated the diffusion process. 
All the DOX-loaded unimolecular micelles clearly showed biphasic DOX release patterns 
at both pH investigated (5.5 and 7.4), characterized by an initial burst release followed by 
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slow and sustained release of the drug. The results obtained demonstrate important 
advantages of the end-grafted arborescent copolymers relatively to randomly grafted 
arborescent copolymers as nanocarriers for drug delivery applications: The end-grafted 
copolymers exhibited better drug release profiles and a similar drug loading capacity for 
hydrophobic DOX, even though the hydrodynamic diameter of these copolymers was 
smaller than their randomly grafted analogues. 
Furthermore, three different strategies were examined to load DOX into G1PBG-eg-
PEO and G2PBG-eg-PEO. The DOX was either physically entrapped (PBG-eg-
PEO/DOX), loaded via electrostatic interactions (PGA-eg-PEO-DOX) or covalently 
conjugated to the unimolecular micelles via pH-sensitive hydrazone bond (PGA-eg-PEO-
Hyd-DOX). While physical entrapment was easy to achieve, the DOX release profiles 
showed an initial burst release which is not ideal for controlled release applications. All 
the systems showed a good drug loading capacity, but encapsulation via electrostatic 
interactions showed the highest DLC and DLE for both generations. In addition, the use of 
electrostatic interactions in this procedure avoided the use of organic solvents, which is a 
significant advantage when compared to physical entrapment. All these systems exhibited 
sustained and pH-sensitive drug release behavior, that is, the drug release rate was slow at 
physiological pH (7.4) but increased at pH 5.5. The conjugated system PGA-eg-PEO-Hyd-
DOX had an intermediate drug loading capacity as compared to the other systems, but it 
displayed the best pH-sensitive release profile of DOX for both generations of PGA-eg-
PEO-Hyd-DOX arborescent copolymers investigated. Therefore the PGA-eg-PEO-Hyd-
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DOX system appears to have obvious advantages over the other two systems, that is, 
enhanced pH-sensitivity and a sustained drug release behavior. 
7.2 Suggestions for Future Work 
The work presented in this Thesis is the first investigation to examine the ability of the 
biocompatible arborescent PBG-g-PEO and PBG-eg-PEO copolymers as nanocarriers to 
encapsulate and control the release rate of doxorubicin (DOX) as model drugs. While these 
unimolecular micelles have already showed controlled and sustained drug release rates, it 
would certainly be interesting to evaluate the cytotoxicity and cellular uptake of these 
systems both in vitro and in vivo. 
7.2.1 Cytotoxicity and Cellular Uptake 
The characteristics of arborescent copolymers such as the size, branching density, and 
porosity can be tailored via systematic variations in the side chains length, substrate length, 
and branching functionality, leading to an extremely versatile range of nanostructures. 
These different structures can affect the manner in which these materials interact with 
biological environments (uptake processes), and ultimately determine their potential for 
cytotoxicity. The size and shape of nanocarriers are key parameters that dominate their 
properties, and hence they may also affect cellular uptake and toxicity. It is indeed known 
that the shape of nanocarriers can influence their circulation time, uptake and intracellular 
interactions.1,2 For example, worm-like nanoparticles have been shown to circulate for a 
prolonged duration after injection in mice as compared to their spherical counterparts.2 In 
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contrast, spherical gold nanoparticles displayed higher cellular uptake than the rod-shaped 
particles in vitro.3 The size of the nanocarriers is another factor that significantly influences 
uptake processes. For example, the uptake of gold nanoparticles in HeLa cells varied with 
their size.4 Therefore, understanding the relation between cellular uptake and toxicity of 
the arborescent nanocarriers in biological systems would represent a big step in designing 
nanocarriers that are efficient but also have minimal toxicity for biomedical applications. 
7.2.2 Active Targeting Strategies for Enhanced Treatment Selectivity 
In the current research, we designed the nanocarriers to take advantage of the so-called 
‘passive targeting strategy’. In this strategy, the drug-loaded nanocarriers can passively 
accumulate in tumors through the enhanced permeability and retention (EPR) effect.5,6 The 
nanocarriers are large enough to escape premature elimination in the kidneys via 
glomerular filtration, but small enough to participate in the EPR effect to passively 
accumulate in tumor tissues.7 Blood vessels surrounding tumor tissues are leaky in 
comparison to normal blood vessels, and thus drug-loaded nanocarriers can effectively 
travel across the fenestrations to reach tumor tissues and accumulate in them, thereby 
exerting their therapeutic effect as the drug is being released. In contrast, free small drugs 
will diffuse non-specifically to most tissues. Due to passive targeting of drug-loaded 
nanocarriers to tumor tissues, the undesirable side-effects of the drugs will be minimized 
as normal cells will be less affected. However, these nanoparticles do not interact with 
cancer cells directly and sometimes have a limited tumor penetration ability. By contrast, 
an ‘active targeting strategy’ can be achieved by introducing on the nanocarriers ligands 
such as antibodies, peptides, or aptamers to interact with overexpressed receptors on the 
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tumor cells, which enables the systems to specifically target tumor sites while sparing the 
rest of the body.8 This strategy increases the interactions between nanocarriers and the 
cells, thus enhancing drug internalization, which might reduce the severe adverse effects 
of the therapy. It would therefore be highly advantageous if the periphery of the arborescent 
nanocarriers were functionalized with a specific targeting molecule capable of actively 
binding to an area of interest. 
The targeting ligands need to be conjugated to the surface of the nanocarriers for cancer 
cell targeting via receptor-mediated endocytosis. One targeting compound that received 
much attention is folic acid, as folate receptors are frequently over-expressed on the surface 
of human tumors including ovarian, brain, breast, colon, renal and lung cancers.9 Folate is 
a stable, non-immunogenic molecule (M = 441 Da), which specifically binds to folate 
receptors. Therefore it would be interesting to design folate-conjugated arborescent 
poly(benzyl L-glutamate)-eg-poly(ethylene oxide) PBG-eg-PEO nanocarriers, to assess 
how efficiently these systems penetrate tumors both in vitro and in vivo. 
The folate-conjugated PBG-eg-PEO nanocarriers could be obtained by coupling the 
folate to the terminal –OH groups of the PEO corona chains of the nanocarriers using an 
esterification reaction. Steglich esterification is a widely used method under mild 
conditions to condense carboxylic acids with alcohols to form esters.10 The reaction usually 
utilizes N,N'-dicyclohexylcarbodiimide (DCC) as a coupling reagent and 4-
dimethylaminopyridine (DMAP) as a catalyst. The primary alcohols present at the end of 
the PEO chains can be coupled with the carboxylic groups of folic acid, and the resulting 
folate-conjugated PBG-g-PEO can be used to prepare doxorubicin-loaded nanocarriers. 
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Following this strategy, we expect that doxorubicin will enter the cells mainly via folate 
receptor-mediated endocytosis, which will enhance the local concentration of doxorubicin 
surrounding cancer cells and thus increase therapeutic efficacy in cancer therapy. 
7.2.3 Synergistic Co-Delivery of Doxorubicin and Paclitaxel 
The use of single chemotherapeutic drug has shown some limitations in cancer 
treatment due to toxicity at high drug dosage, the development of drug resistance, and the 
heterogeneity of cancer.11,12 Combination therapy of two or more drugs has been invested 
to overcome these limitations. Co-delivery is a promising strategy to reduce toxicity and 
to achieve synergistic effects for cancer therapy. 
In recent years, doxorubicin (DOX) and paclitaxel (PTX) have emerged as the most 
commonly used chemotherapeutic drugs in clinical tests against various solid tumors. They 
are drugs with distinct solubility characteristics, have different mechanisms of action and 
non-overlapping toxicities. Therefore, these combinations may exhibit synergistic effects 
in cancer therapy.11 Indeed, the combination of DOX and PTX has been used as the first-
line treatment for metastatic breast cancer and the clinical studies showed increased tumor 
regression rates as compared to the individual drugs.13,14 
In the present research DOX was covalently conjugated to the poly(benzyl L-
glutamate)-eg-poly(ethylene oxide) PBG-eg-PEO unimolecular micelles via a pH-
sensitive hydrazone bond (PGA-eg-PEO-Hyd-DOX). It would be of great interest if PTX 
could also be physically encapsulated by PGA-eg-PEO-Hyd-DOX to obtain nanocarriers 
with both doxorubicin and paclitaxel in the nanoparticles (PGA-eg-PEO-Hyd-DOX/PTX). 
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In this way, doxorubicin and paclitaxel combined could improve therapeutic efficacy, and 
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